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ABSTRACT 
 
 
The initial motivation for crystallization of Bovine Serum Albumin (BSA) is an 
interest to understand how thiomolybdates interact with BSA and suppress copper intake 
from the food sources of cattle. The main objective of my research work is to determine the 
crystal structure of BSA using X-ray crystallography techniques. Once the tertiary structure 
of BSA is determined, its structural information can help us to study the interactions 
between BSA, copper, and thiomolybdates, and to understand the way in which 
thiomolybdates render copper unavailable in cattle. Many trials for the optimal 
crystallization conditions of BSA were attempted in order to grow high-quality BSA 
crystals. However, all crystals only diffract to 8 Å resolution limit. Such resolution is not 
sufficient to solve the tertiary structure of BSA. 
Another objective of my research was to crystallize Thioredoxin-2 (Trx-2) to obtain 
larger crystals which may lead to high resolution crystallographic data, better than 2.4 Å, 
for protein structure refinement. This is because Trx-2 diffraction data that had been 
collected are split at high resolution. The ambiguous data at high resolution might impede 
the structure refinement and even can cause the three-dimensional structure of Trx-2 to not 
be refined successfully. A number of attempts were conducted for crystallizing Trx-2 to 
grow bigger and higher quality of Trx-2 crystals. However, the improvement of crystal 
dimensions was not significant, the diffraction resolution limits are similar to previous 
published data, and the split data at high resolution was still observed. 
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CHAPTER 1: INTRODUCTION 
 
1.1. RESEARCH OBJECTIVE 
Copper deficiency is known as a common issue in cattle (Ward et al., 1996). It is 
prevalent in regions that have high molybdenum concentration in pastures. The formation 
of thiomolybdates (TMs) in the rumen can render the copper unavailable (Suttle, 1991). 
The interactions of copper, molybdenum (Mo) and sulfur (obtained from inorganic or 
organic sources) in ruminants has the adverse effect on the rumen of grazing animals by 
depleting the available copper. My primary research objective is to obtain the 3-D crystal 
structure of bovine serum albumin (BSA) and then to study the interactions of copper (II) 
(Cu2+) and thiomolybdates with BSA. A detailed knowledge of the 3-D structure of this 
protein is imperative to understand its physical properties, and binding modes with 
copper and thiomolybdates. Once the protein tertiary structure is known, it can act as a 
template to investigate the interactions that occur between TMs, Cu2+ and BSA. It is 
anticipated that the mechanism of how thiomolybdates render copper unavailable in BSA 
will be well defined, characterized, and understood through the solved structure. 
High quality crystals in terms of size (at least up to 0.1 mm in each dimension) 
and appearance (single and sharp-edged) are required for structural determination of BSA.  
Excellent crystals that produce high resolution diffraction data, better than 3.0 Å are 
essential to achieve the solution and refinement of the 3-D structure of BSA. If high 
resolution BSA crystallographic data can be collected, then a 3-D macromolecular model 
can be built in order to simulate the potential binding site of Cu2+, TM, BSA and their 
binding characteristic in the bovine ruminant system. Additionally, the crystallization of 
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BSA−Cu2+, BSA−TM and BSA−Cu2+−TM complexes can be used to study their 
individual interactions with each other. 
The secondary research objective is to obtain high quality crystals of thioredoxin-
2 (Trx-2) from H. pylori that can be diffracted to better than 2.4 Å resolution and to refine 
the structure that has been published recently at 2.4 Å resolution (Filson et al., 2003). 
However the published diffraction data at high resolution have shown some split spots 
instead of single spots; this might make the process of protein refinement difficult due to 
the electron density of some neighboring atoms which are close and hardly resolved. 
 H. pylori has been recognized by the World Health Organization (WHO) as a 
type I carcinogen in the pathogenesis of gastric cancer (Williams, 1996), due to its 
significant impact towards duodenal ulcer. Our laboratory is interested in solving the 3-D 
structure of H. pylori thioredoxin in order to study its functions, mechanisms and their 
various interactions with the host cell. The structural analysis of Trx-2 in complex with 
other protein substrates will be explored in order to fully understand the role performed 
by Trx-2 in the redox environment of H. pylori. 
 
1.2. PROTEIN BACKGROUND 
1.2.1. History, Structure and Properties of Bovine Serum Albumin 
Serum albumin has been one of the most extensively studied proteins for many 
years. It is the most abundant protein in blood plasma with a typical concentration of     
50 g/L and functions as a transport protein for numerous endogenous and exogenous 
substances. It also plays an important role in regulating the colloid osmotic pressure of 
blood. It provides about 80% of the osmotic pressure and is responsible for the pH 
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maintenance in blood (Carter and Ho, 1994). Many researchers have studied the 
structures, functions and properties of serum albumins to understand their interactions 
with other molecules and ligands. Some of these albumins are human serum albumin 
(HSA), bovine serum albumin (BSA), equine serum albumin (ESA) and rat serum 
albumin (RSA). The molecules and ligands that have been studied include fatty acids, 
metal ions, pigments, and numerous drugs (McLachlan and Walker, 1977). 
Joseph F. Foster first suggested that the model of albumin was a flexible linkage 
of semi-independent domains (Foster, 1960). Serum albumin has been a model protein 
for many years for physiological studies. Apart from HSA, ESA, RSA, the primary 
sequence of other serum albumins such as mouse serum album (MSA), pig serum 
albumin (PSA), sheep serum albumin (OSA), frog serum albumin (XSA), salmon serum 
albumin (SSA) have been determined. BSA (Brown, 1975) and HSA (Behrens et al., 
1975) were the earliest primary sequences that were determined. So far, the only tertiary 
structures determined of serum albumins are ESA (Ho et al., 1993) and HSA (Carter et 
al., 1989; Carter and He, 1990; He and Carter, 1992). No other 3-D structure of serum 
albumins have been published as of December 2004 according to RCSB Protein Data 
Bank (PDB) and Biological Macromolecular Crystallization Database (BMCD) (Carter et 
al., 1989; He and Carter, 1992). The Protein Data Bank (Berman et al., 2000) is a 
worldwide repository for the processing and distribution of 3-D biological 
macromolecular structures. The Biological Macromolecule Crystallization Database 
contains crystal data and the crystallization conditions, which have been compiled from 
literature. The macromolecules saved in the database include proteins, nucleic acids and 
viruses. 
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The primary sequence of BSA was presented in the same year as HSA (Brown, 
1975; Brown, 1976). Brown proposed that BSA was composed of 582 amino acid 
residues. The sequence has 17 disulfide bonds resulting in nine loops formed by the 
bridges. BSA contains one single cysteine and eight pairs of disulfide bonds arranged in a 
way similar to those of HSA (He and Carter, 1992). BSA also contains a high content of 
Asp, Glu, Ala, Leu and Lys residues which is analogous to HSA and RSA. However, 
there were four amino acid residues (400−403) in the BSA sequence that were not 
determined at that time. Eventually, these four residues were identified as 
Gly−Phe−Gln−Asn (Reed et al., 1980). 
According to the amino acid sequence proposed by Brown, the structural features 
of BSA show that it is composed of three homologous domains. Each has about 190 
residues, linked together by peptide chain as represented as Figure 1.1 and 1.2.  
 
Figure 1.1: Structure organization of BSA (Kragh-Hansen, 1981; reproduced 
with permission of the author). 
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Each domain can be subdivided into two subdomains, namely A−B and C. The 
domains mainly contain a long loop and an intradomainal hinge region. Every subdomain 
can be further subdivided into three helices “X”, “Y” and “Z” (Figure 1.1). Brown has 
compared the three domains (I, II and III) of BSA, which correspond to residues 1−190, 
191−382 and 383−582 respectively. If domains I and II are aligned and compared, they 
show 25% identity, domains II & III and domains I & III show 21% and 18% identity 
respectively. This illustrates that domains I and II are more alike to each other than either 
is to domain III. This somewhat greater similarity between domains I and II implies that 
tandem duplication of a single domain gave rise to the ancestral gene of domains II and 
III. After passage of time, domains II and III diverged significantly. A single tandem half 
gene duplication from these domains was then added to domain I, thus giving the triple 
domain structure of present-day albumin (Brown, 1976). 
Circular dichroism measurements suggest that BSA secondary structure content 
for α- helix, β- sheet, turn and random coil are 48.7%, 0%, 10.9% and 30.7% respectively 
(Oberg and Uversky, 2001). In the secondary structure of BSA, it has been suggested that 
the α-helices are uniformly placed in the subdomains and in the connections between the 
domains. Most of the residues in the long loops (except at the end) and the sections 
linking the domains possibly form α-helices, whereas the intra-domain hinge regions are 
mainly non-helical structure. The three long helices in the subdomain are considered as 
principle elements of the structure. These run parallel with each other, and a trough is 
formed owing to the middle helix (Y) being slightly lower in position. The helices are 
mainly linked together by disulfide bridges (Kragh-Hansen, 1981). 
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Figure 1.2: Amino acid sequence of BSA (Brown, 1976; reproduced with 
permission of the publisher). 
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Almost all the hydrophobic residues are found inside the trough and between the 
helices, while the polar residues can be mostly observed on the outer wall of the structure. 
The two subdomains adhere with their grooves toward each other forming a domain, and 
three such domains eventually form a serum albumin molecule (Kragh-Hansen, 1981).  
In comparison with BSA, the tertiary structure of HSA demonstrates overall 
helical content and high cysteine content with 17 disulfide bonds of the molecule. It has 
three structurally homologous domains. Each domain is made up of two subdomains 
referred as A and B that correspond to Brown’s model as A−B and C (such as 2A−B & 
2C domains of BSA are corresponded to IIA & IIB domains of HSA). Subdomain IA, IB, 
and IIA pack tightly to form an enlarge head for the molecule whereas the extended tail is 
constituted by subdomain IIB, IIIA, and IIIB (Carter et al., 1989). BSA and HSA share 
about 80% primary sequence identity with each other (Peters, 1985). This result implies 
that BSA and HSA are homologous proteins which might have very similar biological 
functions. 
 
Figure 1.3: The tertiary structure of HSA. It has three domains and each domain 
consists of two subdomains which refer as (IA, IB), (IIA, IIB) & (IIIA, IIIB) 
respectively (Carter et al., 1989; reproduced with permission of the publisher). 
 8
The most interesting property of serum albums is the high affinity with various 
kinds of ligands or negatively charged molecules which are located in different binding 
regions in serum albumins. Kragh-Hansen has proposed a number of binding regions on 
the albumin molecule as shown in Table 1.1. The most outstanding feature of the 
albumin-ligand interactions is the presence of a few high affinity binding sites and a 
number of low affinity binding sites that interact with various kinds of ligands such as 
fatty acids, metals, etc (Kragh-Hansen, 1981).  
Compared to the proposed BSA-ligand binding studies, the primary binding 
regions of HSA have been demonstrated to be mostly located in subdomain IIA and IIIA 
of the molecule. Many ligands, for example tryptophan, fatty acids and bilirubin are 
found to interact preferentially in those regions at IIIA and IIA sites respectively (He and 
Carter, 1992). These results are in accordance with Kragh-Hansen proposal. 
Binding Region Domain High Affinity Binding Site 
1 III Fatty Acids 
2 II or III Tryptophan, Octanoate 
3 II Bilirubin 
4 N-terminal end Cu2+, Zn2+ 
5 II Haemin 
Table 1.1: Binding regions of BSA and its binding ligands. 
Spectral and titrimetric studies have showed that the binding of copper (II) ions 
with bovine serum albumin is on a unique and well-defined binding site at its N−terminus. 
The binding site is composed of the first three amino acids Asp−Thr−His− (D−T−H−) 
from the amino terminal end of BSA molecule. It corresponds to the binding region 4 as 
mentioned in Table 1.1 (Peters and Blumenstock, 1967). A second Cu2+−binding site has 
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been suggested by isothermal titration calorimetry (ITC) data that shows that additional 
Cu2+ ions likely bind to a free Cysteine site (a free thiol) in the BSA molecule (Zhang et 
al., 2000; Zhang and Wilcox, 2002). NMR, ESR, visible spectroscopy and X-ray 
crystallography have demonstrated that metals (e.g. Cu2+ and Ni2+) are coordinated in the 
N-terminus of BSA, HSA and other serum albumins that have an N-terminus X−X−His 
sequence in a square planar configuration as indicated in Figure 1.4 (Harford and Sarkar, 
1997).  
Albumins that lack histidine at position 3 in N-terminus sequence have a much 
lower affinity for Cu2+ binding (Peters, 1984). HSA, BSA and RSA all have the histidine 
in the same position 3 and they bind with Cu2+ specifically. Dog serum albumin which 
has a tyrosine in position 3, lacks the specific Cu2+−serum albumin binding site (Harford 
and Sarkar, 1997). This result demonstrates that the third residue histidine in N-terminus 
of serum albumins seems to play an important and specific role in copper binding. 
N
NH
C
H2
CH
(-)N
C
CH
(-)N
CCH
NH2
R1
CONHR
O
R2
M2+
O
 
                                    
M = Cu, Ni 
 
Figure 1.4: The square planar coordination of the metal ions (Cu2+ and Ni2+) 
interact with BSA, HSA and other serum albumins (Zhang and Wilcox, 2002). 
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The formation of thiomolybdates in the ruminant environment has been 
recognized as an antagonist toward copper binding, and a major cause of the copper 
deficiency that occurs in cattle (Clark and Laurie, 1980). The thiomolybdate ions 
including tri-thiomolybdate and tetra-thiomolybdate are involved in the copper 
antagonism behavior. These TMs interact with copper in ruminants to cause copper 
deficiency. A ternary complexion between Cu2+, BSA and TMs has been suggested that 
the binding  between TM and Cu2+−albumin, or between Cu2+ and TM−albumin will be 
initiated rather than Cu2+−TM, because a Cu2+−TM complex forms an insoluble product 
(Quagraine and Reid, 2001). This provides a chemical basis to study the interactions 
between BSA, Cu2+ and thiomolybdates. 
 
1.2.2. Previous Studies on Bovine Serum Albumin 
X-ray crystallographic studies on BSA have been attempted previously by another 
research group in Department of Chemistry at the University of Saskatchewan (Thome, 
2001). In the Thome studies, the initial crystallization attempt did not produce any 
crystals. So, he purified the protein that was purchased from the supplier using size 
exclusion chromatography to collect the purest fractions. The purity of BSA was verified 
by SDS-PAGE and the concentration of BSA was determined by Bradford Assay (Thome, 
2001). 
The protein concentration used for BSA crystallization trials was mainly             
10 mg/ml. The hanging drop diffusion method was applied to grow BSA crystals at room 
temperature and 14°C.  However BSA crystals only appeared at room temperature. The 
crystallization conditions of BSA were 50 – 65% Saturated Ammonium Sulfate with        
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50 mM potassium phosphate buffer (pH 5.6 – 6.6). The BSA crystals took over 2 months 
to form and their sizes were no larger than 0.4 mm in the largest dimension. Addition of 
the salts such as NaCl, KCl or MgCl2 in the crystallization trials reduced the growth time 
of BSA crystals, large crystals typically formed in 3 – 4 weeks. BSA crystals were also 
found in the presence of NiCl2 or CoCl2 as an additive in the crystallization trials (Thome, 
2001). 
Two BSA crystals were sent to University of Calgary for conducting X-ray 
diffraction experiment at room temperature. Both crystals were diffracted with a 
maximum resolution of about 8 Å. The space group of BSA crystals is a primitive 
hexagonal, P6, with cell dimensions of a = 148.24 Å, b = 148.24 Å and c = 356.70 Å;      
α = 90°, β = 90°, γ = 120°. Another two BSA crystals were prepared for X-ray diffraction 
studies on the in-house diffraction system at the Department of Biochemistry, University 
of Saskatchewan. The results showed that no diffraction patterns were recorded. For 
crystals sent to both places, they were crystallized under similar conditions (10 mg/ml 
BSA, 56 – 57% SAS with 50 mM potassium phosphate buffer at pH 5.6 or 5.8). The only 
difference was the BSA crystals that were diffracted on the in-house facility were 
crystallized in the presence of salts, NiCl2 or CoCl2 (Thome, 2001). 
Five BSA crystals which were grown in the presence of different salts (NaCl, KCl, 
MgCl2, NiCl2 or CoCl2) were frozen by the cryo-oil, Paratone-N in order to conduct X-
ray diffraction experiments at low temperature on the in-house diffraction system at the 
Department of Biochemistry, University of Saskatchewan. The results showed that none 
of the BSA crystals were diffracted and ice rings were observed. Therefore, Paratone-N 
was not considered as an appropriate cryo-oil to flash cool BSA crystals (Thome, 2001). 
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In summary, BSA crystals that crystallized under SAS/K-PO4 condition were 
diffracted to 8 Å at room temperature, but at low temperature no diffraction patterns were 
collected due to inappropriate cryoprotectant was chosen. So, at such resolution, the only 
information could be colleted was the crystal symmetry and its unit cell dimensions. As a 
result the three-dimensional structure of BSA still remains unknown.  
 
1.2.3. History, Structure and Properties of Thioredoxin-2 
Thioredoxin (Trx) is a ubiquitous and multifunctional small protein, having an 
active site of conserved amino sequence: −Cys−Gly−Pro−Cys− (−CGPC−). It behaves as 
an electron transporter containing a disulfide bridge (−S−S−) in its oxidized form (Trx-S2) 
and a dithiol in its reduced form (Trx-(SH)2 ); both forms are catalytically redox-active 
(Holmgren, 1985). There are a variety of roles played by different thioredoxins. For 
instances, Trx in plant is known to regulate photosynthetic enzymes in the chloroplast by 
light via ferredoxin (Bunchanan, 1991).  Nevertheless, apart from a few exceptions, most 
thioredoxins have the highly conserved sequence –CGPC– located in their dithiol/ 
disulfide active site (Arner and Holmgren, 2000). The redox reaction that is catalyzed by 
thioredoxin reductase is shown below (Holmgren, 1981; Holmgren and Bjornstedt, 1995): 
    
 
     Thioredoxin Reductase 
 
Thioredoxin-S2 + NADPH + H+                             thioredoxin-(SH)2 + NADP+ (1) 
 
 
 Trx-(SH)2 + protein-S 2                                                 Trx-S2 + protein-(SH)2          (2) 
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The oxidized form of Trx is reduced by NADPH and thioredoxin reductase (TrxR) 
to form Trx-(SH)2 and through the reversible oxidation of the Trx-(SH)2 active site dithiol, 
to a disulfide again (Trx-S2). The thioredoxin, NADPH and thioredoxin reductase 
together form a system called “The Thioredoxin System”.  
The main function of thioredoxin is to reduce the disulfide bonds of target 
proteins to change the conformation and activity of these proteins. The active form of 
thioredoxin is Trx-(SH)2, the two cysteines at the active site are in the thiol form. The 
Trx-(SH)2 behaves as a reducing agent to reduce disulfide bonds in the target proteins. 
After the reduction of the target proteins, the two cysteines form a disulfide bond between 
them. The oxidized form (Trx-S2) can be reduced by the enzyme TrxR accompanied with 
NADPH. The mechanism of protein disulfide reduction catalyzed by the thioredoxin 
system is schemed as below (Arner and Holmgren, 2000; Holmgren, 1981; Holmgren, 
1989; Minarik, 1997): 
 
     Thioredoxin reductase         Thioredoxin          Protein 
 
 
NADPH  FAD   TrxR-(SH)2          Trx-S2  P-(SH)2 
  
NADP  FADH2    TrxR-S2         Trx-(SH)2  P-S2 
 
Figure 1.5: The reaction scheme of thioredoxin catalyzed protein disulfide reduction. 
 
Thioredoxin can be described as a hydrogen donor or disulfide reductase. It can 
also function as a regulatory protein to regulate the thiol-disulfide status of the proteins. 
Thioredoxin is involved in many biological activities such as an antioxidant (Yoshida et 
al., 2003), cofactor (Masutani et al., 2004) and growth factor (Oblong et al., 1994). It can 
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activate and regulate the DNA binding transcription factor NF-κB, and bind with various 
proteins (Powis and Montfort, 2001). 
Thioredoxins have been isolated from different prokaryotic and eukaryotic species 
including mammals, plants, bacteria and yeasts. According to Protein Data Bank, the 
crystal structures of several thioredoxins from Anabaena, Bacillus acidocaldarius, 
Chlamydomonas reinhardtii, E. coli, human, Spinach chloroplast and Trypanosoma 
brucei brucei have been solved by X- ray crystallography. All of them have similar 
conformation, disulfide geometry, and share the common conserved active site −CGPC−. 
Thioredoxins that share the highest sequence similarity with H. pylori Trx 2 are Spinach 
chloroplast (28%), and E. coli (29%). One of them can be used as a search model for 
solving the unknown thioredoxin structure by molecular replacement phasing method. 
In order to understand the common features of thioredoxin, Trx-m from Spinach 
chloroplast (Capitani et al., 2000) can be used as an example. The crystal structure of 
Trx-m has a conserved active-site sequence –Cys–Gly–Pro–Cys– (–CGPC–) and shows 
the highly similar tertiary structure among thioredoxins. It shows that Trx is a protein 
composed of a β-sheet containing 5 parallel and antiparallel strands that forms the core of 
the molecule, and, flanked by four α-helices displayed on the external surface (Figure 
1.6). 
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Figure 1.6: The crystal structure of Trx-m (Spinach Chloroplast) shows the 
molecule composed of a five-stranded β-sheet and surrounded by four α-helices, 
and, active-site sequence –CGPC–. This structure is highly similar to most 
thioredoxins (Capitani et al., 2000; reproduced with permission of the publisher). 
 
The thioredoxin I am currently working on is from the gram-negative bacterium 
Helicobacter pylori (H. pylori) found in the stomach. H. pylori is a spiral shaped 
bacterium identified as the cause of persistent gastric inflammation in human stomach 
(Israel and Peek, 2001; Lamarque and Peek, 2003) and damages duodenal tissue resulting 
in peptic ulcer diseases such as duodenitis and duodenal ulcer and gastric malignancy 
(Walker and Crabtree, 1998).  H. pylori has a direct relationship with the activating of the 
oxidative stress pathway to stimulate the formation of reactive oxygen species such as 
superoxide radicals that are associated with the inflammatory response. Eventually, the 
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production of oxygen species results in oxidative damage to gastric mucosa and a 
predisposition to gastric cancer (Shirin et al., 2001).  
 H. pylori (strain 26695) has a circular genome of 1,667,867 base pairs and 1590 
predicted coding sequence. Among all these sequence, there are two encoding genes that 
are identified as thioredoxins which are Trx A or Trx-1 (HP0824) and Trx or Trx-2 
(HP1458) (Tomb et al., 1997). The molecular weight of Trx-2 has been estimated about 
11.7 kDa with 104 amino acids (Baker et al., 2003). The two thioredoxins only show 
33% primary sequence identity with each other by using sequence alignment software 
“Blast 2” to compare them (Tatusova and Madden, 1999). This result is comparatively 
low although they are the only two genes to encode the thioredoxin in H. pylori 
bacterium. Trx 1 has conserved motif –CGPC– but Trx 2 has unusual motif –CPDC–. 
This suggests that they may have different roles in the cell (Filson et al., 2003).  
 
1.3. Protein Purification and Characterization 
1.3.1. Purification Methods and Strategies 
Microorganisms such as Escherichia coli (E. coli) can be used to produce various 
kinds of proteins in a biological laboratory. This protocol is popular because it shows 
good efficiency and high reproducibility (Higgins and Hames, 1999). Once a protein has 
been overexpressed, cell disruption is employed to release the proteins from the 
organism’s cytoplasm. Purification steps are then required to purify the proteins. The 
purified proteins can be characterized and analyzed to ensure that their purity and 
homogeneity are suitable for crystallization experiments. 
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Cell disruption is a strategy for isolating and extracting proteins from 
microorganism cells. In order to liberate the proteins from the cells in a soluble form, the 
intracellular compartments have to be broken in an appropriate buffer where proteins will 
be stable. The principle of this method is to not destroy or denature the proteins in terms 
of their structure, activities and functions. A number of methods have been established 
and applied including sonication, glass bead vortexing, enzyme digestion, osmotic shock 
or detergent lysis. Sonication is one of the most common cell disruption methods 
applicable to many microorganism sources including E. coli. In this method, a sonicator 
with an appropriate frequency is employed. This works by generating vibrations that 
cause mechanical shearing of the cell wall so that proteins will be released from the cell 
(Bollag et al., 1996). 
Precipitation of proteins by salts, organic solvents, and high molecular weight 
polymers or by altering the temperature or pH of the solution is an effective way for early 
protein purification. Precipitation by addition of a neutral salt is the most widespread way 
to fractionate proteins by the salting-out effect. The salting-out effect is due to the high 
salt concentration. It can be considered as the competition between salt ions and protein 
molecules for free water molecules. As the salt concentration increases, salt ions 
increasingly deprive the protein molecules of their needed solvent molecules. This causes 
the protein molecules to associate with one another until an aggregate or precipitate is 
formed. 
The most common salts used are ammonium sulfate and sodium sulfate due to 
their high solubility, harmlessness to proteins and low cost. Organic solvents such as 
ethanol or acetone can be added into protein solutions to decrease the solubility of the 
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protein by reducing the dielectric constant of the medium. Low concentration PEG 6,000 
and PEG 20,000 are the most frequently used organic polymers; the mechanism is similar 
to that for organic solvents.  
Thermally stable proteins such as canavalin can be heated up to high temperatures 
to achieve purification without denaturation. This heat precipitation treatment is an 
alternative way to purify proteins because most proteins will be denatured and can be 
separated by centrifugation. Adjustments to pH can be another way to purify proteins. 
Proteins have isoelectric points (pI) in certain narrow pH ranges, so that the pH can be 
optimized to lower the solubility of the protein of interest, because the protein has 
minimum solubility at its isoelectric point. Precipitation at low temperature e.g. 4°C is 
generally required to avoid protein denaturation (McPherson, 1998). 
The purification of proteins by various chromatography techniques are standard 
laboratory protocols. Chromatography is an extremely efficient separation technique to 
separate sample components (proteins) between stationary phase (absorbent) and mobile 
phase (buffer) by depending on differential column partitions. Chromatography systems 
can be classified into a few types according to their interaction between the absorbent and 
the sample components. A summary of various types of chromatography used for protein 
purification is shown in Table 1.2 (Janson and Ryden, 1998): 
 Chromatography Type Molecular Property Exploited 
1 Affinity Biological affinity 
2 Hydrophobic Interaction Polarity 
3 Gel Filtration or Size Exclusion Size and shape 
4 Immobilized Metal Ion Affinity Metal binding 
5 Ion Exchange Net charge 
Table 1.2: Chromatography and separation parameters used for protein purification 
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For example, ion-exchange chromatography has a stationary phase where 
ionizable function groups are attached to the stationary phase through chemical bonding. 
These functional groups (fixed ions) located on the stationary phase carry another kind of 
ion (so-called counterion) where the charge is opposite to the functional groups. When 
retention occurs, proteins will displace these counterions and bind with the fixed ions 
through electrostatic interactions. As the salt concentration in the buffer (eluent) increases, 
the binding affinity between the fixed ions and the proteins will be reduced. In elution, 
the salts will displace proteins, due to the greater affinity of the fixed ions for the salts 
than the proteins. The proteins are eluted from the chromatographic column, and 
separation of the proteins can be achieved (Rossomando, 1990). 
 
1.3.2.  SDS Gel Electrophoresis and Purity Determination 
Polyacrylamide gel electrophoresis (PAGE) is an essential procedure used in the 
biological laboratory as an analytical tool to determine the molecule weight and purity of 
a protein. It provides a platform to analyze multiple samples simultaneously and multiple 
components in a single sample. The gel used does not chemically interact with 
biomolecules during electrophoresis.  
Protein electrophoresis depends on the differences in shape, charge density and 
size of the proteins. Proteins are charged at any pH other than their isoelectric point (pI), 
thus the charged particles will migrate toward the electrode of opposite sign under the 
influence of an external electric field. Prior to electrophoresis, protein samples are heated 
in boiling water for 2 – 5 minutes in a sample buffer containing sodium dodecylsulfate 
(SDS). This hot ionic detergent is used to dissociate and unfold protein molecules and it 
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can tightly bind with proteins to confer a uniform negative charge on all of the proteins, 
so that in the electric field, the proteins will migrate toward the anode solely as a function 
of protein molecular weight (Rosenberg, 1996).  
In electrophoretic separation, acrylamide is used as a medium to separate proteins 
according to their sizes. The movements of electrically charged particles are retarded by 
interactions with the surrounding gel matrix. The pore sizes formed in the gel are 
inversely proportional to the concentration of acrylamide, so individual gels can be 
prepared to allow certain molar masses of proteins to be analyzed. In summary, the 
higher the percentage of polyacrylamide gel, the smaller the pore sizes, therefore lower 
molecular weight of protein is more suitable to be characterized (See Table 1.3).  
 
[Acrylamide] %(w/v) Range of Separation for Protein (kDa) 
5 > 1000 
8 300 – 1000 
12 50 – 300 
15 10 – 80 
20 5 – 30 
Table 1.3 Range of separation of proteins in SDS-PAGE of different acrylamide 
concentrations (Sheehan, 2000). 
 
The fundamental principle of gel formation is the polymerization of acrylamide 
via free radical and chemical cross-linking. Polyacrylamide gels are composed of two 
chemicals, acrylamide monomer and N, N'-methylene bisacrylamide (BIS). The reaction 
is initiated by ammonium persulfate (APS) and catalyzed by N,N,N’,N’-
tetramethylethylenediamine (TEMED) to provide free radicals. The acrylamide 
monomers are polymerized to form long chains and the BIS molecules, where 
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incorporated, provide cross-links between the chains. This forms a regular matrix with 
"holes" that serve as pores in the polyacrylamide gel (Harris and Angal, 1989).  
Once the protein samples have been separated in the gel matrix, the next step is to 
locate the position of each sample, therefore, staining is required. Proteins are usually 
stained with Coomassie Blue. It is a non-polar sulphated triphenylamine dye with 
detection limit of 200 ng for proteins. When it binds to the protein, a blue color will be 
displayed and maintained during electrophoresis (Garfin, 1990; Sheehan, 2000). 
The electrophoresis method used is the discontinuous system, where different pHs 
are used to increase the resolution of polyacrylamide gel electrophoresis. In this system, 
two gels, the stacking gel and resolving gel are used, and their pH are held at ~ 6.9 and    
8 – 9 respectively. The stacking gel has a lower gel concentration (~ 3 – 5 %) and neutral 
pH compared to resolving gel. It is used to introduce the sample and build up the sample 
at the interface between the staking and resolving gels to prevent diffusion of sample 
bands. The resolving gel or so-called separating gel has a higher acrylamide 
concentration and is used to separate sample components. Tris-glycine at pH 8 – 9 is used 
as a running buffer to mobilize the sample in the gel electrophoresis system.  
 
1.3.3. Dialysis 
Dialysis is a separation process of substances driven by the concentration gradient 
and their varying diffusion rates through a semi-permeable membrane. It has been 
designed for desalting or buffer changing. Dialysis is widely used in the preparation and 
purification of macromolecules to remove or exchange low molecule weight impurities, 
salts, solvent components and contaminants. It provides a means to change the solution 
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for a protein sample by exchanging small molecules while retaining the macromolecules.  
It involves the equilibration of two solutions across a semi-permeable membrane with a 
size limitation. The membrane itself is made of cellulose acetate and is somewhat 
chemically inert and will not bind with the protein samples (McPhie, 1971). 
In dialysis, the protein solution is placed inside a dialysis bag or tube. The protein 
solution is then dialyzed against several changes of the desired final buffer over a 24 hour 
period. The dialysis bag and tube are commercially available, and the varieties of the 
molecule weight cut-off (MWCO) point are ranged from 100 to 300,000 Daltons 
(Spectrum Laboratory, Inc.). The molecules that are smaller than the specific molecular 
weights can freely pass through the membrane but larger molecules are prevented from 
passage. Normally 3,500 and 10,000 Daltons membranes are used for protein dialysis. 
  
1.3.4. Dynamic Light Scattering and Homogeneity Determination 
Dynamic light scattering (DLS) is a non-invasive solution characterization 
technique that has been employed to study the nucleation and growth of crystals in 
protein solutions (Juarez-Martinez et al., 2001). This technique has been exploited to 
investigate crystal formation by screening stock solutions for any aggregation prior to 
crystallization trial set-up (Protein Solutions, Application Notes).  
Dynamic light scattering is used to measure and monitor intensity fluctuations in 
scattered light as a function of time. This technique is one of the most popular methods 
used to determine the hydrodynamic radius (Rh) of sub-micron sized molecules such as 
proteins. The hydrodynamic radius is the effective size of the molecule as they are 
undergoing constant diffusion or so-called Brownian motion in the solution. The 
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measured intensities caused by the movement of protein particles in the solution are used 
to determine the diffusion coefficient and then calculate the hydrodynamic radius of the 
protein molecules. Hence, the polydispersity and molecular weight of the protein sample 
can be estimated (Protein Solutions, Lakewood, New Jersey).  
The %polydispersity is used as an indicator to determine the homogeneity of a 
protein solution. It can be determined according to hydrodynamic radius (unit: nm) and 
polydispersity (unit: nm) of the protein particles where  
%polydispersity = (Cp / Rh) x 100% 
The polydispersity (Cp) is a value used to represents the standard deviation of a 
molecular weight distribution (or size distribution) of the protein particles (Dynamic 
software application notes). 
Empirical results demonstrate that monodispersed protein samples have higher 
crystallizability than those which are polydispersed. Homogenous protein samples will 
initiate crystal nucleation and growth, so that crystals can be formed (Ferre-D'Amare and 
Burley, 1994; Ferre-D'Amare and Burley, 1997). It has been suggested that purity is not 
the only factor to be considered in protein crystallization, homogeneity of the protein 
sample is an important consideration as well (Ducruix and Giege, 1992). When the size 
distribution of a protein sample obtained from dynamic light scattering is narrow and 
monomodal, this indicates that crystals possibly could be formed. If the size distribution 
shown is either bimodal or trimodal or polydispersed (Figure 1.7), it seems that crystals 
are rarely formed, because aggregates are detected (Zulauf and D' Arcy, 1992). 
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Figure 1.7: The size distributions of proteins that explain the protein 
crystallizability. If the size distribution of a protein is a narrow monomodal, 
protein crystals might form. If the size distribution of a protein is a broad bimodal, 
the presence of aggregates is indicated, protein crystals are unlikely to form 
(Zulauf and D' Arcy, 1992).  
 
The homogeneity of a protein sample solution can be identified through the 
%polydispersity. The general guideline is that a monodispersed and homogenous sample 
solution is one that has %polydispersity less than 15% as shown in DLS experiment. If 
the %polydispersity is more than 30%, the sample solution is considered as polydispersed 
and not homogenous. If the %polydispersity is 15 − 30%, the sample solution shows the 
characteristic of moderate polydispersity (Protein Solutions, Instrument User’s Guide). 
Narrow Monomodal Bimodal 
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1.4. PROTEIN CRYSTALLIZATION 
1.4.1. Principle of Protein Crystallization 
Crystallization of macromolecules is the limiting step in protein crystallography. 
The principles of crystallization of macromolecules are analogous to those of small 
molecules. Protein molecules themselves are distinctive, composed of approximately 
50% solvent though this may vary from 30 − 78% (Matthews, 1985). Proteins are labile, 
fragile, and sensitive to external environments owing to their high solvent content, and 
the weak binding energies between protein molecules in the crystal (Littlechild, 1991). 
The only optimal conditions suitable for their growth are those that cause little or no 
perturbation of their molecule properties. As a result, crystals must be grown from a 
medium where temperature is constant and within a broad range of pH 3 – 10 because 
complete hydration is an essential factor for maintaining the crystal structure integrity. 
There are many differences between small molecule crystals and protein crystals. 
In general, small molecule crystals are grown to large dimensions (1 – 100 cm), they are 
physically hard, brittle, easy to handle, have strong optical properties and can diffract X-
rays intensively. This is because the small molecule crystals exhibit firm lattice 
interactions and highly ordered lattice arrangements within the crystal. In comparison, 
protein crystals are generally smaller in size (1 – 1000 µm), soft and crushed without 
difficulty, and with weak crystal forces. These kinds of crystals, which will redissolve if 
dehydration occurs, have weak optical properties and diffract X-rays weakly. They are 
also temperature sensitive, because protein solubility alters as a function of temperature. 
In theory, as the temperature rises, the solubility of proteins increases, thus, no crystals 
are formed or crystals will be redissolved (Bergfors, 1999). When crystals are exposed to 
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long-standing X-ray radiation, it can cause extensive damage of crystals. This is due to 
the weak lattice forces within the crystal structure (McPherson, 1982) and the X-rays can 
produce sufficient free radicals to cause specific chemical changes on the protein 
molecules such as the breaking of the disulfide bonds (Ravelli and McSweeney, 2000). 
The crystallization of proteins from solution is a reversible equilibrium 
phenomenon. It contains three stages: nucleation, growth and cessation of growth. The 
formation of crystals is due to the decreasing free energy of the system while the 
formation of many new chemical bonds simultaneously outweighs the decreasing entropy 
of the system in order to grow a highly organized internal structure. In other words, the 
free energy of the system is reduced to its energy minimum and a thermodynamic driving 
force exists that provides for the ordering process of crystals (McPherson, 1982). 
The basic strategy of producing protein crystals is to generate a certain degree of 
supersaturation in the solution. At the equilibrium point, the amount of protein molecules 
entering the solution is the same as the amount of protein molecules leaving the solution. 
This is referred to as the solubility limit of a protein. When the solubility of a protein is 
below this limit, the solution is undersaturated. If the solubility is equal to the limit, the 
solution is saturated. Crystals can grow only when the solubility exceeds the limit. Every 
protein has a unique solubility. Decreasing the solubility of the protein is the most 
effective way to create supersaturation for crystal growth. Only in a non-equilibrium 
supersaturated solution, can a crystal grow. Supersaturation can be achieved by different 
approaches including altering the buffer pH, temperature, protein concentration, dielectric 
constant of the medium, and precipitant concentration in order to change the protein 
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solubility to reach the condition that lies just above the supersaturation region 
(McPherson, 1998). 
 
 
Figure 1.8: The solubility phase diagram for crystallization from solution. 
 
A classical explanation of crystal nuclei formation and growth can be visualized 
by the two-dimensional solubility phase diagram shown in Figure 1.8. The solubility 
curve divides the concentration space into undersaturation and supersaturation regions. In 
the undersaturation zone, under the solubility curve, the protein will never crystallize. 
Above the solubility curve, this region can be subdivided into three zones according to 
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level of saturation and the kinetics required for reaching equilibrium. In the precipitation 
zone, excess protein does not remain in solution and exists as an amorphous precipitate. 
The formation of precipitate implies that no crystals will form. Before a crystal can grow 
in solution, nucleation has to occur. Nucleation is the beginning of crystal formation. In 
this process, the nucleus of sufficient size must be formed to initiate aggregation in an 
ordered manner. In the nucleation zone or labile zone, there is a high probability that 
critical nuclei will form spontaneously in solution because this corresponds to an 
increased energy state of the system. In fact, the energy or probability barrier to the 
formation of the first nucleus allows the creation of a supersaturated solution. If the 
degree of aggregation is too high, the solution will be oversaturated and a precipitate will 
be formed. If the degree of aggregation is adequate, stable nuclei can continue to grow to 
larger size without forming precipitate, and then the crystal can be formed and grown. 
The metastable zone is ideal for the growth of crystals without nucleation of new crystals. 
In this zone nuclei will not form, but if nuclei are present or seed crystals are introduced 
then crystals may grow. When a crystal grows to a certain size, it will stop growing 
spontaneously (Ducruix and Giege, 1992). 
The crystallization of proteins is influenced by a numbers of factors, and each 
protein is unique. It is not possible to envisage the conditions that can cause the 
crystallization of a protein.  The various parameters that affect crystallization are not 
independent of each other and their interrelation may be complicated and difficult to 
distinguish (McPherson, 1998). Finding a rational guideline to crystallize 
macromolecules successfully is not an easy task. The only way to do this is to identify the 
important components and refine each of them individually. In general, precipitant type 
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and concentration, buffer type and pH, temperature, and sample concentration are the 
most important factors for protein crystallization. They are considered first when 
performing crystallization experiments. Each parameter is manipulated independently to 
determine its effect on crystallization. Table 1.4 summarizes the factors which effect the 
crystallization of macromolecules. 
 
Physical Chemical Biochemical 
Temperature/Temperature 
fluctuation 
Buffer pH Purity of macromolecule 
Vibration/Sound/Mechanical 
Perturbation 
Precipitant Type Substrate/Coenzyme/Ligand/
Inhibitor/Effectors 
Time/Rate of growth Precipitant Concentration Inherent Symmetric of the 
Macromolecule 
Equilibrium Rate Macromolecule 
Concentration 
Biochemical Modification 
Dielectric Constant of 
Medium 
Ionic Strength Genetic/Post-transitional 
Modification 
Viscosity of Medium Additive/Specific Ions Isoelectric Point 
Pressure Metal Ions Macromolecule Stability 
Gravity Detergent/Surfactant Aggregation state of 
Macromolecule 
Homogeneity of 
Macromolecule 
Degree of Supersaturation Storage time of 
Macromolecule 
Electric/Magnetic Fields Reducing/Oxidizing 
environment 
Source of Macromolecule 
Volume of crystallization 
sample drop 
Present of amorphous 
substances/impurities 
Proteolysis/Hydrolysis 
Methodology/ Approach of 
crystallization 
Cross-linker Microbes contamination 
Table 1.4: Important factors affecting macromolecular crystallization 
(McPherson 1990; McPherson 1998). 
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1.4.2. Kinetic and Thermodynamic Principles of Crystallization 
1.4.2.1. Protein Crystal Nucleation 
Protein crystallization is comprised of three stages: nucleation, crystal growth and 
cessation. Nucleation is a fundamental step in the crystallization process. It takes place 
when the aggregate reaches a critical size at a decisive supersaturation level. The 
nucleation rate of crystallization can determine the number of crystals that may grow. In 
principle, the nucleation of protein crystallization occurs at moderate supersaturation 
levels in the solution. This level corresponds to the region lying within the labile zone 
according to the phase diagram (Figure 1.8). Protein crystal nucleation requires a higher 
degree of supersaturation than the growth of existing crystals. Nucleation occurs only in 
the labile region whereas crystals can grow in both the labile and metastable region. At 
high supersaturation levels, uncontrollable rapid nucleation occurs. Consequently, 
numerous microcrystals will grow. Crystal showers will also be found at higher 
supersaturation levels when no appropriate aggregate is formed. At low supersaturation 
levels as indicated in Figure 1.8, which is close to and above the solubility curve 
boundary, no nucleation will be initiated (Luft and Detitta, 1999; Przybylska, 1989). 
The understanding of the manner of crystal nucleation is indispensable to 
comprehend the effect of various parameters on nucleation for crystal formation. 
Parameter investigations for ribosomal subunit crystals have illustrated that protein purity, 
precipitant type, buffer pH and temperature are classified as essential parameters for 
controlling crystal growth (Yonath et al., 1982). Other important factors include the 
dynamics of the initial equilibration. The control of vapour equilibration experiments of 
hen egg white lysozyme have been conducted to demonstrate that as the equilibrium time 
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increased, fewer and larger crystals were produced. The experiment displayed that the 
lower the rate of evaporation, the lower the nucleation rate. The longer the time required 
to approach critical supersaturation, the bigger the crystals formed. Therefore, a linear 
relationship between crystal size and equilibrium time can be established (Gernert et al., 
1988). 
The best environment for the crucial size of nucleus formation is a high degree of 
supersaturation. The higher the supersaturation level (δFc (1)), the greater would be the 
thermodynamic driving forces to push the system toward equilibrium. This will favor 
nucleus formation, so the energy required for producing the critical nucleus will be 
smaller than at a lower supersaturation level (δFc (2)) as shown in Figure 1.9 (McPherson, 
1998). The number of growing protein crystals mainly relies on the rate of nucleation 
(Penkova et al., 2002). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9:  Diagram of the thermodynamic potential of a crystallization 
system required for forming the critical size of nuclei. 
 
 
1.4.2.2. Protein Crystal Growth and Cessation 
After the critical size of nuclei has been originated at the higher supersaturation 
level, the metastable zone is predicted as the optimum zone for crystal growth. It 
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represents the ideal condition for the growth of diffraction quality crystals. 
Thermodynamics and kinetics are two major aspects that have to be considered when 
discussing protein crystal growth because both small and macromolecule crystallizations 
must adhere to the fundamental laws of thermodynamics. Supersaturation is the thrust to 
drive crystal nucleation and growth. Thermodynamic theory illustrates that the 
equilibrium process of crystallization from a supersaturation solution is energetically 
favorable. The further the system is from equilibrium, the greater the degree of 
supersaturation and the greater the thermodynamic force would be to push the system 
toward equilibrium (McPherson, 1998).  
If nucleation occurs spontaneously, kinetic theory can be applied to determine the 
time scale of the process to take place, and the rate of nucleation and growth. The kinetics 
determines the time required to reach supersaturation and the equilibration of the protein 
solution with the precipitating solution in the reservoir. Protein droplet size and shape, the 
vapor pressure, the distance from the droplet to the reservoir are the variables to be 
considered as major kinetics aspects (Luft and Detitta, 1997; Ries-Kautt and Ducruix, 
1997). For instance, the larger the droplet, the longer the time it takes to reach 
equilibrium with its reservoir. Another example is the larger the distance that separates 
the droplet and reservoir, the slower the droplet equilibrates with the reservoir (Luft et al., 
1996). 
The main factor deciding the growth of protein crystals is the rate of transport of 
protein molecules moving to the existing crystal surface and the probability of protein 
molecules associating with the crystal lattices. The rate of protein growth (k) will be 
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dependent on either or both process mentioned above, so the rate of growth can be 
defined as  
k = Z x p.     (5) 
The equation (5) is the product of the rate of collision of protein molecules with a 
crystal per unit concentration and area (Z) multiplied by the probability of proteins 
associating with the crystal per collision (p). The quicker the crystal grows, the smaller 
the crystal formed and higher the number of crystals (Feher and Kam, 1985). 
As a result of limited research carried out in this field, the explanation about 
cessation of crystal growth is insufficient and remains unclear. However, the 
understanding of this phenomenon is still interesting and a lot of studies can be carried 
out. A hypothesis is proposed that crystal growth errors such as impurities incorporated 
into the crystal that affect the crystal surface are most probably the root cause 
accountable for the cessation of crystal growth (Feher and Kam, 1985). 
 
1.4.3. Crystallization Methods 
There are at least seven practical methods used for macromolecule crystallization 
including vapor diffusion, bulk crystallization, batch, free-interface diffusion, dialysis, 
temperature-induced, and seeding. Among these methods, vapor diffusion and 
microbatch (a new developed method from an old technique) are the most popular means 
being utilized by crystallographers to obtain macromolecule crystals. The method of 
vapor diffusion is undoubtedly regarded as the most widely employed approach for 
crystallization. Nucleation occurs when the sample concentration increases as the droplet 
volume decreases by hydration-driven mechanisms. This is induced by the equilibration 
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of water vapor between the sample droplet and the reservoir solution. The vapor diffusion 
technique is an ideal methodology for screening a broad spectrum of crystallization 
conditions. It can be used to optimize the size of crystals suitable for X-ray diffraction 
analysis. Vapor diffusion methods include hanging drop, sitting drop, sandwich, and 
capillary methods. The most common protocols are the hanging drop and sitting drop 
methods (McPherson, 1998). 
The hanging drop vapor diffusion method is an efficient means of screening 
crystallization parameters. The advantage of this method is that it requires only a small 
volume of droplet, which can be as low as 2 µL per experiment, so a minimum amount of 
sample is consumed for screening and optimization of the crystallization conditions 
(McPherson, 1998). The reason for the popularity of the hanging drop method is the ease 
of performing the experiment, only a 24 well-plate (such as Linbro or VDX plate), grease 
and cover slides are needed. The principle of this approach is straightforward, a drop 
composed of a mixture of macromolecule sample and precipitating solution is placed in 
vapor equilibration with a reservoir solution of precipitant and buffer. To start the trial, 
the precipitating solution composed of precipitant, buffer, additive, etc, is dispensed into 
reservoir. Then equal volumes of the sample and reservoir solution are mixed onto the 
surface of siliconized glass cover slide (Figure 1.10). The drop has a lower concentration 
of precipitant than the reservoir solution, so water or volatile chemicals will escape from 
the drop into the reservoir solution to achieve system equilibrium inside the reservoir. 
Eventually this causes the sample inside the drop to become more concentrated until the 
precipitating concentration in the drop is almost equivalent to the reservoir concentration. 
The major benefits of using the hanging drop method are relative ease of mounting the 
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crystal for X-ray diffraction experiments by inverting the cover slide with a pair of 
forceps. This method can be used to place multiple drops in each reservoir as well, thus 
saving time and material. 
 
 
 
 
 
 
 
Figure 1.10: The hanging-drop vapor diffusion method for protein crystallization 
(Hampton Research, 2001). 
 
Sitting drop vapor diffusion method is performed using a 96−well depression 
plate. One µL of protein solution and 1 µL of reservoir solution are mixed together at the 
top of a ledge (Figure 1.11). The plate is then sealed with sealing tape and placed inside 
the incubator for crystal growth. The basic principle of this method is quite similar to the 
hanging drop method but the differences are that 100 uL of reservoir solution is used 
instead of 1000 uL and the droplet is not hung but sits on the depression platform. The 
advantage of sitting drop is that it requires a small amount of material and is ideal for 
screening a great number of different conditions by using the different screening kits, for 
example the grid screens and crystal screens supplied by different companies such as 
Sigma, Hampton Research, and  Molecular Dimension. 
 
H2O 
Reservoir solution 
Coverslip is sealed 
with grease 
Protein and reservoir solution 
in 1:1 ratio are hung over 
reservoir solution 
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Figure 1.11: The sitting-drop vapor diffusion method for protein crystallization 
(Hampton Research, 2001). 
 
Microbatch method is another approach for rapid protein crystallization using 
micro-volumes of sample. The objective of this method is to reduce the consumption of 
sample by generating crystallization trials in tiny amounts. It is a new method developed 
from the oldest crystallization technique, “The Batch Method”. The batch method has 
been the conventional crystallization strategy for over 150 years (McPherson, 1991). The 
most famous example of a protein crystallized by this method is the crystallization of 
lysozyme (Forsythe et al., 1997). The principle is simple and the procedure involves the 
direct mixing of the unsaturated protein solutions with precipitating solution. The batch 
method alters the protein solubility and changes the dielectric properties of the medium to 
create a supersaturated environment to generate the crystal. This method has been revived 
by preparing the crystallization samples under oil (Figure 1.12). The typical final sample 
droplet volume is about 1 – 2 µL. The major advantages of this approach are automatic 
implementation in an efficient way, high accuracy, low sample consumption, time-saving 
H2O
Reservoir 
solution 
Protein and 
reservoir solution 
in 1:1 ratio 
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screening, and the sample can be protected from evaporation, contamination and physical 
shock by oil (Chayen and Stewart, 1992).  
 
 
Figure 1.12: The microbatch method for protein crystallization (Hampton 
Research, 2001). 
 
The fundamental distinction between the vapor diffusion and microbatch method 
is that the former is a dynamic system in which the conditions are changing throughout 
the whole crystallization process. Thus, there is little control over the experiment once the 
trial has been set up. The latter process is non-dynamic, the final concentration of the 
sample has been determined precisely at the beginning of the experiment. The 
crystallization condition can be maintained with minimum fluctuation for the normal 
crystallization period of about 1 – 3 weeks (Chayen, 1998).  
Other crystallization methods that have been employed include containerless 
crystallization (Chayen, 1996), crystallization in silica gels (Cudney et al., 1994) and  
crystallization under microgravity (Littke and John, 1984).  According to the BMCD 
database, vapor diffusion (62.7%), batch method (~12%) and seeding (5.47%) are the 
most highly employed methods of crystallization (Figure 1.13). 
Protein 
/Precipitant    
drop 
Oil 
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Figure 1.13: Bar chart showing the most commonly used crystallization methods. 
 
1.4.4. Important Considerations in Protein Crystallization 
Crystallization of proteins has involved a multiple parameters route to influence 
the nucleation, growth and cessation. There are some important aspects of protein 
crystallization that must be considered prior to performing protein crystallization 
(Blundell and Johnson, 1976; Ducruix and Giege, 1992; McPherson, 1990). Along with 
the physical and chemical issues, biochemical aspects of the protein have also to be 
examined carefully as these also effect the crystallization of proteins.  
In biochemical aspects, the purity is the first issue always considered. Impure 
protein crystals may contribute to the low resolution X-ray diffraction data, and then the 
protein structure will not be determined successfully. Purity in this case is defined as the 
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lack of any contaminant or impurity such as foreign proteins, dust particles, denatured 
proteins, microbes, and aggregates (McPherson, 1996). In general, the purity of proteins 
must be at least 90% before the beginning of the crystallization trials (Ducruix and Giege, 
1992). Homogeneity of the protein is another major concern for crystallization. If 
aggregates in protein solutions are detected using dynamic light scattering, then the 
protein will be less likely to crystallize (Zulauf and D' Arcy, 1992). Another factor that 
cannot be neglected is the protein itself.  For proteins that do not crystallize easily, it may 
be because they possess surface properties that do not promote the formation of crystal 
contacts. Sometimes although a protein can be crystallized, the diffraction resolution of 
the sample is not good enough for resolving the structure, so protein truncation, mutation, 
limited proteolysis and complex formation can be alternatives to get better quality 
diffraction crystals (Dale et al., 2003). 
In physical aspects, temperature and time are considered the major factors that 
influence the growth of protein crystals. Others like sound, vibration etc may have some 
disruptive effects which are not clearly understood (McPherson, 1982).   
The effect of temperature on protein solubility has been recognized as one of the 
major contributors to protein solubility. Experiments have showed that protein solubility 
is temperature dependent (Christopher et al., 1998). The most widely used temperatures 
for protein crystallization are 4 ºC and 20 ºC. A temperature-induced method has been 
reported as an alternative approach to crystallize macromolecules (Kitano et al., 1998). In 
this method, a protein crystallization plate was initially set up at 20 ºC. Once there were 
no crystals formed at 20 ºC after 3 months, the plate was incubated at 40 ºC for 30 
minutes. After that, the plate was cooled to 20 ºC and incubated at 20 ºC; crystals were 
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formed in 2 days. Another less valuable influence of the temperature effect is that crystals 
grown at two different temperatures may have differences in their morphology. As a 
crystallization technique, temperature control is easy and precise. This factor should be 
taken into account when crystallization is initialized. In general, it may be worthwhile to 
carry out all crystallization trials at two different temperatures if material quantities are 
sufficient. 
Time is another factor that affects crystallization, mainly attributed to the rate of 
growth of individual protein crystals. Some crystals may take a few days to a few weeks 
to grow while others may take a longer time to form the same size of crystal. As a rule of 
thumb, if the growth rate of crystals is minimized, large and defect free crystals will be 
grown. Manipulation of the growth kinetics of crystals is another approach that can be 
attempted even if it is not easy to achieve. The rate of growth is dependent on the level of 
supersaturation of the protein solution. For instance, the appearance of only microcrystals 
implies that the rate of equilibration is too fast. This suggests that the level of 
supersaturation is too high, therefore reduction in the level of supersaturation is desired 
(Heidnner, 1978; McPherson, 1998). 
In chemical aspects, precipitant type and concentration, pH, and buffer are the 
most crucial factors that dominate the process of crystallization among others factors 
such as the effect of adding additives, detergents or reducing agents (McPherson, 1990). 
Precipitating agents can be classified into four categories which are salts, organic 
solvents, long-chain polymers and non volatile organic alcohols/low molecular weight 
polymers. The representatives for the first class of precipitant are ammonium sulfate, 
potassium sodium tartrate, and sodium chloride. Ethanol and methanol are the typical 
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representatives of the second class of precipitating agents. Long-chain polymers consist 
of polyethylene glycol (PEG) 1,000, 3350, 4,000, 6,000, and 8,000. PEG 400 or PEG 600 
and MPD are representatives of the last category. Ammonium sulfate is the most popular 
precipitant, but polyethylene glycol from molecular weight 400 – 20,000 has become 
increasingly popular as a crystallizing agent (McPherson, 1976; McPherson, 1990). The 
advantage of using PEG as a precipitant is that it shares some characteristics with salts 
that compete for water, and exhibits a similar volume exclusion property to organic 
solvents that reduce the dielectric constant of the medium. For salt precipitants, there is a 
study which found that sodium malonate is an excellent precipitant alternative to all 
others salts that have been employed for protein crystallization. It has the advantage of 
high success rate and can serve as a useful cryoprotectant. The choice of precipitants is a 
trial and error procedure (McPherson, 2001).  
After precipitants, the pH and the crystallization buffer are the most important 
variables in protein crystal growth. As a general guideline in the protein crystallization, 
large single good crystals always show up within a narrow range of pH for a protein 
crystallized either by salt or organic solvent (Zeppezauer, 1971). The isoelectric point (pI) 
of a protein is the pH where the total net charges on a protein are equal to zero. At this 
point, protein solubility will be at a minimum therefore crystallization trials can be 
initiated in the range around this point (McPherson, 1982). If the pI is unknown, a pH 
range between 4.0 and 9.0 will normally give crystals. Therefore, this pH range should be 
tried at the beginning of crystallization experiments. Adequate control and monitoring of 
pH during crystallization is an essential step in the preparation of suitable buffers. The 
optimization of microcrystals in terms of their size and quality for X-ray diffraction 
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experiments can be conducted by fine pH adjustment. The buffer can be adjusted up to 
0.05 pH unit, and different types of buffer can be employed in parallel (McPherson, 
1995). 
Once initial crystals are obtained, the crystals can be optimized to improve crystal 
size or to extend the resolution limits. Additives including sugars, alcohols, cations, 
polyamines, detergents or surfactants, and dioxane are considered as useful chemical 
compounds that contribute positively toward protein crystallization (Sauter et al., 1999). 
For instance, detergents can play an important role in altering a polycrystalline state, 
promoting crystal clusters into single crystals, enhancing the diffraction ability and 
improving reproducibility of the growth of a crystal (Guan et al., 2001). β-Octyl- 
Glucoside has been examined for a number of proteins, RNA and protein-nucleic acid 
complexes. Experimental results demonstrated that it has positive effects toward crystal 
growth (McPherson et al., 1986a; McPherson et al., 1986b). Others examples include 
adding polyols such as glycerol to increase structure stability (Sauter et al., 1999; Sousa, 
1995),  or adding a reducing agent such as DTT, cysteine, β-mercaptoethanol or 
glutathione to maintain sulfyhydryl groups in a reduced state for preserving the activity 
and structural integrity of a protein (McPherson, 1998). 
 
1.4.5. Strategies and Approaches to Growing Crystals 
The advances in recombinant DNA technology make pure protein expression 
feasible. Thus, the crystallization of proteins becomes in demand. With the advent of 
commercially available sparse matrix screens, it has become trivial to set up 
crystallization trials covering a huge range of conditions.  
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There are several screening and optimization strategies that have been reported 
including randomized approaches such as sparse matrix (Jancarik and Kim, 1991), 
analytical approaches such as incomplete factorial (Carter and Carter, 1979), biological 
macromolecule database archives (Gilliland, 1988; Gilliland et al., 1994; Gilliland et al., 
1996), automated grid searches (Weber, 1990) and  rational approaches such as screening 
of protein isoelectric point (pI). Other approaches including reverse screening (Stura et 
al., 1994) and rapid screening (McPherson, 1992). All of these approaches are used to 
screen the initial crystallization conditions of the protein and can be used for optimization 
to produce large crystals.  
The sparse-matrix approach is the most popular and has been commercialized by 
Hampton Research (Crystal Screen 1 & 2), Emerald Biostructures (Wizard Screen 1 & 2) 
and Molecular Dimension (Personal Structure Screen 1 & 2). The screens contain 
numerous conditions with different types of precipitating agents, precipitant 
concentrations, buffers, pHs and salts. All three commercially available screening kits 
demonstrate similar outcomes with high yields of crystals in preliminary crystallization 
experiments (Wooh et al., 2003). Once initial crystallization conditions have been found, 
the next step is to optimize the crystallization conditions to give better crystals in terms of 
size and shape. Attempts should be made to obtain single crystals with a minimum 
dimension of at least 0.1 mm in each facet. The advantage of the sparse-matrix strategy is 
that less protein is consumed and fewer trials will be conducted compared to a systematic 
approach. The optimization strategies that are used include adding additives (Sauter et al., 
1999), detergents (Guan et al., 2001; McPherson et al., 1986a), non-ionic surfactants 
(Mustafa et al., 1998), and control of diffusion rate (Chayen, 1997).  
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It is quite often that microcrystals, twinned or multi-crystals are difficult to 
optimize to a single crystal. In these cases, one of the approaches that can be tried to 
obtain single crystals is seeding. Seeding can be used in combination with other 
optimization strategies to gain single large crystals. Indeed, seeding is a great tool to 
separate the process of crystal nucleation from the process of crystal growth. The first 
problem to tackle for seeding is to obtain a few crystals to serve as seeds. Otherwise 
seeding cannot be carried out. If seeds are present, then seeding protocols can be applied. 
There are three major types of seeding commonly used by crystallographers: 
macroseeding, microseeding, and cross-seeding (Bergfors, 2003). 
Seeding is a useful technique used for growing crystals by producing a seed-stock 
solution if spontaneous homogenous nucleation does not occur in the crystallization of 
macromolecules. It is generally believed that the nuclei will be initialized at the higher 
level of supersaturation labile zone (Stura and Wilson, 1991). Therefore, using seeding 
techniques, good quality crystal seeds are selected and introduced into the metastable 
zone from the labile zone. After seeding, the seeded crystals will continue to grow. The 
crystal growth conditions can then be optimized independently without the need to induce 
nucleation by the proteins themselves (Luft and Detitta, 1999). 
Macroseeding involves mature single crystals that can be handled easily and 
washed in a stabilizing solution or its mother liquor a few times, then transferred into 
another pre-equilibrated protein-precipitant drop (Stura and Wilson, 1992). The condition 
of the drop should be a condition expected to give crystal growth, which lies in the 
metastable zone of the phase diagram of protein-precipitant concentration. 
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Microseeding involves the transfer of submicroscopic seeds. The seeds 
themselves are quite small and hard to distinguish independently. Streak seeding is a kind 
of microseeding technique where an animal whisker is utilized to pick up seeds by 
touching an existing crystal. Next, seeds are transferred to the new pre-equilibrated 
protein solution drop by depositing them as a straight line and moving the probe across 
the drop, eventually crystals will grow up along the streak line. The shortcoming of this 
approach is the experimenter can’t control the number of seed crystals transferred. 
Another protocol for microseeding is the serial dilution method, where a few small 
crystals are selected and washed, and then the crystals are crushed so that a seed stock 
solution is prepared. Normally, the seed stock solution is serially diluted to 10-3 − 10-7 to 
avoid too many nuclei inside the solution. Each diluted seed solution is used to examine 
the best seed concentration for growing large single crystals by streak seeding method or 
addition of a small aliquot of seed solution (Stura and Wilson, 1990; Stura and Wilson, 
1991). 
Cross-seeding is another seeding technique, where a homologous protein of the 
target protein is chosen as seed crystals to commence growth in the crystallization 
experiment (Bergfors, 2003). Other less popular seeding techniques include feeding and 
microcrystal selection. Feeding involves more protein being added into the protein drop 
and the advantage of this technique is more protein available for growing the nuclei 
(Bergfors, 2003). The microcrystal selection technique involves removing tiny and excess 
crystals from the drop solution without disturbing the few good crystals  This method is 
quite convenient and does not require manipulation of the good crystals, which is 
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beneficial because during crystal manipulation, the crystals may be damaged (Han and 
Lin, 1996). 
Other less common practices used to make crystals grow larger including dilution 
method and decoupling nucleation method. The dilution method was developed to 
enhance the size of crystals using vapor diffusion protocols. This method requires that 
both protein and mother liquor in the crystallization drop are diluted to certain ratio (for 
example a dilution factor from 1 – 6), while the mother liquor in the well solution 
remains unchanged. The principle of this dilution method is same as the traditional vapor 
diffusion method, but since the concentrations of protein and mother liquor in the drop 
are diluted to n-fold, the crystallization requires a longer time to complete. This ultra-
small volume experiment showed that once the dilution factor is determined to an 
appropriate ratio by a trial and error process, the number of crystals formed will be 
significantly reduced. Fewer nucleation sites will be expected, thus the size and number 
of the crystals can be optimized in this protocol (Dunlop and Hazes, 2003). 
Decoupling nucleation and growth in the vapor diffusion method involves setting 
up the crystallization condition where crystals normally grow in a certain incubation 
period. Afterward, the coverslip with the drop is transferred over wells where the 
precipitant concentration is much lower and normally no crystals will be formed. 
Consequently, fewer and larger crystals will appear. The mechanism allows protein 
nucleation to be induced before any transferring to the lower degree of supersaturation in 
the droplet (metastable condition). The principle is to allow the protein to nucleate in 
labile conditions and grow continuously in metastable conditions (Saridakis and Chayen, 
2000). 
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1.5. PROTEIN CRYOCRYSTALLOGRAPHY 
1.5.1. Cryocrystallography Background 
Cryocrystallography or so-called low temperature X-ray diffraction methods have 
been reported since 1990 for macromolecule X-ray diffraction experiments. For small 
molecules, this technique has long been applied as well. Since 1990, the proportion of X-
ray diffraction experiments in macromolecular crystallography performed at cryogenic 
(near 100K) temperature has increased exponentially (Garman and Schneider, 1997). 
This approach has become an essential technique for crystallographic structure 
determination of biological macromolecules. Cryogenic techniques are now routinely 
applied in many laboratories for X-ray data collection on in-house facilities as well as on 
synchrotron sources (Garman, 2003).  
The most important advantage of applying this technique to macromolecular 
crystallography is the great reduction in X-ray induced radiation damage on crystals at 
low temperature. At room temperature, macromolecular crystals are susceptible to crystal 
damage that is caused by interaction between the molecules in the crystal and the X-ray 
beam. The energy of the X-ray beam will produce reactive radicals and provide energy to 
diffuse through the crystal to break the bonds between atoms in the crystal structure 
(Garman, 1999). Cryo-cooling data collection for macromolecule became popular 
because the diffusion rate of free radicals at low temperature is much lower than that at 
room temperature, thus radiation damage can be minimized (Garman, 2003). The 
cryotechnique prevents the formation of ice within the macromolecular sample by adding 
a cryoprotectant, so that the lattice order of the crystals can be preserved. Thus, X-ray 
data collection can be exploited to remarkable effect for biological macromolecule 
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structure determination. For data collection at low temperature, a significant 
improvement of data resolution can be gained and the duration of data collection can be 
extended due to the crystal lifetime being lengthened. Therefore, one or more complete 
data sets can be taken from a single crystal (Garman and Schneider, 1997). Using the 
cryogenic techniques to cool crystals can also prevent phase change, space group or 
lattice transformation of most macromolecular crystals during X-ray data collection 
(Hope, 1988).  
The cryocrystallography technique should be applied when this will improve the 
quality of X-ray data under such circumstances (Watenpaugh, 1991):  
1) Crystal packing is more stable at cryogenic temperature than at room 
temperature; 
2) The macromolecule is unstable at room temperature; 
3) The reaction rate of protein-substrate complexes is greatly reduced at low 
temperature;  
4) Crystals are diffracted at high resolution.  
The primary target of cryogenic data collection is to cool the crystal without 
damage to the crystal lattice. The crystal is removed from the drop and should be soaked 
into the “cryosolution” for between one second and few minutes or even a few days. It 
may be necessary to introduce the cryosolution slowly, either by dialysis or serial transfer, 
to avoid damaging the crystal. Otherwise direct transferring may be applied. The crystal 
should be allowed to equilibrate with the solution completely prior to crystal mounting 
and flash cooling (Rodgers, 1994).  
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For cryogenic data collection, the crystal is held by the surface tension of the 
cryosolution (thin film) across a thin fiber-made loop attached to micro tube with a metal 
mounting pin. For short or long term storage, crystals are plunged into cryogen (liquid 
nitrogen, liquid propane or liquid ethane) and transferred to a Dewar for storing and 
transporting of crystals for future data collection at any synchrotron facility. For instant 
cryogenic data collection, the crystal with mounting pin is placed directly on a magnetic 
base in the goniometer head under gaseous nitrogen at 100 K. One benefit of using the 
thin fiber loop method to mount the crystal is that the mosaic spread of the crystal can be 
greatly reduced. This is due to the lower and more uniform background of the thin film. 
The mosaic spread of crystal is defined as the divergence of a scattered X-ray beam that 
is caused by the irregularity of orientation of small blocks of unit cells in the crystal. The 
X-ray absorption effect can also be minimized due to the uniform surface tension in the 
thin film. This free-standing method for mounting crystals is employed to avoid the 
crystal coming into contact with any mechanical support which can enhance the mosaic 
spread of the crystal (Teng, 1990). 
 
1.5.2. Principle of Cryoprotectant 
During cryocrystallography, the crystal is cooled to cryogenic temperatures. In an 
effort to minimize crystal damage during cryogenic cooling, cryoprotective reagents or 
cryoprotectants are added into the solution to prevent the formation of crystalline ice in 
the internal and external solution as well as at the interface between crystal and solution. 
Once the cryoprotectant is added into the mother liquor, the cryosolution is formed.  
 A general method for maintaining the integrity of protein crystals has been 
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demonstrated by substituting the crystal mother liquor with salt-free aqueous/organic 
liquid mixture of high organic concentration and low freezing point. Organic solvents 
such as MPD, methanol, ethanol, isopropanol, ethylene glycol and glycerol are chosen 
(Petsko, 1975).  
Glycerol is one of the most common cryoprotectants used in protein 
cryocrystallography. It has been reported that glycerol can be employed as a very useful 
cryoprotectant to provide cryoprotection for 50 typical protein crystallization solutions 
(Garman and Mitchell, 1996). Ethylene Glycol, MPD and PEG are also widely used. 
Other uncommon cryoprotectants such as sucrose have been reported as a satisfactory 
cryoprotectant (Sharma et al., 1994). The cryoprotectants which have been successfully 
used by crystallographers are illustrated in Table 1.5 (Rodgers, 1994). The concentration 
of the cryoprotectants may be higher or lower than the ones indicated in Table 1.5, 
because after a number of years, more cryo-conditions have been explored. 
 
Cryoprotectant Concentration (%) 
(2R,3R)-(-)-Butane-2,3-diol 8 (v/v) 
Erythritol 11 (w/v) 
Ethylene Glycol 11-30 (v/v) 
Glucose 25 (w/v) 
Glycerol 13-30 (v/v) 
MPD 20-30 (v/v) 
PEG 400/600 25-35 (v/v) 
Sucrose 14 (w/v) 
Xylitol 22 (w/v) 
Table 1.5: List of cryoprotectants used successfully in flash-cooling the 
macromolecular crystals. 
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The simplest approach to choosing good cryoprotectant conditions is to include 
cryoprotectants in the established mother liquor as a matter of trial and error. The most 
effective way to find out their optimal concentrations is to perform an initial examination 
by adding a small amount of cryoprotectant as mentioned in Table 1.5 into mother liquor. 
A scheme based on this strategy is shown in Figure 1.14. 
The main challenge of cooling the crystal to cryogenic temperatures is to avoid 
the formation of crystalline ice within the sample. So, the cryoprotectant added to the 
crystal simply slows the crystal nucleation so that a rigid glass is formed prior to ice 
formation within the crystal lattice. 
 
 
 
Figure 1.14: Pathway for determining the optimal cryoprotectant concentration. 
 
 
Another approach is to use an immiscible oil such as Paratone-N in combination 
with cryoprotectants to replace the external liquid around the crystal, or using dry 
Select several putative 
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Glycol and PEG 600)
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cryoprotectant 
 
Mix the individual 
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mother liquor 
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the diffraction pattern of 
each cryosolution with 
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vitrification of the drop
 
Determine the minimum 
concentration of each 
cryoprotectant 
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paraffin oil to cover the crystal (Kwong and Liu, 1999). When crystals are damaged by a 
high concentration of cryoprotectant, the former procedure can be used because this 
procedure substantially lowers the concentration of cryoprotectant used. It can also 
increase the diffraction quality of the crystals. The latter method is simple and does not 
require that the crystal soaks in solution which can disturb the packing lattice by diffusing 
into the crystal. So, it has been suggested that this method can be tried as a first choice 
before trying other cryoprotectants. 
Crystals that are induced by high salt concentrations such as ammonium sulfate 
are frequently faced with the problem of finding a suitable cryoprotectant because of the 
limited solubility of many salts in aqueous/organic mixtures. The consequence of adding 
the cryoprotectant into a salt-rich mother liquor is that salt precipitates can be formed that 
can harm the crystals. To avoid this problem, the method best employed is to use other 
salts in high solubility such as malonate or tartrate to replace ammonium sulfate in the 
mother liquor (McPherson, 2001; Rodgers, 1997). 
 
1.5.3. Crystal Handling, Mounting, Cooling, Storage and Transportation 
Crystal mounting for cryocrystallography can be carried out using capillary tubes, 
fine glass capillary tubes, thin glass spatulas, and thin loop films. However, the free-
standing loop mounting technique has become the prevalent procedure for crystal 
mounting at cryogenic temperatures (Rodgers, 1997). 
Originally the loops were made from copper or tungsten wire with 1 − 2 mm 
diameters and 25 – 75 µm thickness, but now, they are made from fine nylon fibers with 
0.05 – 1.0 mm diameters and 10 & 20 µm thickness. These types of cryo-loops show 
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minimal background diffraction due to the optically clear environment and the loops are 
thin enough to be convenient for fast freezing. The major advantages of using this 
approach to lift up, transfer, flash cool the crystal are the production of lower X-ray 
scatter and lower X-ray absorption. Uniform results can be obtained compared to the 
conventional mounting techniques such as capillary mounting (Teng, 1990). 
 The loop itself serves as a platform to support the crystal in place and to keep it 
away from foreign material which has detrimental effects to the crystal. It is a good idea 
to select a loop size which is just wide enough to keep the crystal from dropping off. For 
instant data collection, the crystal is picked up and flash-cooled immediately. The cold 
stream is first deflected from the nitrogen gas nozzle, the crystal is placed on the 
goniometer, and then the obstruction of the flow is removed immediately. 
If the crystal needs a faster rate of cooling, or will be sent away to synchrotron 
facilities for data analysis, the crystal can be rapidly plunged beneath the surface of liquid 
nitrogen for a few seconds to a few minutes. Next, the crystal is moved to a 
diffractometer for experiment or transferred to a storage tank for storage and 
transportation (Parkin and Hope, 1998).  
The other advantage of cryocrystallography is the potential for storing and 
transporting crystals as soon as they have been flash-cooled. Well-diffracted crystals can 
be kept and sent to a synchrotron after screening at an in-house facility. Another factor to 
be considered is that crystals can grow to a limiting size and subsequently degrade. So, 
crystals can be flash cooled at their finest conditions until data collection is performed. 
Crystals must be kept at cryogenic temperatures, so a liquid nitrogen Dewar which is 
portable and provides protection from mechanical shock is highly recommended. In 
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principle, once the crystals have been successfully cooled to cryogenic temperatures, they 
can be kept for an indefinite time (Parkin and Hope, 1998).  
 
1.6. X-RAYS DIFFRACTION 
1.6.1. Proteins, Crystals and X-rays 
X-rays are generated when electrons collide with the atoms of a metal target, e.g. 
copper. The electrons are liberated from a heated filament and accelerated by high 
voltage towards the metal target (Stout and Jensen, 1989). 
X-rays are a form of electromagnetic radiation, where wavelength is about 0.1 – 
10 nm (1 −100 Å) on the electromagnetic spectrum (Petrucci et al., 2002). The major 
reason that X-rays have been chosen to study the 3-D structures of proteins in 
crystallography because the range of wavelengths of X-rays we choose (0.5 Å – 1.6 Å) is 
on the same order of magnitude as the bond length of the atoms within protein molecules. 
The bond length between atoms within a protein is about 0.15 nm or 1.5 Å, thus these 
wavelengths can be utilized to visualize the geometry and structure of protein molecules 
through X-ray diffraction (Blow, 2002).   
Individual atoms in a molecule can diffract X-rays; however, they are weak 
scatterers of X-rays. Therefore, X-rays may pass through a single molecule without any 
diffraction, so diffraction might be too weak to be detected by any instrument. However, 
one can solve the problem by analyzing a crystal diffraction pattern rather than a 
molecule. This is because a crystal is composed of a number of repeating patterns (unit 
cells) in a regular and ordered manner. Each molecule within the crystal therefore 
diffracts equally, and thus strong diffracted X-ray beams can be measured (Rhode, 2000). 
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1.6.2. Bragg’s Law 
W. L Braggs managed to visualize the scattering X-rays from a crystal by 
considering that the diffracted beams were reflected by planes passing through points of a 
crystal lattice. The diffracted X-rays are scattered by the crystal at a certain angle of 
reflection (θ). This reflection is analogous to that from a mirror, for which the angle of 
incident X-ray beam is equal to the angle of diffracted X-ray beam. The incident and the 
diffracted X-rays are in the same plane and the X-rays of wavelength (λ) are normal to a 
set of diffracting planes (Figure 1.15). The constructive interference between X-rays 
scattered from successive planes in the crystal will only take place if the path difference 
(2d) between the X-rays is equivalent to an integral number of wavelength (λ). That is the 
Bragg’s law equation (Glusker and Trueblood, 1985):  
    nλ = 2d sin θ 
 
 
Figure 1.15: The geometry of diffraction and its relationship to Bragg’s Law 
(Glusker and Trueblood, 1985). 
 
In Bragg's law, if the wavelength and the diffraction angle of a reflection are 
known, the perpendicular distance between the lattice planes in the crystal (interplanar 
spacing, d) can be easily calculated. As the angle increases, d must become smaller for 
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the path length to remain equal to one wavelength. The equation can be rearranged as: 
     d = nλ / (2 sinθ) 
The minimum interplanar spacing (dm), where dm = λ/2 (sinθmax), is also 
interpreted as the resolution of an electron density map. Since the maximum possible 
value of sinθ is 1, so the smaller the dm value, the higher the resolution will be of the X-
ray diffraction pattern. For instance, if the radiation used for X-ray generation has a 
wavelength of 1.54 Å, then the maximum resolution that can be observed with this 
radiation would be 0.77 Å (Blundell and Johnson, 1976; Glusker et al., 1994). Most 
proteins seldom diffract better than 1.5 Å (Glusker et al., 1994). If a protein is diffracted 
to a high resolution level (above 2 Å), most fine macromolecular structures can be solved 
and refined by crystallography. 
 
1.6.3. Asymmetric Unit, Space Group, Unit Cell and Bravais Lattices  
Crystals can be characterized by three elements to precisely define the 
arrangement, coordination, and periodicity of the fundamental unit of which they are 
composed. These 3 elements are symmetry properties, repetitive features and distribution 
of the atoms in the repeating unit. 
Protein molecules are inherently asymmetric. The asymmetric unit is the smallest 
component in the crystal. The asymmetric unit may consist of one molecule, part of a 
molecule or several molecules not related by symmetry. If only one molecule occupies a 
unit cell, then the cell itself is chiral and has no symmetry elements at all. This object is 
termed as the asymmetric unit because no part of it is systematically related to any other 
by crystallographic properties. That means it has no symmetry elements such as rotation 
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axis or mirror plane (Figure 1.16). In most cases, the unit cell contains more than one 
identical molecule or oligomeric complexes (dimer, trimer, tetramer, etc.) in an 
arrangement that produces symmetry elements. So, the largest aggregate of molecule(s) 
in a cell that possesses no symmetry element but can be juxtaposed on other identical 
entities by symmetry operation is called the asymmetric unit (Rhode, 2000). 
A set of symmetry operations includes rotation, reflection, inversion, rotatory-
inversion, screw axes, glide plane, and translation. These operations can be applied to an 
asymmetric unit. Combination of all these elements in all possible ways generates a total 
of 230 unique, three-dimensional space groups of symmetry operation. These 230 space 
groups are described in International Tables for X-ray Crystallography Vol. A. (Hahn, 
2002). 
 
Figure 1.16:  There are six unit cells in this crystalline lattice. In each unit cell   
contains two molecules, the asymmetric unit is a dimer (Rhode, 2000; reproduced 
with permission of the author).  
 
The unit cell is the basic building block of the crystal and is repeated infinitely in 
three dimensions. The directions of constructive interference depend only on the size and 
shape of the unit cell. The dimensions of a unit cell are designated by six parameters: the 
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length of 3 unique edges (a, b, c) which run along x, y and z coordinates respectively, and 
3 unique angles (α, β, γ) as indicated in Figure 1.17.  
 
 
Figure 1.17: The unit cell with edges, a, b, c and angles, α, β and γ (Stout and 
Jensen, 1989). 
 
In virtually all cases, a crystallographer is concerned only with the content of the 
individual unit cell and the coordinate of the atoms within the unit cell. There are 14 
allowable unit cell types classified as Bravais lattice to distinguish their characteristic. 
The Bravais lattices themselves can be divided into five types of lattice, which are 
primitive (P), centered (C), body-centered (I) , face-centered (F) and rhombohedral (R)  
(McPherson, 2003; Stout and Jensen, 1989). 
Any crystal can be regarded as being established by consecutively translational 
repetition of the unit cell and its content along a, b, c by distance |a|, |b|, |c| respectively, 
until a continuous three–dimensional array of repeated unit cells in a regular manner has 
been created (Glusker et al., 1994; Glusker and Trueblood, 1985; Rhode, 2000).  
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The simple symmetry operations and elements needed to describe unit cell 
symmetry are translation, rotation and reflection. The symmetry of a unit cell is described 
in 230 space groups (like P212121). The space group is a group of symmetry operations 
consistent with an infinitely extended, regularly repeating pattern. Protein is an 
asymmetric object since all amino acids except glycine have chirality. However, the D-
form of amino acids does not exist in proteins and only the L form does. Thus, there are 
less symmetry elements (mirror planes, inversion centers and glide planes) involved 
within the unit cell, and less space groups can be used to designate the protein. This limits 
the possible space groups to 65 out of the 230 mathematically possible ones (McRee, 
1999).   
There are seven crystal systems used to classify the symmetry of the crystal, this 
corresponds to the seven fundamental shapes for unit cells, consistent with the 14 Bravais 
lattices as displayed in Table 1.6 (Glusker et al., 1994; Stout and Jensen, 1989). 
 Crystal System Bravais Lattices  Lattice Angle 
1 Triclinic P a≠b≠c α≠β≠γ 
2 Monoclinic P, C a≠b≠c α=γ= 90°≠β 
3 Orthorhombic P, C, I, F a≠b≠c α=β=γ=90° 
4 Tetragonal P, I a=b≠c α=β=γ=90° 
5a Trigonal P a=b≠c α=β=90°,γ=120° 
5b Rhombohedral R a=b=c α=β=γ<120°,≠90° 
6 Hexagonal P a=b≠c α=β=90°,γ=120° 
7 Cubic P, I, F a=b=c α=β=γ=90° 
Table 1.6: The seven crystal systems (Glusker et al., 1994; Stout and Jensen, 1989). 
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1.6.4. X-ray diffraction Data Collection 
 For data collection purposes, the most important factor required for evaluating 
data quality is the completeness of the X-ray data including all the indices and their 
associated intensities, with their standard uncertainties (Dauter, 1999). Two factors that 
influence the data completeness are the geometric and informative content. The 
geometric factor, arising from the symmetry of crystal lattice and the detector setup, is a 
quantitative factor related to a number of variables including the approach of angular 
rotating method, the selection of the total rotation range appropriate for the crystal 
symmetry, crystal-to-detector distance, crystal mosaicity and beam divergence. The 
informative factor includes the quality of the data, the dynamic range of detector and the 
R-factor. The longer the exposure time, the greater the intensities and the signal-to-noise 
ratio, and the better the data quality obtained (Dauter, 1997; Dauter, 1999). 
 The X-ray data quality for macromolecular crystallography is assessed by a global 
indicator, the merging R-factor (Rmerge) or symmetry R-factor (Rsym). The merging R-
factor is defined by the following equation (Blundell and Johnson, 1976):  
Σhkl Σi ⎮Ii(hkl) – 〈 I(hkl) 〉⎮ 
                                Σhkl Σi  Ii (hkl) 
where (Ii(hkl)) is all observed intensities and 〈 I(hkl) 〉 is the average value of all observed 
intensities.  
The Rmerge value will be between 20 – 40% while the signal/noise (I/ σ(I)) falls 
around 1.0 − 2.0 (Dauter, 1999). The quantity of merging R-factor is almost universally 
used for evaluating X-ray diffraction data.  
Rmerge (I) = 
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CHAPTER 2: MATERIALS AND METHODS 
 
2.1. CHEMICALS 
Additive:  
The volatile reducing agent, DTT (OmniPur® Grade), was purchased from VWR 
International Ltd (Ontario, Canada). 
 
Buffers: 
Reagent Reagent Grade Supplier 
Citric Acid Anhydrous 
(C6H8O7) 
OmniPur® VWR Canlab (Ontario, Canada) 
HEPES (C8H18N2O4S) 
Biotechnology Performance 
Certified 
MES (C6H13NO4S.H2O) 
Biotechnology Performance 
Certified  
Sigma-Aldrich Canada Ltd 
(Ontario, Canada) 
Potassium Phosphate, 
monobasic(KH2PO4) 
ACS 
Potassium Phosphate, 
dibasic (K2HPO4) 
ACS 
Sodium Acetate Anhydrous 
(CH3COONa) 
AnalaR® 
VWR Canlab 
 (Ontario, Canada) 
Sodium Cacodylate 
(C2H6AsO2Na) 
Sigma Ultra Sigma-Aldrich Canada Ltd (Ontario, Canada) 
Sodium Citrate 
(Na3C6H5O7.2H2O) 
AnalaR® VWR Canlab  (Ontario, Canada) 
Tris (C4H11NO3) Reagent 
Sigma-Aldrich Canada Ltd 
(Ontario, Canada) 
 
Precipitants: 
PEG 400, PEG 600, PEG 1,000, PEG MME 2,000, PEG 4,000, PEG 6,000 and 
PEG 8,000 were purchased from Fluka Chemical Cooperation (Wisconsin, USA). 
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Cryoprotectants: 
Reagent Reagent Grade Supplier 
Ethylene Glycol (C2H6O2) ACS 
Sigma-Aldrich Canada Ltd 
(Ontario Canada) 
Glucose (C6H12O6) ACS 
Glycerol (C3H8O3) ACS 
VWR Canlab 
 (Ontario, Canada) 
MPD (C6H14O2) Purum 
PEG 400 Purum 
PEG 600 Purum 
Fluka Chemical Coop.  
(Wisconsin, USA) 
Sucrose (C12H22O11) Ultra Pure 
Xylitol (C5H12O5) - 
Fisher Scientific 
 (Ontario, Canada) 
 
Salts: 
Reagent Reagent Grade Supplier 
Copper Sulfate (CuSO4) 
Sigma-Aldrich Canada Ltd 
(Ontario Canada) 
Potassium Acetate 
(CH3COOK) 
Fisher Scientific 
 (Ontario, Canada) 
Ammonium Sulfate 
(NH4)2SO4 
Cadmium Chloride (CdCl2) 
Calcium Chloride (CaCl2) 
Cobalt Chloride (CoCl2) 
Copper Chloride (CuCl2) 
ACS 
Lithium Chloride (LiCl) OmniPur® 
Lithium Sulfate (Li2SO4) 
Magnesium Chloride 
(MgCl2.6H2O) 
Manganese Chloride 
(MnCl2.4H2O) 
Nickel Chloride 
(NiCl2.6H2O) 
Potassium Chloride (KCl) 
Potassium Sodium Tartrate 
(KNaC4H4O6) 
Sodium Chloride (NaCl) 
Tri-Sodium Citrate 
(Na3C6H5O7) 
Zinc Acetate 
((CH3COO)2Zn.2H2O) 
ACS 
Zinc Chloride (ZnCl2) General Reagent 
VWR Canlab  
(Ontario, Canada) 
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Proteins: 
BSA protein was purchased from Sigma-Aldrich Canada Ltd (Ontario, Canada). It 
was minimum 99% electrophoresis grade and essentially fatty acid free (A0281). 
Trx-2 protein was overexpressed and purified from the cloned vectors pPROK1 
(Clotech, California, USA) containing the H. pylori gene. The construct was provided by 
Dr. Leslie Poole from Wake Forest University (Baker et al., 2003).  
 
Protein Overexpression: 
Antibiotics ampicillin-Na salt and chloramphenicol (OmniPur® Grade) were 
purchased from Sigma-Aldrich Canada Ltd (Ontario, Canada) and VWR International 
Ltd (Ontario, Canada) respectively. 
Peptone (Granulated), yeast extract (Granulated, Microbiology Grade), and 
sodium chloride (ACS Grade) which were used for the purpose of preparing the LB 
medium were all purchased from VWR International Ltd (Ontario, Canada). 
 
Protein Purification: 
The DNase I from bovine pancreas (OmniPur® grade), DTT (OmniPur® Grade), 
potassium phosphate monobasic (KH2PO4, ACS Grade) and potassium phosphate dibasic 
(K2HPO4, ACS Grade) used for the preparation of potassium phosphate buffer solutions 
at pH 7.0 (The buffer solution mixture of the monobasic potassium phosphate and dibasic 
potassium phosphate is referred as potassium phosphate buffer solution or “K-PO4 buffer 
solution”.) were purchased from VWR International Ltd (Ontario, Canada). Lysozyme, 
AEBSF-HCl (HPLC Grade) and Tris-HCl were purchased from Sigma-Aldrich Canada 
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Ltd (Ontario, Canada) and CalbioChem (San Diego, California, USA) respectively. The 
packing media, carboxylmethyl cellulose CM52, for cation exchange column 
chromatography was purchased from VWR International Ltd (Ontario, Canada). 
Two types of dialysis membrane were used. Spectra/Por® 1 (MWCO: 6,000 ~ 
8,000 Dalton; Diameter: 20.4 mm, Flat Width: 32 mm and Volume/length: 3.3 ml/cm) 
was purchased from VWR International Ltd (Ontario, Canada) and Spectra/Por® 3.1 
(MWCO: 3,500 Dalton; Diameter: 10.0 mm, Flat Width: 16 mm and Volume/length: 0.81 
ml/cm) was purchased from Fisher Scientific Ltd (Ontario, Canada). 
Two types of Amicon ultracentrifuge membranes were used and purchased from 
Fisher Scientific Ltd (Ontario, Canada). Regenerated cellulose membranes with NMWL 
3,000 either in diameter of 25 mm (Millipore, for 10ml stirred cell) or 63.5 mm 
(Millipore, for 200 ml stirred cell) were used to concentrate Trx2 protein solutions. 
Another ultrafiltration membrane with NMWL: 30,000 in 25 mm diameter (Millipore, for 
10 ml stirred cell) was used to concentrate BSA protein solutions. 
 
Protein Characterization: 
The Bradford reagent, low-molecular weight range Sigma marker, 40% 
acrylamide/bis-acryamide, TEMED (C6H16N2) and Tris base (C4H11NO3) were all 
purchased from Sigma-Aldrich Canada Ltd (Ontario, Canada). Ammonium persulfate 
(OmniPur® Grade), glacial acetic acid (ACS Grade), glycerol (ACS Grade), methanol 
(HPLC Grade), sodium dodecyl sulfate (C12H25SO4Na, OmniPur® Grade) and gel drying 
film (V7131, 25.4 cm x 28 cm) were purchased from VWR International Ltd (Ontario, 
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Canada). Glycine (C2H5NO2, electrophoresis grade) was purchased from Fisher Scientific 
Ltd (Ontario, Canada). 
 
2.2. EQUIPMENT 
The two balances used were a Sartorius BP 221S for delicate sample 
measurement (weight capacity= 220 g, readability= 0.0001 g), and a Sartorius BP 410 for 
normal sample measurement (weight capacity: 410 g, readability =0.01 g). 
The centrifuges used were Beckman CoulterTM model Micofuge®18 Centrifuge 
with the maximum speed at 14,000 rpm for small quantity of protein samples up to 1.5 ml 
and Beckman’s model J2-HS Centrifuge with the maximum speed at 8,000 and 18,000 
rpm were used for 500 ml & 50 ml sample solutions respectively. 
The Dynamic Light Scattering (DLS) instrument used was a DynaPro-99 Model 
with Dynamic software version 5.26.39 that located in the Saskatchewan Structural 
Science Center (SSSC) at University of Saskatchewan. 
The liquid chromatography instruments used were BioCAD SPRINT and 
BioCAD 700E perfusion chromatography system with BioCAD software version 3.0. 
Both systems were coupled to Advantec super fraction collectors model SF-2120. The 
two columns used were self-packed POROS® 20 Micro HQ anion exchange column 
(Diameter: 10 mm, Length: 100 mm, and Column Volume: 7.84 ml) and self-packed 
carboxymethyl cellulose CM 52 cation exchange column (Diameter: 26 mm, Length: 250 
mm, and Column Volume: 132.72 ml). 
The microscope used was an OLYMPUS model SZ6045 (1.0 − 6.3 X) with 10 X 
magnification eyepieces and attached with a DP-12 digital camera for image recording. 
 66
The pH meter used was a VWR SympHony model SB 21 and calibrated by 3 
different standard buffer solutions (pH: 4.01, 7.00 and 10.01) within a range of ± 0.01 – 
0.02 pH units. 
Two stirred cells used for ultrafiltration were purchased from Fisher Scientific Ltd 
(Ontario, Canada). These include a 10 ml stirred cell (model 8010, diameter: 25 mm) and 
a 200 ml stirred cell (model 8200, diameter: 63.5 mm). 
The UV-VISIBLE spectrometer used was a Cary 50 Bio Model with WinUV 
software package, and coupled with a Hewlett Packard HP Deskjet 3420 series printer.  
The X-ray diffractometer used was a DX8 Proteum Model attached with a 4K 
CCD detector and connected with Kyro-flex low temperature set-up (Temperature range: 
90 – 300K). The software that used for data collection was Proteum version 1.4.1 
(Brucker AXS Inc., Madison, Wisconsin, USA). The X-ray instrument is located in the 
crystallography laboratory at the SSSC of the University of Saskatchewan.  
 
2.3. PROTEIN OVEREXPRESSION 
The protein overexpression protocol only applied to the Trx-2 protein; BSA 
protein was directly obtained from the supplier. The pPROK1 vector (Clontech) 
containing Trx-2 gene was transformed into E. coli BL21 (DE3) pLysS using the heat 
shock method as described previously (Filson et al., 2003). Glycerol stocks stored at 
−80°C were transferred into a sterilized falcon tube containing 5 ml of LB solution with 
50 µg/ml of ampicillin and 34 µg/ml of chloramphenicol. The falcon tube was put inside 
the shaker at 37°C at a speed of 250 rpm overnight in order to grow the cell culture in 
broth.  
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About 1 ml of the overnight culture was transferred into a 300 ml volumetric flask 
that contained 100 ml of sterilized LB medium solution with 50 µg/ml of ampicillin and 
34 µg/ml of chloramphenicol. The culture grew under the same condition as the 5 ml LB 
solution. 
Ten milliliters of the overnight grown culture was transferred into a 2800 ml 
Fernbach flask that contained 1 L LB solution with 50 µg/ml of ampicillin and 34 µg/ml 
of chloramphenicol. Finally, 4 L of cells were cultivated. When the cultures started to 
grow in shaker (37°C / 250 rpm), 1 ml of medium solution was taken to act as “Blank” in 
order to monitor the process and the optical density (OD) value was measured at the 
wavelength of 595 nm until the OD595 reached about 0.6 – 0.8. Once the OD range was 
attained, 0.4 mM IPTG was added to induce the overexpression of the Trx-2 protein. 
After addition of the IPTG, the cells were grown for a further 3 hours. The cells were 
then pelleted by centrifugation in 500 ml centrifuged bottles for 15 minutes at a speed of 
8,000 rpm at 5°C. After centrifugation, the supernatants were discarded and the cell 
pellets were collected into a falcon tube and then stored at –80°C until used. 
 
2.4. PROTEIN PURIFICATION 
2.4.1. Purification of Bovine Serum Albumin 
2.4.1.1. Anion Exchange Chromatography 
Prior to operating the anion exchange chromatography, the column was 
equilibrated with 50 mM Tris-HCl (pH 8.5) buffer solutions. For purifying BSA, a 5 ml 
sample of 10 mg/ml BSA solution was prepared. After filtration, the BSA solution was 
loaded onto HQ 20 anion exchange column. Both 50 mM Tris-HCl (pH 8.5) buffer 
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solution and 50 mM Tis-HCl/0.5 M NaCl (pH 8.5) buffer solution were used as gradient 
buffers for sample fractioning. The flow rate was set at 20 ml/min. A total of 16 fractions 
were collected and the UV absorbance at the wavelength of 280 nm was used for protein 
sample detection. The fractions that showed an absorbance peak were kept. All sample 
solutions and buffers were filtered by 0.22 µm sterile Millex®GP filters before use. 
  
2.4.1.2. Ultrafiltration 
The BSA solutions from the column fractions were reconcentrated in order to 
recover the proteins. Reconcentration of the diluted BSA solutions was accomplished by 
using a 10 ml Amicon ultrafiltration stirred cell with ultrafiltration membrane (NMWL: 
30,000). The ultrafiltration stirred cell was pressurized under 70 psi of nitrogen gas at 4oC. 
The BSA solutions were reconcentrated to about 1.5 ml for overnight dialysis. 
 
2.4.1.3. Dialysis 
Before the BSA solution was transferred to the dialysis membrane (Spectrum), the 
membrane was rinsed with DIW for 10 − 20 minutes. The dialysis reservoir was filled 
with 2 L of 50 mM K-PO4 (pH 6.0). The dialysis buffer was changed at every hour for 3 
changes and then the dialysis was continued overnight. Finally, the BSA solution was 
reconcentrated to 10 mg/ml as determined by Bradford Assay (Bradford, 1976) for 
crystallization trials. 
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2.4.2. Purification of Thioredoxin-2  
2.4.2.1. Cell Lysis 
The weight of the thawed pellets from the freezer was measured to calculate the 
total volume of lysing buffer (5mM K-PO4 buffer solution at pH 7.0 including 1 mM 
DTT, 2mM AEBSF, 20 µg/ml lysozyme and 20 µg/ml DNase) needed to extract and 
isolate Trx-2 proteins from the cell. Five milliliters of buffer were used per 10 g of cell 
pellets. The suspended cell pellets were sonicated on ice for 1 minute. The lysed protein 
solution was then transferred into a small centrifuge tube (50ml, Nalgene) and 
centrifuged for 30 minutes using the JA–25.50 rotor at a speed of 14,000 rpm at 5°C. The 
supernatants were collected, a 30% ammonium sulfate cut was performed to remove 
further contaminants by adding an appropriate amount of precipitant according to the 
ammonium sulfate precipitation table (Bollag et al., 1996). For example, 176 g of 
ammonium sulfate was required for 1000 ml of supernatant. After 30 minutes of stirring 
at 4°C, the solution was then centrifuged for 30 minutes at a speed of 14,000 rpm at 5°C 
and the supernatants were collected.  
 
2.4.2.2. Dialysis 
Following the 30% ammonium sulfate cut, the supernatant was dialyzed by a    
2 L of 5 mM K-PO4 buffer solutions (pH 7.0) with 2mM DTT overnight with 3 – 4 
changes of dialysis buffer.  
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2.4.2.3. Anion Exchange Chromatography 
Prior to the anion exchange chromatography, the column was equilibrated with a 
5 mM K-PO4 buffer solution (pH 7.0). A 5 ml sample was loaded onto a self-packed HQ 
20 column. The proteins were not bound with the anion column, so these were eluted 
from the column very quickly. The fractions containing Trx-2 were collected by fraction 
collector in a 10 ml volume at the flow rate of 5 ml/min. The fractions that showed an 
absorbance peak were kept aside for the next step. In the anion exchange chromatography 
purification protocol, a 5 mM K-PO4 buffer solution (pH 7.0) and a 5 mM K-PO4/1 M 
NaCl buffer solution (pH 7.0) were used as gradient buffers for sample fractioning. 
Before proceeding to the next purification procedure, as a result of high volume of 
fractionated protein solutions, concentration of the protein fractions by ultracentrifugation 
was essential to reduce the volume of protein solutions and the time consumed for cation 
exchange chromatography. All samples and buffers were filtered before loading to the 
perfusion chromatography system (BioCAD 700E).  
 
2.4.2.4. Ultrafiltration 
The concentration of the protein solution was required after every 
chromatographic procedure in order to reconcentrate the protein. Reconcentration of the 
diluted Trx-2 solutions from the chromatographic fractions was accomplished using a 10 
ml or 200 ml Amicon ultrafiltration stirred cell with ultrafiltration membrane (NMWL 
3,000). The ultrafiltration cell was pressurized under 70 psi of nitrogen gas inside a 4oC 
incubator and the Trx 2 solutions were concentrated to 5 – 10 ml for cation exchange 
chromatography. 
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2.4.2.5. Cation Exchange Chromatography 
Prior to the cation exchange chromatography, the column was equilibrated with a 
5 mM K-PO4 buffer solution (pH 7.0). The pre-concentrated Trx-2 solution was injected 
into a 5 ml loop, and a 5 mM K-PO4 buffer solution (pH 7.0) was blended with a 40 mM 
K-PO4 buffer solution (pH 7.0) for gradient elution of Trx-2 protein with UV detection at 
the wavelength of 280 nm. The fractions containing Trx-2 protein were collected for 
overnight dialysis in order to remove the salts from the gradient buffers or others 
impurities. Again, the Trx-2 solution was reconcentrated to about 1 – 2 ml for overnight 
dialysis. 
  
2.4.2.6. Dialysis after Cation Exchange Chromatography 
The dialysis reservoir was filled with 500 ml of 30 mM K-PO4 buffer solution 
(pH 7.0). The dialysis reservoir was replaced after one hour and repeated three times, and 
then overnight dialysis was continued. After that, the concentration of purified Trx-2 was 
determined by Bradford assay as described in Section 2.5.3. 
 
2.5. PROTEIN CHARACTERIZATION 
2.5.1. SDS- PAGE Electrophoresis  
SDS-PAGE is a commonly applied technique for protein analysis and 
characterization using small quantities of proteins of interest. This method is employed to 
characterize protein purity, because the purity of the protein plays a crucial role in the 
protein crystallization trials (Ducruix and Giege, 1992). 
 
 72
A 10% gel for BSA and a 15% gel for Trx-2 were prepared according to the 
standard recipe shown in Appendix 2 (Sambrook and Russell, 2001). The gel was placed 
into the electrophoresis device that contained Tris-Glycine electrophoresis buffer in the 
lower buffer chamber. For most of the sample preparations, 20 µL of sample solution was 
mixed with 20 µL SDS-gels loading buffer. The samples were boiled for 5 minutes, and 
then centrifuged for another 5 minutes at a speed of 14,000 rpm. The standard sample 
used to verify the molecular weight of protein of interest was “Low Molecular Weight 
Protein” marker (66, 45, 36, 29, 24, 20, 14 & 6.5 KDa). Both samples and standards were 
loaded into wells of the pre-cast gel. The electrophoresis was run at a constant current,     
50 mA, for approximately 30 – 45 minutes until the blue bands almost reached the 
bottom of the glass plate. The gel was removed from the glass plate and transferred to the 
staining solution, Coomassie Brilliant Blue. After one hour, the staining solution was 
replaced with destaining solution 1 (30% Methanol/10% Acetic Acid) for another hour. 
After that the gel was destained by destaining solution 2 (5% Methanol/7% Acetic Acid) 
overnight. The next day, the destaining solution was discarded and the drying solution 
(40% methanol/10% glycerol/7.5% acetic acid) was applied to soak the gel in a few 
minutes. Then, the gel was dried for a few hours for final inspection of the gel contents in 
order to determine the purity of the protein samples. 
 
2.5.2. Dynamic Light Scattering Measurement 
The dynamic light scattering analysis was performed in the Saskatchewan 
Structural Science Center (SSSC). The protein sample solution was scanned at least 20 
times continuously at 20oC with an acquisition time of 3 seconds per scan. The protein 
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sample solution was diluted to 1 mg/ml with DIW prior to DLS measurement. The 
protein sample solution was kept on ice all the time before the experiment. All samples 
were filtered by MicroFilter (0.02 µm membrane) to remove all dust and particles from 
the solution. Prior to the sample measurement by DLS, a water blank sample was carried 
out to ensure the cuvette and syringe used were clean and uncontaminated. 
Approximately 20 µL of protein sample solution was injected into the cuvette that was 
then placed into the chamber to collect the %polydispersity to evaluate the homogeneity 
of the protein. 
 
2.5.3. Bradford Assay 
The protein concentration was determined by the Bradford Assay (Bradford, 
1976). Six standard solutions were prepared to build a quadratic calibration curve where 
R2 should be higher than 0.95. The Bradford reagent, 0.1 µg/µL of BSA stock solution 
and DIW were mixed accordingly to Table 2.1. 
To determine the concentration of purified BSA protein, 0.5 µL of protein 
sample solution was added to 499.5 µL of DIW and 500 µL of Bradford reagent. 
Therefore, the BSA sample solution was diluted to 1: 2000. For purified Trx-2 protein, 1 
µL of Trx-2 sample solution was added to 499 µL of DIW and 500 µL of Bradford 
reagent. Therefore, the Trx-2 sample solution was diluted to 1: 1000. Once the sample 
solutions have been measured by UV/VIS, the concentration must be converted from 
µg/ml into mg/ml (1000 µg/ml) to calculate the true concentration of the sample. The 
sample solutions and standards must be undisturbed at least 10 − 15 minutes before 
taking any measurement at the wavelength of 595 nm by UV/VIS spectrometer. The 
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sample has to be blanked in the wavelength of 595 nm prior to every measurement. A 
standard calibration curve was plotted as the absorption values versus the concentration 
of the standards. The concentration of purified protein sample can then be determined by 
fitting the measured absorbance value to the standard calibration curve of the Bradford 
Assay. 
 [Bradford Std.] 
(µg/ml) 
0.1 µg/µL 
BSA (µL) DIW (µL) 
Bradford 
Reagent (µL) BSA (µg) 
0 0 500 500 0 
1 10 490 500 1 
2 20 480 500 2 
3 30 470 500 3 
5 50 450 500 5 
10 100 400 500 10 
 
Table: 2.1 Preparation of Bradford Assay standard solutions. Each standard 
solution contains DIW, Bradford reagent and 0.1 µg/µL BSA stock solution. The 
final volume of the individual standard solutions is 1000 µL (1 ml) each.  
 
2.6. PROTEIN CRYSTALLIZATION 
2.6.1. Preparation of Buffer Solutions 
There are a number of buffer solutions that were prepared in the protein 
crystallization trials. The buffer solutions included citric acid, HEPES, MES, potassium 
phosphate, sodium acetate, sodium cacodylate, tri-sodium citrate and Tris.  
The buffer solution mixture of potassium phosphate monobasic (KH2PO4) and 
potassium phosphate dibasic (K2HPO4) is referred as potassium phosphate buffer solution 
or “K-PO4 buffer solution”. The 1 M individual buffer stock solutions were prepared by 
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dissolving 136.09 g of KH2PO4 and 174.18 g of K2HPO4 powders into DIW to 1 L 
respectively. Finally, 1 L of 50 mM K-PO4 buffer solution of the pH of interest can be 
prepared by mixing the 1 M K2HPO4 and 1 M KH2PO4 solutions  according to the Table 
2.2 (Sambrook and Russell, 2001). This 100 ml mixture was diluted further to 2000 ml by 
DIW in order to obtain desired pH and concentration of K-PO4 buffer solution. 
pH Volume of 1 M K2HPO4 (ml) Volume of 1M KH2PO4 (ml) 
5.8 8.5 91.5 
6.0 13.2 86.8 
6.2 19.2 80.8 
Table 2.2: The preparation of 50 mM K-PO4 buffer solution at different pHs at 25°C. 
A 1 M stock solution of citric acid buffer was prepared by dissolving 9.606 g of 
citric acid powder into DIW to 50 ml. This solution is referred to as “citric acid buffer 
solution” or “CA buffer solution”. 
A 1 M stock solution of HEPES buffer was prepared by dissolving 11.915 g of 
HEPES powder into DIW to 50 ml. This solution is referred to as “HEPES buffer 
solution”. 
A 1 M stock solution of 2-morpholinoethanesulfonic acid (MES) buffer was 
prepared by dissolving 1.438 g of MES powder into DIW to 50 ml. This solution is 
referred to as ‘MES buffer solution”. 
A 1 M stock solution of sodium acetate buffer was prepared by dissolving 4.104 g 
of sodium acetate powder into DIW to 50 ml. This solution is referred to as “sodium 
acetate buffer solution” or “NaAc buffer solution”. 
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A 1 M stock solution of sodium cacodylate buffer was prepared by dissolving 
8.000 g of sodium cacodylate powder into DIW to 50 ml. This solution is referred to as 
“sodium cacodylate buffer solution” or “Na-CACO buffer solution”. 
A 1 M stock solution of tri-sodium citrate buffer was prepared by dissolving 
12.905 g of tri-sodium citrate powder into DIW to 50 ml. This solution is referred to as 
“sodium citrate buffer solution” or “Nacit buffer solution”.  
A 1 M stock solution of Tris(hydroxylmethyl)aminomethane buffer was prepared 
by dissolving 6.055 g of Tris powder into DIW to 50 ml. This solution is referred to as 
‘Tris buffer solution”. 
All the buffer stock solutions that mentioned above were filtered through 0.22 µm 
sterile Millex®GP filters prior to use. The desired pH values of all the buffers mentioned 
above were adjusted by adding either concentrated HCl or 10 M NaOH prior to bring 
solutions to 50 ml.  
 
2.6.2. Crystallization Methods 
The methods used for crystallization were the vapor diffusion method, both 
hanging drop and sitting drop methods, and the microbatch method. Hanging drop vapor 
diffusion method used a VDX 24-well plate that had a fine bead of vacuum grease 
applied around the edge of the well. Precipitating solutions (1000 µL each) that were 
composed of precipitant, buffer solution, additive, and DIW were pipetted into the 24 
reservoirs of the crystallization plate individually. Then 1 µL of protein solution was 
pipetted onto the center of a clean siliconized 22 mm circle glass cover slide and mixed 
with 1 µL of reservoir solution immediately. The cover slide was inverted using tweezers 
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without losing the drop and sealed over the reservoir with gentle pressure to ensure a 
proper seal. The plate was placed inside the 4oC or 20oC incubator for crystal growth. 
The sitting drop vapor diffusion method was performed using 96-well 
CrystalClear Strip plate. The method was similar to the hanging drop method, but only 
100 µL reservoir solution was needed instead of 1000 µL. In this method, 1 µL of protein 
solution and 1 µL of reservoir solution were mixed together at the top of the ledge, and 
finally the plate was sealed with sealing tape and placed inside the 4oC or 20oC incubator 
for crystals growth.  
The microbatch vapor diffusion method directly mixing 0.5 µL of protein solution 
and 0.5 µL of precipitating solution in a well and then 9 µL of oil (either paraffin oil or 
Al’s oil) was added into same well immediately. At the end, the 72-well “MicroBatch” 
plate was filled up with the oil to fully cover all the wells. The plate was placed inside the 
4oC or 20oC incubator for crystals growth.  
 
2.7. PROTEIN CRYOCRYSTALLOGRAPHY 
2.7.1. Flashing Cooling of Protein Crystals 
A few potential and commonly used cryoprotectants for crystal freezing are 
glycerol, ethylene glycol, MPD, PEG 400, PEG 600, glucose, sucrose and xylitol. All of 
them were tried to screen the cryo-conditions of BSA and Trx-2 crystals. The 
cryosolution was prepared according to the well solution that produced crystals. The 
composition of potential cryosolution included cryoprotectant, precipitant, buffer, salt, 
additive and DIW. The concentrations of the precipitant, buffer, salt or additive (if 
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needed) in the cryosolution were kept the same as the well solution and only DIW was 
replaced by selected concentration of the cryoprotectants. For instance, one of the best 
crystallization conditions of BSA (precipitant/buffer: 55% SAS/25mM NaAc at pH = 5.1) 
where crystals were consistently grown was chosen for this preliminary screening. 
Glycerol was the first cryoprotectant chosen for the screening at different concentrations 
from 15% − 35%. Cryosolutions, about 5 µL, which have different concentrations of 
glycerol (without any crystal) were prepared to immerse into liquid nitrogen for 5 − 10 
seconds and then observed as to whether the cryosolution drop was glassy upon freezing. 
Other cryoprotectants were examined under the same methodology. However, diffraction 
experiments have to be carried out in order to examine the diffraction pattern of the 
samples to assure that the chosen cryoprotectants can cryoprotect the protein crystal 
appropriately and diffract to high resolution for protein structure determination. 
The method used for crystal cooling was very similar to that used for testing the 
cryosolution. Suitable crystals that were sharp-edged and large (a minimum 0.1 mm and 
0.05 mm in each dimension for BSA and Trx-2 crystals respectively) were selected for X-
ray diffraction experiments. There were two usual ways to cryoprotect crystals. The first 
method was to put 5 µL of cryosolution just beside the drop of crystal ready to be lifted 
up, with the use of CrystalCap and CryoLoop aided by the CrystalWand (purchased from 
Hampton Research). A crystal was removed from the drop and transferred into the 
cryosolution for a given amount of time, after which the crystal was ready for X-ray 
diffraction. The second method was to mix the same volume of cryosolution directly onto 
the drop of the crystal (such as 5 µl + 5 µl), afterward, the crystal was transferred into the 
full cryosolution as quickly as possible. For BSA crystals that grown in high 
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concentration of SAS conditions, a thin layer was formed on the drop; therefore, the 
second method was applied to dilute out the layer, and then the crystal could be 
transferred into pure cryosolution without any difficulty. Otherwise, if the crystal can be 
easily looped up, the first method can be applied conveniently.  For the second method, 
instead of cryosolution, mother liquor can be used as well. 
 
2.7.2. Protein X-Ray Diffraction 
Frozen BSA and Trx-2 crystals were diffracted on the in-house X-ray diffraction 
facility at the SSSC. Crystals were cryoprotected by the selected cryosolution. The 
procedure as described in Section 2.7.1 for cryoprotecting the crystals was followed. The 
crystal was mounted on the goniometer head using a cryo-loop. The cryo-jet (Kryo-flex, 
Bruker) as part of the X-ray diffractometer was used to freeze the crystal. The cryo-jet 
used liquid nitrogen to achieve the temperature desired for cryo-temperature diffraction. 
The temperature was set to 100 K. The X-rays were generated using copper radiation at 
the wavelength of 1.5418 Å. 
After crystal mounting, the crystal was aligned to the center of the X-ray beam 
and the detector was placed to an appropriate distance (normally at 7 cm for initial 
exposure). For X-ray diffraction experiments, the crystals were exposed to X-rays for 60 
seconds to collect a still image. If there was a diffraction pattern shown on the image, an 
initial image was collected to determine the cell dimensions of the crystal. The exposure 
time of initial image was 300 seconds. The purpose of increasing the exposure time of the 
initial image from 60 to 300 seconds was to increase the intensities of all diffraction spots. 
The stronger the intensities of the diffraction spots, the more reliable of the unit cell 
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dimensions could be determined. After the exposure time, the diffraction resolution limit 
of crystal was determined and analysis of diffraction pattern was analyzed by PROTEUM 
software to determine the unit cell dimensions and space group of the crystal. 
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CHAPTER 3: RESULTS AND DISCUSSION 
 
3.1. BOVINE SERUM ALBUMIN 
3.1.1. Introduction 
BSA is a soluble and large globular protein and has a molecular weight of 
approximately 66,400 Dalton. The primary structure of BSA (Brown, 1975) has been 
known for a few decades but its crystal structure has not been solved. In order to 
investigate and understand the antagonistic behavior of thiomolybdates towards copper in 
the bovine ruminant environment, the tertiary structure of BSA must be determined. 
Growing high quality crystals is an essential requirement to obtain the structural 
information of BSA in order to determine the location of binding sites of thiomolybdates. 
Therefore, pure and homogenous BSA protein is required prior to performing the protein 
crystallization trials.  Once high quality BSA crystals are obtained, finding the 
appropriate cryo-conditions for flash-cooling the BSA crystals is important to diffract 
crystals to high resolution using X-ray radiation.  
 
3.1.2. Purity Determination of Bovine Serum Albumin 
The first crystallization trials were done using SAS/K-PO4 (Thome, 2001) and the 
BSA was purchased from the supplier without any purification prior to use. However, the 
reproducibility of growing crystals under SAS/K-PO4 conditions was low and the growth 
period of crystals was long (at least 2 – 3 months). So, the impurity of the BSA samples 
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was suspected as the main reason that impeded the growth of BSA crystals when the BSA 
concentration was 10 mg/ml. 
The supplier claimed that the BSA supplied was a minimum 99% electrophoresis 
purity grade product. SDS-PAGE analysis was used to determine the purity of BSA. The 
SDS-PAGE gels were prepared as described in Section 2.5.1. From the SDS-PAGE gel 
displayed in Fig. 3.1, it was observed that there were quite a number of low-molecular-
weight and high-molecular-weight contaminants shown in the original BSA sample (Lane 
2). This seemed to show that the BSA bought from commercial source was not ideally 
pure enough for crystallization trials. Even after performing centrifugation (Lane 3) and 
the following ultrafiltration (Lane 4) twice respectively, the impurities still existed. Hence, 
purification of BSA by perfusion chromatography was carried out for the purpose of 
getting much purer sample to obtain good diffraction quality crystals and obtaining 
consistent results.  
 
       1                             2                 3                4 
Figure 3.1: SDS-PAGE analysis of original BSA samples. The arrow on the left 
indicates the 66 KDa molecular weight level (1: Protein marker, 2: BSA sample 
directly obtained from supplier, 3: BSA sample after 2x centrifugation, 4: 
BSA sample after 2x centrifugation followed by 2x ultrafiltration. The 
concentrations of BSA samples were 10 mg/ml). 
66 KDa
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3.1.3. Purification of Bovine Serum Albumin  
3.1.3.1. Purification of BSA by Anion Exchange Chromatography 
A filtered BSA sample was injected onto the anion exchange column (see Section 
2.4.1.1), and 16 fractions were collected. According to UV absorbance value of 0.7329 at 
the wavelength of 280 nm as shown in Figure 3.2, fraction numbers #8 and #9 
represented the highest purity samples among all the fractions. These 2 fractions were 
used for further SDS-PAGE analysis to confirm the purity of the BSA samples. 
 
 
Figure 3.2: Chromatogram of BSA fractions in anion exchange chromatography.  
 
3.1.3.2. SDS-PAGE Analysis after Anion Exchange Chromatography 
The result of the BSA purification after anion exchange chromatography is shown 
on Figure 3.3. The SDS-PAGE gels were prepared as described in Section 2.5.1. Lane 2 
and lane 3 were the two BSA samples collected from fractions #8 and #9 after anion 
exchange chromatography. From the SDS-PAGE gel shown in Figure 3.3, there were no 
high-molecule weight impurities higher than 66 KDa, but there were still some low 
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molecule weight impurities in the sample, so the purities of BSA samples were 
considered higher than 95%. It clearly showed the intensive reduction of the overall 
amount of contamination presented in the BSA samples. 
 
 
    1                               2         3           4          5         
Figure 3.3: SDS-PAGE analysis of BSA samples after anion exchange 
chromatography. The protein marker is shown on the leftmost column as 
indicated by the arrows.  (1: Protein marker, 2 & 3: BSA sample solutions 
collected from chromatographic fraction # 8 and # 9, 4 & 5: BSA sample 
solutions collected from chromatographic fraction # 10 and # 11, the two 
unlabelled lanes are the BSA samples from other test run). 
 
3.1.3.3. SDS-PAGE Analysis after Ultrafiltration and Dialysis 
After anion exchange chromatography, the fractions that contained BSA were 
reconcentrated by the ultrafiltration method (see Section 2.4.1.2), and dialyzed overnight 
(see Section 2.4.1.3). After reconcentration of the BSA sample solutions and overnight 
dialysis, SDS-PAGE analysis was performed to determine protein purity. From the SDS-
PAGE gel shown in Figure 3.4, there were still some low-molecule weight impurities 
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after purification through chromatography, ultrafiltration and dialysis, however, the 
quality was deemed to be good enough for protein crystallization trials. 
 
          1                           2           3 
Figure 3.4: SDS-PAGE analysis of purified BSA samples. The protein marker is shown 
on the leftmost column as indicated by the arrows. For running a SDS-PAGE analysis, 20 
µL of BSA sample solutions from the individual fractions were mixed with 20 µL of 
SDS-gel loading buffers respectively (1: Protein marker, 2: BSA sample after 
overnight dialysis; 3: BSA sample after ultrafiltration). 
 
3.1.4. Concentration Determination of Purified Bovine Serum Albumin 
After overnight dialysis, the actual concentration of BSA sample solution was 
measured by Bradford method. Six Bradford standards were prepared according to Table 
2.1 (see Section 2.5.3), and used to establish the calibration curve to determine the 
concentration of BSA sample solution (Figure 3.5). From Table 3.1, the UV absorbance 
value of the sample was detected as 0.6453 at the wavelength of 595 nm. According to 
the calibration curve, it corresponded to 11.3 mg/L. After the conversion to the dilution 
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factor 1: 2000 (see Section 2.5.3), the true BSA concentration was determined as 22.6 
mg/ml. In order to prepare a 10 mg/ml BSA sample solution, 442.5 µl concentrated BSA 
sample solution was mixed with 557.5 µl buffer, then the solution was combined and 
centrifuged to ensure complete mixing to get a 1000 µl of 10 mg/ml purified BSA 
solution. This final solution was ready for protein crystallization trials as well as DLS 
measurement to determine the homogeneity of the protein.  
Sample 
Measured 
Concentration 
(mg/L) 
Absorbance  
(Abs) 
BSA Final 
Concentration 
(mg/ml) 
BSA 11.3 0.6453  22.6 
Table 3.1: The Bradford Assay absorbance data of the concentrated purified BSA 
sample solution, the final concentration of the purified BSA is 22.6mg/ml. 
Standard Calibration Curve of Bradford Assay
y = -0.00187x2 + 0.07692x + 0.01368
R2 = 0.99623
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Figure 3.5: The Bradford Assay calibration curve used to determine the 
concentration of purified BSA sample solution at the wavelength of 595 nm. 
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3.1.5. Homogeneity Determination of Bovine Serum Albumin  
The monomodal histograms for purified BSA (Figure 3.6) and unpurified BSA 
(Figure 3.7) sample solutions from the DLS experiments are shown. Both curves were 
highly symmetrical and narrowly distributed. The %polydispersity of purified BSA and 
unpurified BSA solutions were 12.2% and 12.6% respectively for the 1 mg/ml BSA 
samples. These values were less than 30% upper limit of protein crystallizability as 
described in the literature (Ferre-D'Amare and Burley, 1997) or 15% upper limit of 
polydispersity as mentioned in the supplier instrument user’s manual. The calculations of 
%polydispersity were based on the intensity peak distribution. The DLS experimental 
results of both purified and unpurified BSA sample solutions demonstrated that, in terms 
of homogeneity, their qualities were equivalent, they were considered as homogenous and 
monodispersed proteins. The BSA protein samples, whether purified or not, were 
homogenous and ready for protein crystallization trials as measured by DLS.  
From my observations while performing the DLS experiments, the experimental 
results were occasionally not so consistent. This might be attributed to the micro-volume 
of the sample solution and the sensitivity of the instrument, even a tiny bubble might 
have a significant effect on the results. I suggest that %polydispersity determined from 
DLS experiments can be only regarded as a reference indicator. If the %polydispersity is 
more than 30%, it is very likely that crystals will not form in crystallization trials. If the 
%polydispersity is less than 30%, crystals are more likely to grow (Ferre-D'Amare and 
Burley, 1994; Ferre-D'Amare and Burley, 1997; Zulauf and D' Arcy, 1992). 
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Figure 3.6: Monomodal histogram of 1 mg/ml purified BSA solution. The 
%polydispersity of the 1 mg/ml purified BSA sample solution is 12.2%. 
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Figure 3.7: Monomodal histogram of 1 mg/ml unpurified BSA solution. The 
%polydispersity of the unpurified 1 mg/ml BSA sample solution is 12.6%. 
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3.1.6. Crystallization Trials of Bovine Serum Albumin  
A number of different crystallizing conditions, (see Appendix 1 for the summary 
of BSA crystallization trials) including different types of precipitants, precipitant 
concentrations, protein concentration, buffers, pHs, salts, additives, and different 
crystallization methods (see Section 2.6), have been attempted. The initial trials of BSA 
crystallization were based on the crystallization conditions done by Thome (Thome, 
2001). Crystals were grown in potassium phosphate buffer solutions between pH 5.5 − 
6.2 (Asanov et al., 1997a; Asanov et al., 1997b). The precipitant used for BSA 
crystallization was saturated ammonium sulfate (SAS) at a concentration of about 40 – 
60%. The concentration of BSA can be varied from 10 mg/ml to 80 mg/ml, but between 
the ranges of 50 – 60 mg/ml were highly reproducible. Crystals normally took at least a 
month to appear and spent another month to grow to bigger sizes before cessation of 
crystal growth.  
The first conditions that I tried and got BSA crystals were under 52.5 – 57.5% 
SAS/100 mM K-PO4 at pH 6.0 condition using hanging drop diffusion method in a 2 – 3 
month period (Thome, 2001). BSA from the supplier was directly used, without any 
purification prior to BSA crystallization trials and its concentration was 10 mg/ml. 
However, the crystallization results could not be reproduced even after adding different 
kinds of salts (NaCl, MgCl2, KCl, CdCl2, ZnCl2, and NiCl2) in an attempt to enhance the 
crystals growth rate. Only CoCl2 showed that it can be a useful additive to grow crystals 
in about 2 months. The crystallization trials were repeated in the similar conditions 
(SAS/K-PO4) with or without salts NaCl, MgCl2 and KCl at different temperatures (4°C 
and 15°C), but no crystals formed. Therefore, BSA was purified by anion exchange 
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chromatography to improve its purity and try to crystallize BSA in a shorter period of 
time after protein purification.  A solution of 10 mg/ml purified BSA was crystallized, 
under 55 – 60% SAS/50 mM K-PO4 (pH 5.7 – 6.0)/1 – 20 mM CoCl2 conditions. These 
crystals can be produced in about 1 – 2 months.  
The crystallization results showed that the crystallization of purified BSA was still 
not reproducible. As a result of the poor reproducibility of crystals formation under 
SAS/K-PO4 conditions, high concentrations (30 – 80 mg/ml) of unpurified BSA were 
attempted (Dr Luo, personal communication) instead of 10 mg/ml purified BSA in most 
of the crystallization trials. The purpose is to crystallize protein under the same 
crystallization conditions (SAS/K-PO4) which 10 mg/ml of purified BSA gave crystals. 
The changing the concentration of BSA from low concentration (10 mg/ml) to high 
concentration (e.g. 60 mg/ml) demonstrated that under such modified conditions BSA 
protein can be crystallized without any purification and the quality of crystals did not 
deteriorate. The growth period of such unpurified BSA crystals was similar to the 
purified BSA crystals. The most important factor to consider for using high concentration 
of BSA in the crystallization trials was the higher reproducibility of the BSA crystals 
grown in the crystallization trials compared to the 10 mg/ml of unpurified BSA and 10 
mg/ml of purified BSA. Although the SDS-PAGE gel shown on Figure 3.8 illustrated 
that the unpurified 50 − 60 mg/ml BSA proteins have some high molecular-weight 
impurities as well as some low molecular-weight impurities (see the arrows on lane 4, 5), 
a number of single crystals still can be produced under such conditions. Therefore, the 
purification of BSA was not required if highs concentration of BSA were used in the 
crystallization experiments. In summary, the most successful trials occurred at 51 – 55% 
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SAS/50 mM K-PO4 (pH 5.6 – 5.9)/with or without CoCl2 using hanging drop diffusion 
method when protein concentration was about 50 – 60 mg/ml. Consequently, purity is not 
considered to be playing a crucial role in the BSA crystallization experiments if the BSA 
concentration is maintained at high concentration (e.g. 50 mg/ml above) in the SAS/K-
PO4 or later the SAS/NaAc crystallization conditions. 
 
 
 
                    1                     2         3                      4        5 
Figure 3.8: SDS-PAGE analysis of original and purified BSA samples. The 
protein marker is shown on the leftmost column as indicated by the arrows. The 
other two arrows on the top highlight the high-molecular-weight impurities in the 
BSA samples. For running a SDS-PAGE analysis, 1 µL of 10 mg/ml BSA 
samples were mixed with 19 µL DIW and 20 µL of SDS-gel loading buffers, and 
0.5 µL of 50 mg/ml (or 60 mg/ml) BSA samples were mixed with 19.5 µL DIW 
and 20 µL of SDS-gel loading buffers respectively (1: Marker, 2: Unpurified 10 
mg/ml BSA, 3: Purified 10mg/ml BSA, 4 & 5: Unpurified 50 & 60 mg/ml 
BSA). 
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The crystals produced under SAS/K-PO4 conditions in high concentration of BSA 
were not very stable. For instance, the crystals kept in 20°C incubator were clear and 
glassy under inspection by microscope. When the crystal plate was put back to incubator 
after first inspection and taken out again within 10 minutes, it was found that the drops 
where crystals had grown started to precipitate. The BSA crystals no longer existed and 
the drops were covered by precipitate instead. The reproducibility of crystal formation 
under K-PO4 buffer solution was not satisfactory and fluctuated. Therefore, a highly 
similar crystallization condition was established except that the growing buffer solution 
has been changed from K-PO4 buffer solution to sodium acetate (NaAc) buffer solution 
(Christopher et al., 1998). The rest of the chemical reagents including the precipitant and 
additive, and the concentrations of individual components of the crystallization solution 
remained the same. After altering the K-PO4 buffer solution to NaAc buffer solution, the 
quality of crystals was better in terms of appearance and shape, the stability of crystals 
was enhanced and the quantity of crystals was higher as well (Figure 3.9).  
A variety of salts have been evaluated for adding into SAS/K-PO4 or SAS/NaAc 
buffer solutions to enhance the crystal-growing rate. The salts can be classified as 
monovalent ions such as LiCl, NaCl and KCl, and divalent ions such as MgCl2, CoCl2, 
NiCl2, ZnCl2 and CdCl2. Only CoCl2 showed a positive influence in getting single 
crystals. The sizes of crystals grown were between the ranges of 0.1 mm − 0.4 mm, other 
salts neither enhanced the growth rate of crystals nor produced any crystals that were 
suitable for X-ray diffraction. Therefore, CoCl2 was chosen as an additive in the 
crystallization trials in NaAc buffer solution because the growth rate of crystals grown in 
such conditions will be slightly faster than those without CoCl2 in the crystallization trials. 
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Figure 3.9: The quality of BSA crystals was improved and the quantity of BSA 
crystals was increased after altering the buffer solution from 50 mM K-PO4 (left) 
to 25 mM NaAc (right). The scale bar represents a distance of about 0.2 mm. 
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Other buffer solutions such as sodium cacodylic, MES, citric acid and tri-sodium 
citrate buffers that have similar pH range (5.0 − 7.0) to K-PO4 or NaAc buffer solutions 
have been tried. The crystals appeared after at least a month, they were neither sharp-
edged nor stable as the ones grown in NaAc buffer solution, and most of them were 
formed in precipitate (Figure 3.10). Sodium acetate buffer solution was therefore 
considered as the best buffer solution among all the buffer solutions that have been 
attempted. 
The Hampton Research’s grid screens (MPD, (NH4)2SO4, PEG 6,000 & PEG 
6,000/LiCl) and crystal screens (I & II) were also used to perform initial general 
screening to examine the protein supersaturation conditions. Using the grid screen, it was 
found that 30% PEG 6,000/1 M LiCl/100 mM MES at pH 6.0 can produce needle-like 
crystal under hanging drop diffusion method. The concentration of BSA used in the 
crystallization trials, either purified or unpurified, was 10 mg/ml. The result outcomes 
were not consistent and reproducible. Some trials for optimizing the crystallization 
conditions has been attempted, these included using high concentration (e.g. 30 mg/ml) of 
unpurified BSA, screening of precipitant concentration (5 − 30% PEG 6,000), using 
different kinds of salts with different concentrations (NaCl, KCl, MgCl2, NH4(SO4)2), 
different precipitants with different concentrations (PEG 400, PEG 600, PEG 1,000, PEG 
MME 2,000, PEG 4,000 and PEG 8,000), different buffer solutions (Tris, HEPES), and 
using sitting drop or microbatch methods to repeat some crystallization conditions. After 
all these trials have been attempted, no single crystal was obtained and most of the 
crystals grown were needle clusters.  
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Figure 3.10: The difference between the BSA crystals grown in different buffer 
solutions at 20°C. The crystals on the left were grown in 100 mM sodium cacodylate 
buffer solution at pH 5.2 (52% SAS). The crystal in the right was grown in 25 mM 
NaAc buffer solution at pH 5.3 (48% SAS). The scale bar represents a distance of 
about 0.4 mm.  
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Another condition that showed crystals was 20% PEG MME 2,000/10 mM 
NiCl2/100 mM Tris at pH 8.5. The concentration of BSA mostly used in the 
crystallization trials was 10 mg/ml, either purified or unpurified; the rest of 
concentrations used were unpurified BSA. The optimization trials were done using sitting 
drop or microbatch method. The broad screening of buffer pH (7.0 – 9.0) and precipitant 
concentrations (10 – 40%) were carried out, and different BSA concentrations (5.0, 7.5, 
10 & 20 mg/ml) have been used as well. The optimization strategies that were applied to 
both crystallization methods included narrowing the pH range of the buffer solutions and 
reducing the concentration of the precipitants. These strategies could not successfully 
optimize the multi-crystals to single crystals. The crystals grown were either too small or 
no single crystals were formed.  
Although the optimization of these two conditions has been tried, the attempts to 
optimize the multi crystals to single crystals were unsuccessful and the reproducibility of 
crystal formation was poor as well. Both crystallization conditions gave needle clusters.  
The crystals grown in SAS/NaAc are much better than those grown at the SAS/ 
K-PO4 condition in terms of crystal size, quality, growing time and reproducibility. For 
X-ray data collection, only the crystals which were sharp-edged, single and grown from 
clear drops as shown in Figure 3.11 were considered as good crystals and were selected 
to perform in-house X-ray diffraction experiments for screening the cryo-conditions of 
the crystals as well as determining the diffraction limits of the crystals themselves.  
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Figure 3.11: BSA Single Crystal (about 0.35 mm x 0.35 mm x 0.40 mm). The scale bar 
represents a distance of 0.2 mm approximately. This single crystal grown in 51% 
saturated ammonium sulfate with 25 mM sodium acetate buffer solution and 10 mM 
CoCl2. The 2 µl protein equally mixed with 2 µl precipitating solution in 24-well VDX 
plate at 20°C using hanging drop diffusion method. 
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Compared to previous work (Thome, 2001); the crystallization conditions of BSA 
have been modified in two aspects. First, the K-PO4 buffer solution has been changed to 
NaAc buffer solution in order to enhance the crystal reproducibility and crystal quality, in 
terms of size and appearance. Second, the concentration of BSA has been increased from 
10 mg/ml to 50 – 60 mg/ml (or even higher up to 80 mg/ml) that makes the purification 
of BSA protein unnecessary.  
The best crystallizations of BSA crystals which are highly reproducible are 
summarized in below: 
 
50mg/ml: 48 – 50 % SAS 
25mM Sodium Acetate (pH 5.2 – 5.3) 
10mM CoCl2 or without any additive 
Hanging or sitting drop 
20°C 
 
60mg/ml: 48 – 52 % SAS 
25mM Sodium Acetate (pH 5.4 – 5.6) 
10mM CoCl2 or without any additive 
Hanging or sitting drop 
20°C 
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3.1.7. Cryocrystallography of Bovine Serum Albumin 
Cryoprotectants such as ethylene glycol, glycerol, glucose, sucrose, MPD, PEG 
400, PEG 600, and xylitol have been tried (see Section 2.7.1). Preparing cryosolutions 
using 25 – 35% glycerol made the frozen drop looked glassy after immersing the drop 
into liquid nitrogen for few seconds, so 25 – 35% glycerol was preliminary used for 
cryoprotecting all BSA crystals that were produced under the SAS/K-PO4 or SAS/NaAc 
conditions either with or without any additives. MPD, PEG 400 and PEG 600 were 
demonstrated to be inappropriate cryoprotectants, because once the cryosolutions were 
immersed in liquid nitrogen, the drop became opaque. This implies that once these 
cryosolutions were used to mount the crystals, the crystals would not be properly flash-
cooled. Other cryoprotectants, 25 – 30% ethylene glycol, 35 – 40% sucrose, 30 – 35% 
glucose and 30% Xylitol showed promising results in the preliminary cryo-solution 
examination. 
On observation, a higher concentration cryosolution or mother liquor was needed 
to cryoprotect the crystals grown in SAS precipitating solution. After a 1 – 2 month 
crystallization period, the concentration of the ammonium sulfate was no longer the same 
as in the initial condition. This is the likely reason why these kinds of crystals seemed to 
dissolve once the mother liquor from the same well or the same SAS concentration in the 
cryosolution were added to the crystal drop. Consequently, a higher concentration of 
mother liquor or cryosolution might be needed. For instance, 55% SAS/25% glycerol/   
25 mM NaAc cryosolution was used to flash cool the crystals that were grown in 50% 
SAS/25 mM NaAc solution. Normally, the concentration of SAS required was 5 – 10% 
higher in the cryosolution than that in the reservoir solution.  
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After the preliminary examination for testing the suitable cryoprotectants, various 
cryosolutions were prepared to examine their ability to cryoprotect the BSA crystals. The 
cryosolutions prepared were the same as the precipitating solutions that produced crystals 
except DIW were replaced by cryoprotectants and the concentration of SAS would be 
increased by 5 – 10% in some cases. The minimum sizes of BSA crystals for X-ray 
diffraction studies were at least 0.10 mm in each dimension. All cryo-conditions tested 
are summarized in Table 3.2. Diffraction of BSA crystals under a variety of cryo-
conditions was carried out at the SSSC (see Section 2.7.2). The results demonstrated that 
none of the cryo-conditions allows crystals to be diffracted to better than 8 Å resolution. 
For instance, 55% SAS/30% Xylitol/25 mM NaAc (pH 5.2) cryosolution seems that it 
can flash cool the crystal quite well based on its glassy appearance as shown in Figure 
3.12. However, the crystal did not diffract at all. So, such cryosolution conditions did not 
guarantee that the crystal would diffract if the judgment was based on the glassy 
appearance of the crystal solution. Among all cryoprotectants, ethylene glycol and xylitol 
were the worst, no diffraction pattern was observed. The other cryoprotectants such as 
sucrose displayed diffractions to limited resolution beyond 10 Å. Other cryoprotectants 
such as paraffin oil have shown similar results to 35% sucrose with both displaying ice 
rings in the diffraction pattern, therefore, they were not considered as ideal 
cryoprotectants. Replacement of the saturated ammonium sulfate by sodium malonate has 
been tried, but no diffraction was observed. 
In X-rays diffraction experiments, the performances of cryosolutions, in terms of 
resolution, that contain the NaAc buffer solution are better than those contain K-PO4 
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buffer solution. This might be attributed to the nature of buffer itself or because the sizes 
of the crystals grown in K-PO4 buffer were smaller than those grown in NaAc buffer. 
 
 
Figure 3.12: BSA single crystal inside the loop located on the goniometer, the 
cryosolution used was 55% SAS/30% xylitol/25 mM NaAc (pH 5.2).  
 
The best cryo-conditions that BSA crystal can be diffracted to 8 Å are 
SAS/NaAc/25% glycerol and SAS/NaAc/30% glucose respectively. Comparing these two 
and the other conditions, it suggests that the most satisfactory cryoprotectants used were 
25 – 35% glycerol and 30 – 35 % glucose. There were no ice-rings on both cases but the 
best diffraction obtained was only to resolution of 8 Å. This resolution is not sufficient 
for solving a protein tertiary structure.  
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Cryoprotectant 
(Cy) 
[Cy] 
(%) 
[BSA] 
(mg/ml) 
[Precipitant] Buffer/pH Additive 
Crystal 
(mm) 
Resolution 
(Å) 
EG 25 50 55% SAS K-PO4 /5.6 NA 0.40 ND 
 30 80 50%SAS K-PO4 /5.6 NA 0.15 ND 
Glycerol 25 60 49% SAS K-PO4 /5.7 NA 0.10 ~ 10.0 
 30 60 48% SAS K-PO4 /5.7 NA 0.10 ND 
 35 60 49% SAS K-PO4 /5.8 NA 0.10 ND 
 25 50 47% SAS NaAc/5.2 NA 0.25 ~ 9.0 
 25 50 45% SAS NaAc/5.4 NA 0.30 ~ 8.0 
 25 60 48% SAS NaAc/5.2 NA 0.25 ~ 10.0 
 25 50 48% SAS NaAc/5.5 10mMCoCl2 0.20 ~ 10.0 
 25 50 50% SAS NaAc/5.5 10mMCoCl2 0.30 ~ 9.5 
 30 60 50% SAS NaAc/5.4 NA 0.30 ~ 9.0 
 35 60 54% SAS NaAc/5.2 NA 0.20 ~ 9.6 
 30 50 55% SAS NaAc/5.2 3% Xylitol 0.10 ND 
Glucose 30 60 51% SAS NaAc/5.2 10mMCoCl2 0.10 ~ 9.0 
 30 60 56% SAS NaAc/5.4 10mMCoCl2 0.10 ~ 8.6 
 30 30 49% SAS NaAc/5.4 NA 0.10 ~ 8.0 
 35 60 48% SAS NaAc/5.5 NA 0.10 ~ 8.8 
 35 60 51% SAS NaAc/5.5 NA 0.10 ~ 10.8 
Sucrose 35 30 54% SAS NaAc/5.2 NA 0.15 ND 
 35 60 55% SAS NaAc/5.1 NA 0.10 ND 
 35 70 57% SAS NaAc/5.4 NA 0.15 ND 
Xylitol 30 50 55% SAS NaAc/5.2 NA 0.10 ND 
 
Table 3.2: Summary results of various cryo-conditions of BSA crystals that were 
prepared for X-ray diffraction experiments at the SSSC. The preparation of cryosolution 
was done according to concentration of cryoprotectant, precipitant, additive, buffer, and 
buffer pH. The concentrations of all K-PO4 and NaAc buffer solutions are 50 mM and 25 
mM respectively. The concentrations of SAS shown above are the crystallization 
conditions. ND: No diffraction. 
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Even though the crystals cannot be diffracted to resolutions better than 3.5 Å, the 
low resolution data was collected to define the unit cell parameters of a BSA crystal. A 
BSA crystal grown in 49% SAS/25 mM NaAc at pH 5.4 was cryoprotected by 30% 
glucose. The cell dimension of the crystal was determined in the SSSC X-ray laboratory, 
which was a = 147.624 Å, b =147.624 Å, c = 351.117 Å; α = 90°, β = 90°, γ = 120° and 
the crystal space group was hexagonal P6 (Figure 3.13).  
 
Figure 3.13: X-Ray Diffraction Pattern of a BSA crystal that cryoprotected by 
30% glucose. The diffraction resolution is 8.0 Å. 
 
According to Matthew’s coefficient (Matthews, 1968), the range of solvent 
content of BSA crystal is shown on Table 3.3. The calculation is based on the assumption 
of 1 – 9 molecules per asymmetric unit (a.s.u) and the molecular weight of BSA is 66,400 
Da. From Table 3.3, it shows that there are a number of possibilities of the solvent 
~ 8.0 Å 
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content of BSA crystals. The Matthew‘s coefficient of protein crystals is usually between 
1.7 – 3.5 Å3/Da, so most likely there are 6 – 8 molecules exist in one asymmetric unit in a 
crystal unit cell. 
No. of molecule/ a.s.u. Matthews coefficient Solvent content (%) 
1 16.6 92.5 
2 8.3 85.1 
3 5.5 77.6 
4 4.2 70.2 
5 3.3 62.7 
6 2.8 55.3 
7 2.4 47.8 
8 2.1 40.4 
9 1.9 32.9 
10 1.7 25.5 
Table 3.3: Summary result of the number of molecules in an asymmetric unit 
(a.s.u.) within a unit cell of a BSA crystal.  
 
Compared to the diffraction data collected above with the previous work done 
(Thome, 2001), the space group and cell parameters of the BSA that collected by Thome 
are: P6, a = 148.24 Å, b = 148.24 Å, c = 356.70 Å and α = 90°, β = 90°, γ = 120°. This 
indicates that both results done by me and Thome are similar with each other. The cell 
dimensions of crystals are almost same as each other, and the space groups of both 
crystals are hexagonal, P6. The major difference is Thome employed room temperature 
techniques to diffract crystals but I used the cryo-temperature technique to diffract 
crystals. This implies that BSA crystals diffracted either at room temperature or at cryo-
temperature are weakly diffracted to 8 Å.  
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The results tell us that we have to find another way to obtain well diffracted BSA 
crystals in order to solve its crystal structure. Otherwise, structural information of BSA 
protein can not be gained and no clues for finding the binding site of thiomolybdates or 
copper ions on BSA. The results demonstrate that BSA crystals grown in SAS/K-PO4 or 
SAS/NaAc and cryoprotected by glycerol or glucose do not diffract very well. The reason 
is still unclear, but this might attributed to protein characteristics. This is probably due to 
three-dimensional flexibility in some flexible regions (such as N-terminus or C-terminus 
regions) of BSA that causes crystal lattices in these regions disordered. In order to 
diffract BSA crystals to high resolution, we need to either grow BSA crystals under a 
totally new condition, or find another cryoprotectant or cryo-condition that can protect 
the BSA crystals. Limited proteolysis may be worth to trying to remove the suspect 
flexible region to obtain high-quality crystals if this is a reason that leads to poor 
diffraction of BSA crystals (Xie et al., 1996). 
For looking at new crystallization conditions, a number of crystallization 
screening kits supplied by different vendors (Emerald Biostructures, Molecular 
Dimension, etc) can be explored or different crystallization strategies can be applied as 
well. Seeding might be attempted to transfer some BSA crystal seeds into PEG 6,000/ 
MES/LiCl precipitating conditions, to observe whether BSA crystals could be grown 
under such circumstances. Replacement of SAS by another precipitant is worthwhile to 
try for decreasing the crystal growth rate and reducing the difficulty in handling the 
crystals during cryocrystallography. For finding suitable cryo-conditions to flash cool 
BSA crystals, a combination of different cryoprotectants might be attempted. 
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3.2. THIOREDOXIN-2 
3.2.1. Introduction 
Trx-2 (HP1458) is one of the Trx homologues from Helicobacter pylori, which 
has a molecular weight of approximately 12 KDa. X-ray diffraction data of Trx-2 has 
been collected at 2.4 Å (Filson et al., 2003). Hence, the data is expected to provide 
information to determine the structure of Trx-2. However, the reflections at high 
resolution are split (Figure 3.14), which means each spot is divided into 2 pieces, so 
better quality crystals that can diffract to high resolution and without split spots are 
required. The purification procedure was followed as previously described (Filson et al., 
2003) to obtain pure and homogenous proteins. Different crystallization conditions for 
crystallizing Trx-2 were attempted. Then, cryo-conditions to flash-cool the Trx-2 crystals 
were examined. 
 
Figure 3.14: X-ray diffraction pattern of a Trx-2 crystal that had been collected at 
2.4 Å resolution (Filson et al., 2003) is shown on the left. The arrow indicates 3 
split spots. The graph on the right is the enlarge portion of these split spots. 
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3.2.2. SDS-PAGE Analysis after Overexpression and Cell Lysis 
The SDS-PAGE analysis results were shown in Figure 3.15 to demonstrate the 
improvement of the purity of Trx-2 proteins. After the protein overexpression (see 
Section 2.3), the Trx-2 proteins were released from the cell and purified through lysis 
(Lane 2), centrifugation (Lane 3), ammonium sulfate precipitation (Lane 4), overnight 
dialysis (Lane 5) and anion exchange chromatography (Lane 6 & 7). The impurities that 
originated from the cells were removed through the protein purification procedures. 
 
 
               1      2     3       4         5        6        7      8 
Figure 3.15: SDS-PAGE analysis of Trx-2 samples after overexpression and 
purification. The arrow on the left indicates the 14 KDa molecular weight level 
(1: Protein marker, 2: After lysis, 3: After centrifugation, 4: After 
ammonium sulfate precipitation, 5: After dialysis, 6 & 7: Fraction 1 & 2 in 
anion exchange chromatography, 8:  After ultrafiltration). 
 
 
14 KDa
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3.2.3. Purification of Thioredoxin-2 
3.2.3.1. Anion Exchange Chromatography Purification 
After lysis and overnight dialysis, anion exchange chromatography was 
performed. The Trx-2 sample solution was loaded onto the HQ 20 column (see Section 
2.4.2.3). Seven fractions were collected and only the first two fractions (fraction number 
#1 and #2) contained purified Trx-2 and represented as protein samples according to 
chromatogram (Figure 3.16). The UV absorbance of this peak was detected as 0.6837 at a 
wavelength of 280 nm. These 2 fractions were used for the further SDS-PAGE analysis 
for determining the purity of Trx-2 protein. Comparing lane 2 with lane 6 or 7 (Figure 
3.15), the purity of Trx-2 was improving. Lane 8 demonstrated that after ultrafiltration 
(see Section 2.4.2.4) Trx-2 was approximately 90% pure. It also showed that the intensive 
reduction of the overall amount of contamination presented in the Trx-2 protein samples 
through the protein purification. So, the purification of Trx-2 proteins by cation exchange 
chromatography (see Section 2.4.2.5) would be continued in order to obtain high purity 
Trx-2 protein.  
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Figure 3.16: Chromatogram of the purification of Trx-2 sample solutions 
collected in anion exchange chromatography. 
 
3.2.3.2. Cation Exchange Chromatography Purification 
The Trx-2 sample solution was reconcentrated using ultrafiltration after anion 
exchange chromatography; 5 – 10 ml of reconcentrated sample solution was loaded into 
the self-packed carboxymethyl cation exchange column. Eventually, 40 fractions were 
collected, and only the fractions #26 – #30 represented the highest purity of Trx-2 
proteins among all fractions collected according to the UV detector where UV 
absorbance value was given as 0.7494 at the wavelength of 280 nm as shown in Figure 
3.17.  
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Figure 3.17: Chromatogram of the purification of Trx-2 sample solutions collected 
in cation exchange chromatography. 
 
These 5 fractions were collected individually and used for further SDS-PAGE 
analysis to confirm their purity. From Figure 3.18, it demonstrated that there were no 
high-molecular-weight and low-molecular-weight impurities in the sample, so the purity 
of Trx-2 sample was considered as greater than 99%. The fractions were combined and 
concentrated to 1 – 2 ml.  
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          1                2                3                 4                5                 6 
Figure 3.18: SDS-PAGE analysis of Trx-2 sample solutions after cation exchange 
chromatography. The leftmost column represents the “Low Molecular Weight 
Protein” marker and the arrow on the left indicates the individual molecular 
weight levels. The other 5 columns represented the Trx-2 samples that collected 
from fractions #26 – #30. (1: Protein marker, 2: Purified Trx-2 collected from 
fraction # 26 after 2nd cation column chromatography, 2: Fraction #27, 4:  
Fraction #28, 5: Fraction #29,   5:  Fraction #30). 
 
3.2.4. Concentration Determination of Purified Thioredoxin-2  
Six Bradford standards were prepared according to Table 2.1. All standards were 
used to establish the calibration curve shown in Figure 3.19 to determine the 
concentration of Trx-2. Two sets of samples that from the same purified Trx-2 samples 
were prepared to determine the actual concentration of Trx-2 after purification. From 
Table 3.4, the absorbance values of both samples were detected as 0.4337 and 0.4316 
respectively. These values were corresponded to 6.3 mg/L and 6.3 mg/L individually. 
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The concentration average of the Trx-2 was 6.3 mg/L. After the conversion of the 1000 
times dilution factor (see Section 2.5.3), the true Trx-2 concentration was determined as 
6.3 mg/ml. The purified Trx-2 samples were then utilized to perform the DLS 
measurement for determining the homogeneity of Trx-2 protein.  
Standard Calibration Curve of Bradford Assay
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Figure 3.19: Bradford assay calibration curve for purified Trx-2 sample solutions. 
 
Sample Concentration (mg/ml) Absorbance 
  
Trx Sample 1 
  
6.3 
  
0.4316 
  
Trx Sample 2 
  
6.3 
  
0.4337 
Average 6.3  
Table 3.4: Bradford assay absorbance data of the purified Trx-2 sample solutions 
to determine the true concentration of purified Trx-2 sample solutions. 
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3.2.5. Homogeneity Determination of Purified Thioredoxin-2  
Prior to sample measurement, the Trx-2 sample solutions of 6.3 mg/ml were 
diluted to 1.0 mg/ml for DLS measurements (see Section 2.5.2). From the monomodal 
histogram of 1 mg/ml of Trx-2 displayed in Figure 3.20, the curve was highly 
symmetrical and narrow distributed. The %polydispersity (%PolyD) calculated was based 
on the distribution of peak intensity. The %PolyD of purified Trx-2 was 12.5% which 
was less than the upper limit 30% that described in the supplier application note (Protein 
Solutions, New Jersey, USA) as well as the literature (Ferre-D'Amare and Burley, 1997). 
Thus, the purified Trx-2 proteins can be considered to be monodispersed. The quality of 
the purified Trx-2 was satisfactory to perform crystallization trial in terms of purity and 
homogeneity.  
 
Figure 3.20: Monomodal histogram of 1.0 mg/ml of purified Trx-2 
solution. The %polydispersity of the purified sample solution is 12.5%. 
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3.2.6. Crystallization Trials of Thioredoxin-2 
The Trx-2 protein has been crystallized and the crystallization condition has 
already been published (Filson et al., 2003). The condition is 30% PEG 6,000/0.1 M 
(NH4)2SO4/10 mM DTT. However, the crystallization condition was re-optimized in 
order to obtain much better quality crystals (see Appendix 1 for the summary of Trx-2 
crystallization trials). Initially, the crystallization condition: 30% PEG 6,000/100 mM 
citric acid buffer (pH 4.5)/vapor diffusion method was considered as the most satisfactory 
condition among all Hampton Research screening kits conditions. The crystals formed 
within 1 – 2 weeks. There were many crystals in the drops but quality of the crystals was 
better than the crystals that were grown under all other screening conditions in terms of 
crystal appearance. The crystallization condition was similar to the published result as 
well. After that, the additive and detergent screens were employed to optimize the 
crystallization condition. Acetonitrile, n-butanol, DTT and methylene chloride were 
found to produce better crystals in terms of shape among all of the reagents used. 
However, DTT was the best among all of them. The initial trials that have been attempted 
were based on 24 – 36% PEG 6,000/100 mM citric acid buffer (pH 3.7 − 4.5)/10 mM 
DTT sitting drop method. The well solution of the sitting drop method contained 90 µl of 
the precipitating solution that mixed with 10 µl of 100 mM DTT. The drop volume was 2 
µl of Trx-2 mixed with 2 µl of well solution. The rod-like long crystal showers appeared 
as shown in Figure 3.21 after about 3 − 7 days and another 1 – 2 weeks for growing 
before cessation. Different precipitants (PEG 4,000 and PEG 8,000), precipitant 
concentrations (14 – 36% PEG), different additives [acetonitrile, n-butanol and 
methylene chloride], additive concentrations (5 – 50mM) and pHs (3.6 – 4.9) have been 
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tried to optimize the crystallization condition. Other optimization strategies such as 
adding paraffin or Al’s oil to slow down the evaporation rate, dilution method used to 
reduce the numbers of the crystals and seeding (either macro- or micro-) have been 
attempted in order to obtain single crystals. However, the most reproducible and reliable 
single crystals were grown at 24% − 26% PEG 6,000/10 mM DTT/100mM citric acid 
buffer at pH 4.0 − 4.2 using either hanging drop or sitting drop diffusion methods as 
shown in Figure 3.21. Co-crystallization of PEG 6,000/10 mM DTT/100 mM citric acid 
buffer with 10% glycerol has also been tried. The crystal growth time was almost the 
same but crystal sizes were slightly smaller.   
     
Figure 3.21: The optimization of Trx-2 crystals. Initial crystal grown from screening 
kit is shown on the left, the condition is: 33 % PEG 6000/1000 mM citric acid buffer 
(pH 4.3). After optimization, Trx-2 multiple crystals were optimized into single 
crystals as shown on the right, the condition is: 24% PEG 6000/100 mM citric acid 
buffer (pH 4.2)/10 mM DTT. The scale bar represents a distance of about 0.2 mm. 
Trx-2 single crystal shown on the right (about 0.12 mm x 0.12 mm x 0.9 mm).  
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3.2.7. Cryocrystallography of Thioredoxin-2  
At first, glycerol at different percentages from 10% − 30% was examined for its 
capability to cryoprotect the Trx-2 crystals by immersing the cryosolution into liquid 
nitrogen about 5 – 10 seconds (see Section 2.7.1). Glycerol at 10% was found to be 
suitable to properly freeze the mother liquor, so 10% glycerol was used as cryoprotectant 
for the Trx-2 crystals that crystallized under the PEG 6,000/citric acid buffer/DTT 
condition. The concentration of the precipitant, buffer, salt in the well solution remained 
the same, only the DIW was replaced by 10% glycerol. The sizes of crystals were 
between 0.05 − 0.15 mm at the minimum dimension. Other cryoprotectants such as 
ethylene glycol, glucose, PEG 400, PEG 600, MPD, sucrose and xylitol were also tried. 
Only 15 – 20% glucose and 10 – 15% PEG 400 were considered appropriate, because 
after immersing the cryosolutions without any crystal into liquid nitrogen, the frozen 
solution looked glassy. 
After the preliminary screening for choosing appropriate cryoprotectants, Trx-2 
crystals were used to examine the cryo-conditions using 10% glycerol, 15 – 20% glucose, 
and 10 – 15% PEG 400. For the screening using the X-ray diffractometer (see Section 
2.7.2) of Trx 2 crystals, a crystal was scooped up and soaked in 25 % PEG 6,000/100 mM 
citric acid buffer (pH 4.2)/10 mM DTT with 10 % PEG 400. As a result, a 3.2 Å 
diffraction data was preliminary obtained. No ice ring was formed and observed in the 
diffraction image as shown in Figure 3.22. The cell dimension of Trx-2 crystal was 
determined in the SSSC laboratory, which was a = b = 42.65 Å, c = 64.64 Å; α = β = γ = 
90° and its space group is tetragonal, P4. 
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Figure 3.22: X-ray Diffraction Pattern of a Trx-2 crystal that cryoprotected by 
10% PEG 400. The diffraction resolution is 3.2 Å.  
 
There were another two Trx-2 protein crystals that were sent to synchrotron at 
Chicago for X- ray diffraction experiments in order to obtain better resolution data. The 
crystals that were sent for data collecting were under the crystallization conditions as 
shown below: 
1) 7.6 mg/ml of Trx-2, 25% PEG 6,000, 10mM DTT, 100mM Citric Acid 
Buffer at pH 4.1, 20oC (Cryoprotectant: 10% glycerol) 
2) 7.6 mg/ml of Trx-2, 25% PEG 6,000, 10mM DTT, 100mM Citric Acid 
Buffer at pH 4.0, 20oC (Cryoprotectant: 15% PEG 400) 
The final result showed that these two crystals diffracted to 3.0 Å and 2.5 Å 
respectively. The outcomes were close to the in-house experimental data that had been 
~ 3.2 Å 
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tested prior to sending to synchrotron.  These two crystals were diffracted to 3.2 Å and 
2.8 Å respectively using in-house X-ray diffractometer at the SSSC. However, the 
diffraction data showed that there was still some splitting on the high resolution data 
(Figure 3.23). Consequently, the previous published data (Filson et al., 2003) was still 
considered as the best data set that was suitable for further protein structure refinement. 
Therefore, the structure refinement of Trx-2 shall be continued using the previous 
published data. Table 3.4 listed below is the summary for all crystals that have been 
cryoprotected by the cryosolution. 
 
Figure 3.23: X-ray diffraction pattern of a Trx-2 crystal was collected at 3.2 Å 
resolution at the SSSC is shown on the left. The arrow indicates the splitting spots. 
The graph on the right is the enlarge portion of these split spots. 
 
From Table 3.5, it clearly demonstrates that glucose is not an appropriate 
cryoprotectant. When the glucose was at 15%, ice rings were displayed in the diffraction 
pattern and the data showed high mosaicity. Once the concentration of glucose increased 
from 15% to 20%, the crystal only diffracted to a resolution of 4 Å. Thus, glucose was 
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not considered as an ideal cryoprotectant. On the other hand, 10% glycerol and 10 – 15%   
PEG 400 demonstrated that there were suitable cryoprotectants for Trx-2 crystals.   
The crystals grown from the co-crystallization of PEG 6,000 with 10% glycerol 
was directly put under X-ray beam without transferring the crystal to a cryosolution prior 
to X-ray diffraction experiments. The 10% glycerol that was originally included in the 
crystallization condition can be used as a cryoprotectant to flash-cool the crystal. The 
resolution of those co-crystallized crystals was 2.8 Å which is similar to the ones grow in 
normal crystallization condition (without glycerol), and used glycerol as the 
cryoprotectant during cryocrystallography. The advantage of co-crystallization is when 
performing X-ray diffraction experiments, crystals can be directly mounted to goniometer 
position on the X-ray diffractometer without transferring to a cryosolution. The direct 
mounting of a crystal can save the operation time and reduce the crystal handling. 
Crystals are sensitive to physical environment. The longer a crystal is exposed to the air, 
the higher the chance that the crystal will deteriorate during the handling of the crystal. 
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Cryoprotectant (Cy) [Cy] (%) [Precipitant]  Buffer 
(pH) 
Crystal 
(mm) 
Resolution 
(Å) 
10 25% PEG 6000 CA/3.8 0.05 x 0.70 ~3.3 
10 26% PEG 6000 CA/3.8 0.06 x 0.25 ~2.8 
Co-crystallization 
with glycerol 
10 27% PEG 6000 CA/3.9 0.06 x 0.20 ~3.1 
Glucose 15 26% PEG 6000 CA/4.1 0.08 x 1.0 ND 
 20 26% PEG 6000 CA/4.0 0.08 x 0.30 ~4.0 
Glycerol 10 24% PEG 6000 CA/4.0 0.06 x 0.45 ~3.8 
 10 25% PEG 6000 CA/4.1 0.08 x 0.60 ~3.2 
 10 25% PEG 6000 CA/4.2 0.07 x 0.30 ~3.2 
 10 25% PEG 6000 CA/4.4 0.14 x 0.60 ~3.8 
 10 26% PEG 6000 CA/4.1 0.08 x 0.60 ~3.1 
 10 26% PEG 6000 CA/4.1 0.14 x 0.80 ~3.6 
 10 27% PEG 6000 CA/3.9 0.06 x 0.20 ~3.1 
PEG 400 10 22% PEG 6000 CA/4.0 0.12 x 0.95 ~3.3 
 10 25% PEG 6000 CA/4.2 0.07 x 0.30 ~ 3.2 
 10 25% PEG 6000 CA/4.4 0.14 x 0.60 ~4.1 
 10 27% PEG 6000 CA/4.2 0.07 x 0.55 ~3.5 
 15 25% PEG 6000 CA/4.0 0.10 x 0.80 ~2.8 
 15 26% PEG 6000 CA/4.0 0.06 x 0.30 ~3.9 
 15 27% PEG 6000 CA/4.0 0.05 x 0.50 ~4.8 
Table 3.5: Summary results of various cryo-conditions of Trx-2 crystals that were 
prepared for X-ray diffraction experiments at the SSSC. The concentration of citric acid 
(CA) buffer and purified Trx-2 are 100 mM and 7.6 mg/ml respectively. The additives 
used are 10 mM DTT for all trials. The concentrations of PEG 6000 shown above are the 
crystallization conditions. ND: No diffraction. 
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Chapter 4: CONCLUSION AND FUTURE PERSPECTIVES 
 
4.1. SUMMARY OF BOVINE SERUM ALBUMIN  
Bovine Serum Albumin (BSA) is a soluble and large globular protein and has a 
molecular weight of approximately 66,400 Dalton. The primary structure of BSA has 
been determined for a number of years. However, the three-dimensional crystal structure 
of BSA has never been solved, probably because high quality protein crystals have not 
been crystallized.  
The goal of determining the crystal structure of BSA is due to the interest in 
understanding how thiomolybdates bind to BSA and render copper unavailable for 
absorption by cattle. Copper deficiency is a nutritional issue that occurs among cattle in 
Saskatchewan. However, even though BSA crystals have been crystallized, due to the 
nature of the crystals themselves, the crystals only can be diffracted to a very low 
resolution of about 8 Å. Such resolution is not useful enough for solving the three-
dimensional protein structure of BSA.  
Initially, the crystallization conditions of BSA followed the previous results done 
by Dean Thome from Department of Chemistry at the University of Saskatchewan 
(Thome, 2001), which was originated from published work (Asanov et al., 1997b). The 
first crystallization condition that I used to produce crystals was 2 µl droplets of 10 
mg/ml unpurified BSA solution grown in 55% SAS/100 mM K-PO4 buffer solution (pH 
6.0) using hanging drop vapor diffusion technique . The time spent was about 2 – 3 
months. However, this result was not reproducible. Therefore, characterization and 
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purification of BSA was carried out. At the same time, a number of salts and buffers as 
well as different precipitants were attempted. The screening strategy using sparse matrix 
approach (Jancarik and Kim, 1991) by Hampton Research was first initiated but the 
results were not satisfactory. Only PEG 6,000/LiCl/MES and PEG MME 
2,000/NiCl2/Tris gave multi-crystals but these kinds of crystals could not be optimized to 
single crystals. So, SDS-PAGE and DLS techniques were applied to characterize the 
purity and homogeneity of BSA. Purity was initially suspected as the major issue to 
impede the crystal growth. However, once high concentrations of BSA were used to 
crystallize the protein, purification of BSA became unnecessary. The homogeneity of 
unpurified and purified BSA is not much different after performing the DLS 
measurements. Although extensive trial and error crystallization experiments have been 
conducted, the crystals do not diffract better than 3.5 Å. The optimization strategies that 
have been attempted to produce well-diffracted single crystals include changing the 
physical and chemical parameters of crystallization conditions such as pH and 
temperature, as well as adding different additives such as various kinds of salts, glycerol, 
sucrose and xylitol.  
The crystallization of BSA was initiated by Thome previously at the University of 
Saskatchewan (Thome, 2001). Compared to our results, it showed that both crystals 
crystallized in different ways, in terms of protein concentration and buffer solution as 
well as different diffraction conditions. However, the unit cell information of both 
crystals demonstrated in a very similar result. Below is the comparison table for both data 
sets obtained from Dean and me (Table 4.1). 
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 Thome Tai 
Crystallization 
Condition 
10 mg/ml purified BSA 
50 – 65% SAS 
 50 mM K-PO4 at pH 5.6 – 6.6  
with 1 – 50 mM NaCl, KCl, 
MgCl2 NiCl2, and CoCl2 
50 – 60 mg/ml unpurified BSA 
48 – 52 % SAS 
25 mM NaAc at  pH 5.2 – 5.6 
with 10 mM CoCl2 or 3% Xylitol 
or 3 % sucrose 
Diffraction 
Temperature 
Room temperature Cryo-temperature at 100 K 
Cryo-condition Not applicable    25 – 35 % Glycerol  or 
           30 – 35% Glucose 
Cell Parameter 148.24 Å x 148.24 Å x 356.70 Å  147.62 Å x 147.62 Å x 351.12 Å 
Space Group P6 P6 
Best Resolution 8 Å  8 Å 
Table 4.1: The Comparison between BSA crystallographic data done by Thome and me. 
 
4.2. SUMMARY OF THIOREDOXIN-2 
Helicobacter pylori (H. pylori) was declared as a type I carcinogen by 
International Agency for Research on Cancer (IARC) (IARC, 1994). Two genes encoding 
thioredoxin which are Trx-1 and Trx-2 are found on the H. pylori genome (Tomb et al., 
1997). Thioredoxins are a class of small 12-kDa redox proteins known to be present in all 
eukaryotic and prokaryotic organisms. Both of them are capable of reducing protein 
disulfide bonds. However, the catalytic site of Trx-2 contains a unique non-conserved 
motif: Cys − Pro− Asp − Cys at the N-terminal domain of the molecule. 
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The crystal structure of Trx-2 has been solved. At high resolution of the data 
collected from X-ray diffraction experiments, there are some split spots, possibly owing 
to the tendency of the long thin (0.1  mm x 0.1 mm x 1 − 2 mm) crystals to bend with the 
contours of the frozen drops in the loop (Filson et al., 2003). The crystallization condition 
of Trx-2 was optimized from its original published condition in an attempted to grow 
bigger crystals (in terms of shortening the length and widening the width of the crystal) in 
order to get higher resolution of diffraction data (e.g. above 2 Å) and avoid the spot 
splitting that occurred in the previous crystals. The crystallization condition was 
optimized from 30% PEG 6,000/0.1 M (NH4)2SO4/10 mM DTT to 24 – 26% PEG 6,000/ 
100mM citric acid buffer (pH 4.0 – 4.2)/10 mM DTT. Both crystals were conducted in 
cryo-temperature for X-ray diffraction. 
 Published Data Tai 
Crystallization 
Condition 
10 mg/ml Trx-2 
30% PEG 6,000/ 0.1 M 
(NH4)2SO4/ 10 mM DTT 
7.6 mg/ml Trx-2 
24 − 26 % PEG 6,000/  
100mM citric acid/ 10 mM DTT 
Crystal 
Dimension 
0.1 mm x 0.1 mm x 1 – 2 mm 0.12 mm x 0.12 mm x 0.9 mm 
Cryo-condition 10 – 15% Glycerol 
10% Glycerol   or 
10 – 15% PEG 400 
Cell Parameter 40.21 Å x 40.21 Å x 64.65 Å   42.65 Å x 42.65 Å x 64.64 Å 
Space Group P41 P4 
Best Resolution 2.4 Å  2.8 Å (*2.5 Å ) 
Table 4.2: The Comparison between Trx-2 published crystallographic data and my 
results (*Note: the crystal was diffracted to 2.8 Å at in-house X-ray diffractometer and 
the same crystal was diffracted to higher resolution, 2.5 Å, by synchrotron radiation).
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4.3. CONCLUSIONS 
The three-dimensional structure of BSA is not solved because well-diffracted 
crystals could not be crystallized even though extensive experiments have been 
conducted. For both protein crystallizations and X-ray diffraction experiments performed 
by Thome and me, either the less pure (directly purchased from supplier) or in-house 
purified protein, both gave the same resolution of crystallographic data after performing 
the diffractions experiments at room temperature or cryo-temperature. These 
unsatisfactory results might be attributed to the protein itself, although the reason remains 
unknown. I speculate that the flexible portions of BSA protein might be interfering with 
the formation of a well ordered crystal lattice. Other aspects that may be considered are 
the saturated ammonium sulfate was not a very ideal precipitant. When the crystals were 
exposed to the atmosphere during crystal handling, ammonium sulfate salt formed 
quickly in the protein droplet, and the crystals started to precipitate. Therefore, finding a 
replacement for saturated ammonium sulfate becomes important. Due to the lack of high 
resolution diffraction data of BSA crystals, the three-dimensional crystal structure of 
BSA still remains unknown. Therefore, the study of the binding site of copper on BSA 
and the mechanism of thiomolybdates that render the copper unavailable in cattle cannot 
be determined. 
The crystallization conditions of Trx-2 were optimized using different 
crystallization strategies to grow crystals to much larger dimensions in order to improve 
the diffraction resolution limit, at least above 2.4 Å which would be higher than the 
published diffraction resolution limit and without any split spots. However, the 
improvement of crystal dimensions is slight, the diffraction resolution limits are similar 
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and the split spots at high resolution data are still observed. Compared to published data, 
only similar qualities (in terms of diffraction resolution limits and size of crystals) of Trx-
2 crystals were grown. Therefore, the published X-ray diffraction data of Trx-2 is still 
considered as the best data that can begin to continue the protein structure refinement to 
determine the three-dimensional crystal structure of Trx-2. 
 
4.4. FUTURE WORK 
The crystallization conditions of BSA have been studied exhaustively; the buffer 
solutions such as sodium acetate and potassium phosphate have shown that crystals can 
grow under similar pH ranges in different buffers. Other buffer solutions which have 
parallel pH range are also worth trying in the future. I strongly suggest that the main 
focus should concentrate on changing the precipitant, saturated ammonium sulfate (SAS), 
using other replacements such as different kinds of salts or different types of PEGs to 
replace it.  
Various cryoprotectants have been tried. Only glycerol and glucose have showed 
positive outcomes, so I propose to co-crystallize the BSA protein using the precipitating 
solution that gave crystals previously with glycerol or glucose in the crystallization trials 
in future  (Sousa, 1995; Sousa, 1997). The concentrations of the co-solvent can use 
similar conditions that worked for the cryoprotection of BSA crystals. For example use 
50 − 55% SAS/25% glycerol/25mM NaAc buffer/10mM CoCl2 or 50 − 55% SAS/30% 
glucose/25mM NaAc buffer/10mM CoCl2 to crystallize BSA proteins. Otherwise lower 
cryoprotectant concentration can be attempted as well if the crystallization doesn’t work 
in the first place. 
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Limited proteolysis may offer another strategy to crystallize BSA protein, limited 
proteolytic digestion has been demonstrated as an alternative and valuable method for 
crystallizing hard-to-crystallize proteins (Danley et al., 2000; Leppanen et al., 1999)  
Evidence has shown that after BSA was cleaved by pepsin at pH 3.5, one of the 
fragments (COOH-terminal fragment) can be crystallized at 4% PEG 1,000/0.04 M 
cacodylate/pH 6.0. However, the dimensions of the BSA crystal grown in this method 
was not sufficient for conducting X-ray diffraction experiments and then no further 
results have been published (McPherson, 1976). But it might offer another clue for 
crystallizing BSA. Therefore, instead of purchasing the BSA from commercial sources, 
recombinant BSA may become necessary. In this case, the conditions of protein 
crystallization of mutated protein become broader, because one single protein can be 
mutated to various protein mutants and each mutant can have different crystallization 
conditions. The protein mutation includes N-terminal or C-terminal deletions, loop 
insertions, residues truncations and point mutations. These kinds of techniques may 
provide a number of choices for getting better quality crystals (Dale et al., 2003). 
Another alternative strategy is instead of growing of BSA crystals, crystallization 
of sheep serum albumin (OSA) or goat serum albumin (GSA) can be tried. These kinds of 
serum albums (BSA, GSA and OSA) from cattle, goat and sheep respectively all are 
ruminant species. All of them have faced the similar type of molybdenum–induced 
copper deficiency. Even a low intake of molybdenum can negatively affect copper 
intention in the sheep (Dick, 1954), and goat as well (Frank et al., 2000).  
On the other hand, in order to find out the solution to solve the protein structure of 
Trx-2, few strategies can be attempted. First, a much higher resolution data, beyond 2 Å, 
 129
might be useful for the structure solution to get a clearer electron density of polypeptide 
chains. Second, improving the freezing condition of the crystals, such as using bigger or 
longer loop to mount the crystals in order to not allow crystals to be bent, can be tried. 
Thus, the splitting of the spots in the X-ray diffraction data can be avoided. Third, 
changing the crystallization conditions of Trx-2 can be attempted in order to grow bigger 
crystals in terms of crystal dimensions, or growing crystals in a different space groups 
might produce higher resolution and more reliable diffraction data.  
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APPENDIX 1 
 
Table A-1: Purified BSA Crystallization Trials 
 
Buffer pH Precipitant [Precipitant] (%) Additive 
[BSA]  
 
(mg/ml) 
Temp (oC) Method 
25 mM NaAc 5.1, 5.2, 5.3, 5.4 SAS 47.5, 50, 52.5, 55, 57.5, 60 N/A 50 20 Hanging Drop 
25 mM NaAc 5.3, 5.4, 5.5, 5.6 SAS 47, 48, 49, 50, 51, 52 20% Glycerol 40 20 Hanging Drop 
25 mM NaAc 5.3, 5.4, 5.5, 5.6 SAS 48, 49, 50, 51, 52, 53 N/A 40 20 Hanging Drop 
100 mM NaAc 4.0, 4.5, 5.0, 5.5, 6.0 IPA 10, 15, 20, 25, 30 0.2 M CaCl2 10 20 Microbatch 
100 mM NaAc 4.0, 4.5, 5.0, 5.5, 6.0 IPA 10, 15, 20, 25, 30 0.2 M CaCl2 10 20 Sitting Drop 
50 mM K-PO4 5.5, 5.6, 5.7, 5.8 SAS 52, 53, 54, 55, 56, 57 N/A 10 20 Hanging Drop 
50 mM K-PO4 5.5, 5.6, 5.7, 5.8 SAS 52, 53, 54, 55, 56, 57 10 mM NaCl 10 20 Hanging Drop 
50 mM K-PO4 5.5, 5.6, 5.7, 5.8 SAS 52, 53, 54, 55, 56, 57 50 mM NaCl 10 20 Hanging Drop 
50 mM K-PO4 5.5, 5.6, 5.7, 5.8 SAS 52, 53, 54, 55, 56, 57 10 mM KCl + 10 mM MgCl2 10 20 Hanging Drop 
50 mM K-PO4 5.5, 5.6, 5.7, 5.8 SAS 52, 53, 54, 55, 56, 57 50 mM KCl + 50 mM MgCl2 10 20 Hanging Drop 
50 mM K-PO4 5.9, 6.0, 6.1, 6.2 SAS 52, 53, 54, 55, 56, 57 N/A 10 20 Hanging Drop 
50 mM K-PO4 5.9, 6.0, 6.1, 6.2 SAS 52, 53, 54, 55, 56, 57 10 mM NaCl 10 20 Hanging Drop 
50 mM K-PO4 5.9, 6.0, 6.1, 6.2 SAS 52, 53, 54, 55, 56, 57 50 mM NaCl 10 20 Hanging Drop 
50 mM K-PO4 5.9, 6.0, 6.1, 6.2 SAS 52, 53, 54, 55, 56, 57 10 mM KCl + 10 mM MgCl2 10 20 Hanging Drop 
50 mM K-PO4 5.9, 6.0, 6.1, 6.2 SAS 52, 53, 54, 55, 56, 57 50 mM KCl + 50 mM MgCl2 10 20 Hanging Drop 
50 mM K-PO4 5.7,5.8,5.9,6.0 SAS 55, 56, 57, 58, 59, 60 1, 5, 10, 20  mM CoCl2 10 20 Hanging Drop 
50 mM K-PO4 5.7, 5.8 SAS 57, 58, 59 10, 25 mM CoCl2 10 20 Hanging Drop 
50 mM K-PO4 5.6, 5.7,5.8,5.9 SAS 55, 56, 57, 58, 59, 60 10 mM CoCl2/ NiCl2/ZnCl2/CdCl2 10 20 Hanging Drop 
50 mM K-PO4 5.6, 5.7,5.8,5.9 SAS 55, 56, 57, 58, 59, 60 50 mM NaCl/KCl/MgCl2/LiCl 10 20 Hanging Drop 
50 mM K-PO4 5.6, 5.8 SAS 56, 58, 60 100, 250, 500, 1000 mM LiCl 10 20 Hanging Drop 
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Table A-1 (continued) 
 
50 mM K-PO4 5.8 SAS 55, 56, 57, 58, 59, 60 0, 1, 5, 10 mM CoCl2 12 20 Hanging Drop 
50 mM K-PO4  5.6, 5.7, 5.8, 5.9 SAS 55, 56, 57, 58, 59, 60 10 mM CoCl2 10 20 Hanging Drop 
50 mM K-PO4 5.7, 5.8, 5.9, 6.0 SAS 55, 56, 57, 58, 59, 60 10 mM CoCl2 10 20 Hanging Drop 
50 mM K-PO4 5.6, 5.7, 5.8, 5.9 SAS 48, 49, 50, 51, 52, 53 N/A 47 20 Hanging Drop 
100 mM MES 5.6, 5.8, 6.0, 6.2, 6.4 PEG 6000 28 1 M LiCl 10 4 Hanging Drop 
100 mM MES 5.6, 5.8, 6.0, 6.2, 6.4 PEG 6000 26, 28 1 M LiCl 10 4 Sitting Drop 
100 mM MES 5.8, 6.0, 6.2, 6.4 PEG 6000 20, 22, 24, 26, 28, 30 1 M LiCl 5 20 Hanging Drop 
100 mM MES 5.8, 6.0, 6.2 PEG 6000 28 25, 50, 100, 200 mM (KCl/ CoCl2) 10 20 Hanging Drop 
100 mM MES 5.5, 6.0, 6.5, 7.0 PEG 6000 28 0.011, 0.11, 0.55, 1.1, 2.2, 3.3 M LiCl 10 20 Hanging Drop 
100 mM MES 5.0, 5.5, 6.0, 6.5, 7.0 PEG 6000 2.5, 5.0, 7.5, 10, 12.5 N/A 10 20 Sitting Drop 
100 mM MES 5.0, 5.5, 6.0, 6.5, 7.0 PEG 6000 2.5, 5.0, 7.5, 10, 12.5 N/A 10 20 Hanging Drop 
100 mM MES 5.0, 5.5, 6.0, 6.5, 7.0 PEG 6000 2.5, 5.0, 7.5, 10, 12.5 N/A 10 20 Microbatch 
100 mM MES 5.6, 5.8, 6.0, 6.2 PEG 6000 26, 28, 30, 32, 34, 36 1 M LiCl 10 20 Hanging Drop 
100 mM MES 5.6, 5.8, 6.0, 6.2 PEG 6000 28 25, 50, 100, 200, 1000 mM LiCl 10 20 Hanging Drop 
100 mM MES 5.6, 5.8, 6.0, 6.2 PEG 6000 22.5, 25, 27.5, 30, 32.5, 35 0.1 M LiCl 10 20 Hanging Drop 
100 mM MES 5.6, 5.8, 6.0, 6.2 PEG 6000 20, 22, 24, 26, 28, 30 1 M LiCl 10 20 Hanging Drop 
100 mM MES 6.0 PEG 6000 24, 26, 28, 30, 32, 34 1 M LiCl 5 20 Hanging Drop 
100 mM MES 6.0 PEG 6000 24, 26, 28, 30, 32, 34 1 M LiCl 10 20 Hanging Drop 
100 mM MES 5.8, 6.0, 6.2, 6.4 PEG 6000 20, 22, 24, 26, 28, 30 1 M LiCl 5 20 Hanging Drop 
100 mM MES 5.8, 6.0, 6.2, 6.4 PEG 400 10, 15, 20, 25, 30, 35 1 M LiCl 8.5 20 Hanging Drop 
100 mM MES 5.8, 6.0, 6.2 PEG 400 28 1 M LiCl 10 20 Hanging Drop 
100 mM MES 5.8, 6.0, 6.2 PEG MME 2000 28 1 M LiCl 10 20 Hanging Drop 
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100 mM MES 5.6, 5.8, 6.0, 6.2 PEG 4000 24, 26, 28, 30, 32, 34 1 M LiCl 10 20 Hanging Drop 
100 mM MES 5.8, 6.0, 6.2 PEG 4000 28 1 M LiCl 10 20 Hanging Drop 
100 mM MES 5.8, 6.0, 6.2 PEG 8000 28 1 M LiCl 10 20 Hanging Drop 
100 mM Tris 7.0, 7.5, 8.0, 8.5, 9.0 PEG 6000 20, 25, 30, 35, 40 N/A 10 20 Microbatch 
100 mM Tris 7.0, 7.5, 8.0, 8.5, 9.0 PEG MME 2000 20, 25, 30, 35, 40 10 mM NiCl2 10 20 Microbatch 
100 mM Tris 8.3, 8.6, 8.9, 9.2, 9.5 PEG MME 2000 21, 23, 25, 27, 29 10 mM NiCl2 10 20 Sitting Drop 
100 mM Tris 9.0, 9.1, 9.2, 9.3, 9.4, 9.5 PEG MME 2000 21, 23, 25, 27, 29 10 mM NiCl2 10 20 Sitting Drop 
100 mM Tris 7.0, 7.5, 8.0, 8.5, 9.0 PEG MME 2000 20, 25, 30, 35, 40 10 mM NiCl2 4.5 20 Sitting Drop 
100 mM HEPES 6.0, 6.5, 7.0, 7.5, 8.0 PEG 6000 20, 25, 30, 35, 40 N/A 10 20 Microbatch 
100 mM Na-CACO 5.5, 6.0, 6.5, 7.0 PEG 8000 5, 10, 15, 20, 25, 30 200 mM (CH3COO)2Zn 10 20 Hanging Drop 
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Table A-2: Unpurified BSA Crystallization Trials 
 
Buffer pH Precipitant [Precipitant] (%) Additive  [BSA]  (mg/ml) Temp ( 
oC) Method 
25 mM NaAc 4.7, 4.8, 4.9, 5.0 SAS 37.5, 40, 42.5, 45, 47.5, 50 N.A 60, 120 20 Hanging Drop 
25 mM NaAc 4.5, 5.0, 5.5 SAS 37.5, 40, 42.5, 45, 47.5, 50 N.A 60 20 Hanging Drop 
25 mM NaAc 4.7, 4.9, 5.1, 5.3 SAS 37.5, 40, 42.5, 45, 47.5, 50 N/A 50, 60 20 Hanging Drop 
25 mM NaAc 5.1, 5.2, 5.3, 5.4 SAS 47.5, 50, 52.5, 55, 57.5, 60 N/A 50, 60 20 Hanging Drop 
25 mM NaAc 5.2, 5.3 SAS 53, 54, 55, 56, 57, 58 N/A 50 20 Hanging Drop 
25 mM NaAc 5.2, 5.3 SAS 53, 54, 55, 56, 57, 58 10 mM CoCl2 50 20 Hanging Drop 
25 mM NaAc 5.1, 5.2, 5.3, 5.4 SAS 45, 47, 49, 51, 53 - 58 N/A 50, 60 20 Sitting Drop 
25 mM NaAc 5.1, 5.2, 5.3, 5.4 SAS 45, 47, 49, 51, 53, 55 N/A 50, 60 20 Hanging Drop 
25 mM NaAc 5.1, 5.2, 5.3, 5.4 SAS 54, 55, 56, 57, 58, 59 N/A 50, 60 20 Hanging Drop 
25 mM NaAc 5.1, 5.2, 5.3, 5.4 SAS 54, 55, 56, 57, 58, 59 N/A 50, 60 20 Sitting Drop 
25 mM NaAc 5.1, 5.2, 5.3, 5.4 SAS 45, 47, 49, 51, 53 - 58 N/A 50, 60 20 Sitting Drop 
25 mM NaAc 5.3, 5.4, 5.5, 5.6 SAS 47, 48, 49, 50, 51, 52 20% Glycerol 30 20 Hanging Drop 
25 mM NaAc 5.1, 5.2, 5.3, 5.4 SAS 48, 50, 52, 54, 56, 58 25% Glycerol 50, 60 20 Sitting Drop 
25 mM NaAc 5.2, 5.3 SAS 48, 50, 52, 54, 56, 58 N/A 50, 60 20 Hanging Drop 
25 mM NaAc 5.0 - 5.5 SAS 48, 50, 52, 54, 56, 58 10 mM CoCl2 50, 60 20 Hanging Drop 
25 mM NaAc 5.0, 5.2, 5.4, 5.6 SAS 50, 52, 54, 56, 58, 60 10 mM ZnSO4 50, 60 20 Hanging Drop 
25 mM NaAc 4.9 - 5.6 SAS 48, 50, 52, 54, 56, 58 N/A 50, 60 20 Hanging Drop 
25 mM NaAc 5.2, 5.3, 5.4, 5.5 SAS 48, 50, 52, 54, 56, 58 N/A 50, 60 20 Hanging Drop 
25 mM NaAc 5.3, 5.4, 5.5, 5.6 SAS 47, 48, 49, 50, 51, 52 10 mM CoCl2 50, 60 20 Hanging Drop 
25 mM NaAc 5.0, 5.1, 5.2, 5.3 SAS 38, 40, 42, 44, 46, 48, 50, 52, 54 1% Sucrose 30, 40 20 Sitting Drop 
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Table A-2 (continued) 
 
25 mM NaAc 5.0, 5.1, 5.2, 5.3 SAS 36, 38, 40, 42, 44, 46, 48, 50 1% Sucrose 50, 60 20 Sitting Drop 
25 mM NaAc 5.2, 5.3, 5.4, 5.5 SAS 54 1, 3, 5, 10, 15, 20% Sucrose 60 20 Hanging Drop 
25 mM NaAc 5.2, 5.3, 5.4, 5.5 SAS 54 1, 3, 5, 10, 15, 20% Xylitol 60 20 Hanging Drop 
25 mM NaAc 4.9 - 5.6 SAS 44, 46, 48, 50, 52, 54, 56, 58 3% Xylitol 30, 40, 50, 60 20 Sitting Drop 
25 mM NaAc 5.1, 5.2, 5.3, 5.4 SAS 40, 45, 50, 55, 60, 65 N/A 70, 80 20 Hanging Drop 
25 mM NaAc 5.1, 5.2, 5.3, 5.4 SAS 27.5, 32.5, 37.5 N/A 70, 80 20 Hanging Drop 
25 mM NaAc 5.0, 5.1, 5.2, 5.3 SAS 40, 41, 42, 43, 44, 45 N/A 70, 80 20 Hanging Drop 
25 mM NaAc 5.3, 5.4, 5.5, 5.6 SAS 40, 42, 44, 46, 48, 50 10 mM CoCl2 70, 80 20 Hanging Drop 
25 mM NaAc 5.3, 5.4, 5.5, 5.6 SAS  43, 44, 45, 46, 47, 48 N/A 70, 80 20 Hanging Drop 
25 mM NaAc 4.9 - 5.6 SAS 44, 46, 48, 50, 52, 54, 56, 58 3% Sucrose 10, 20, 30, 40 20 Sitting Drop 
25 mM NaAc 4.9 - 5.6 SAS 44, 46, 48, 50, 52, 54, 56, 58 3% Sucrose 50, 60, 70, 80 20 Sitting Drop 
25 mM NaAc 5.3, 5.4, 5.5, 5.6 SAS 49 0.5, 1.0, 1.5, 2.0, 2.5, 3.0% Sucrose 30 20 Sitting Drop 
25 mM NaAc 5.2, 5.3, 5.4, 5.5 SAS 52, 53, 54, 55, 56, 57 20, 25, 30% Glycerol 50, 60 20 Hanging Drop 
25 mM NaAc 5.1, 5.2, 5.3, 5.4 SAS 40, 45, 50, 55, 60, 65 N/A 30, 40 20 Hanging Drop 
25 mM NaAc 5.3, 5.4, 5.5, 5.6 SAS 46, 48, 50, 52, 54, 56 N/A 30, 40 20 Hanging Drop 
25 mM NaAc 5.1, 5.2, 5.3, 5.4 SAS 45, 47, 49, 51, 53 - 58 N/A 30, 40 20 Sitting Drop 
25 mM NaAc 5.3, 5.4, 5.5, 5.6 SAS 47, 48, 49, 50, 51, 52 N/A 30, 40 20 Hanging Drop 
25 mM NaAc 5.3, 5.4, 5.5, 5.6 SAS 47, 48, 49, 50, 51, 52 10 mM CoCl2 30, 40 20 Hanging Drop 
25 mM NaAc 5.1, 5.2, 5.3, 5.4 SAS 50, 52.5, 55, 57.5, 60, 62.5 10 mM Na-Citrate 50, 60 20 Hanging Drop 
25 mM NaAc 5.1, 5.2, 5.3, 5.4 SAS 49, 51, 53, 55, 57, 59 3% Sucrose 60, 70 20 Hanging Drop 
25 mM NaAc 5.1, 5.2, 5.3, 5.4 SAS 49, 51, 53, 55, 57, 59 3% Xylitol 50, 60 20 Hanging Drop 
25 mM NaAc 5.1, 5.2, 5.3, 5.4 SAS 45, 47, 49, 51, 53, 55 3% Xylitol 50 20 Hanging Drop 
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Table A-2 (continued) 
 
25 mM NaAc 5.0, 5.1, 5.2, 5.3 SAS 52, 53, 54, 55, 56, 57 3% Sucrose 60 20 Hanging Drop 
25 mM NaAc 5.0, 5.1, 5.2, 5.3 SAS 52, 53, 54, 55, 56, 57 3% Xylitol 50 20 Hanging Drop 
25 mM NaAc 5.2, 5.3, 5.4, 5.5 SAS 48, 49, 50 N/A 60 20 Hanging Drop 
25 mM NaAc 5.2, 5.3, 5.4, 5.5 SAS 48, 49, 50 10 mM CoCl2 60 20 Hanging Drop 
25 mM NaAc 5.2, 7.2 Na-Malonate 50 - 60 N/A 50, 60 20 Hanging Drop 
25 mM NaAc 5.2, 5.3, 5.4, 5.5 Na-Malonate 2.7, 2.8, 2.9, 3.0, 3.1, 3.2 M 10 mM CoCl2 60 20 Hanging Drop 
50 mM NaAc 5.0, 5.2, 5.4, 5.6 SAS 40, 42, 44, 46, 48, 50 0.2 M K/Na Tartrate 60 20 Hanging Drop 
100 mM NaAc 4.0, 4.5, 5.0, 5.5, 6.0 MPD 20, 25, 30, 35, 40 0.02 M CaCl2 5, 10 20 Sitting Drop 
100 mM NaAc 4.0, 4.5, 5.0, 5.5, 6.0 MPD 10, 15, 20, 25, 30 0.2 M CaCl2 10 20 Sitting Drop 
100 mM K-PO4 5.5 - 6.2 SAS 52, 53, 54, 55, 56, 57 N/A 10 4 Hanging Drop 
100 mM K-PO4 5.5 - 6.2 SAS 52, 53, 54, 55, 56, 57 N/A 10 15 Hanging Drop 
100 mM K-PO4 5.5 - 6.2 SAS 52, 53, 54, 55, 56, 57 50 mM NaCl 10 4 Hanging Drop 
100 mM K-PO4 5.5 - 6.2 SAS 52, 53, 54, 55, 56, 57 50 mM NaCl 10 15 Hanging Drop 
100 mM K-PO4 5.5 - 6.2 SAS 52, 53, 54, 55, 56, 57 50 mM MgCl2 10 4 Hanging Drop 
100 mM K-PO4 5.5 - 6.2 SAS 52, 53, 54, 55, 56, 57 50 mM MgCl2 10 15 Hanging Drop 
100 mM K-PO4 5.5 - 6.2 SAS 52, 53, 54, 55, 56, 57 N/A 10 4 Sitting Drop 
100 mM K-PO4 5.5 - 6.2 SAS 52, 53, 54, 55, 56, 57 N/A 10 15 Sitting Drop 
100 mM K-PO4 5.0, 5.5, 6.0, 6.5 SAS 40, 45, 50, 55, 60, 65 N/A 10 4 Sitting Drop 
100 mM K-PO4 5.0, 5.5, 6.0, 6.5 SAS 40, 45, 50, 55, 60, 65 50mM (Nacl, KCl, MgCl2) 10 4 Sitting Drop 
100 mM K-PO4 5.0, 5.5, 6.0, 6.5 SAS 40, 45, 50, 55, 60, 65 N/A 10 15 Sitting Drop 
100 mM K-PO4 5.0, 5.5, 6.0, 6.5 SAS 40, 45, 50, 55, 60, 65 50mM (Nacl, KCl, MgCl2) 10 15 Sitting Drop 
100 mM K-PO4 5.5, 6.0 SAS 50, 52.5, 55, 57.5, 60, 62.5 N/A 5 20 Hanging Drop 
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Table A-2 (continued) 
 
100 mM K-PO4 5.5, 6.0 SAS 50, 52.5, 55, 57.5, 60, 62.5 50 mM MgCl2  5 20 Hanging Drop 
100 mM K-PO4 5.6, 5,8 SAS 54, 55, 56, 57, 58, 59 N/A 5 20 Hanging Drop 
100 mM K-PO4 5.6, 5,8 SAS 54, 55, 56, 57, 58, 59 50 mM NaCl 5 20 Hanging Drop 
100 mM K-PO4 5.4, 5.6, 5.8, 6.0 SAS 40, 45, 50, 55, 60, 65 50 mM NaCl 3.0, 5.0, 7.5 20 Hanging Drop 
100 mM K-PO4 5.6, 5.8, 6.0, 6.2 SAS 50 - 61 N/A 20 20 Sitting Drop 
100 mM K-PO4 5.6, 5.8, 6.0, 6.2 SAS 50 - 61 50 mM NaCl 20 20 Sitting Drop 
100 mM K-PO4 5.9, 6.0, 6.1, 6.2 SAS 52, 53, 54, 55, 56, 57 N.A 10 20 Hanging Drop 
100 mM K-PO4 5.9, 6.0, 6.1, 6.2 SAS 52, 53, 54, 55, 56, 57 50 mM NaCl/ KCl/ MgCl2 10 20 Hanging Drop 
100 mM K-PO4 5.0, 5.5, 6.0, 6.5 SAS 40, 45, 50, 55, 60, 65 1 mM CdCl2/CoCl2/NiCl2/ZnCl2 10 20 Hanging Drop 
100 mM K-PO4 5.0, 5.5, 6.0, 6.5 SAS 40, 45, 50, 55, 60, 65 50 mM CdCl2/CoCl2/NiCl2/ZnCl2 10 20 Hanging Drop 
100 mM K-PO4 5.0, 5.5, 6.0, 6.5 SAS 40, 45, 50, 55, 60, 65 N/A, 50 mM NaCl/KCl/MgCl2 5, 10 20 Sitting Drop 
100 mM K-PO4 5.5 - 6.2 SAS 52, 53, 54, 55, 56, 57 N/A 5, 10 20 Sitting Drop 
50 mM K-PO4 5.4 - 6.1 SAS 45, 47.5, 50, 52.5, 55, 57.5 10 mM CoCl2 10 20 Hanging Drop 
50 mM K-PO4 5.4 - 6.1 SAS 45, 47.5, 50, 52.5, 55, 57.5 10 mM NiCl2 10 20 Hanging Drop 
50 mM K-PO4  5.6, 5.7, 5.8, 5.9 SAS 55, 57, 59, 61, 63, 65 N/A 10, 20 20 Hanging Drop 
50 mM K-PO4  5.7, 5.8, 5.9, 6.0 SAS 55, 57, 59, 61, 63, 65 10 mM CoCl2 10, 20 20 Hanging Drop 
50 mM K-PO4 5.4, 5.6, 5.8, 6.0 SAS 40, 45, 50, 55, 60, 65 N/A 30, 40 20 Hanging Drop 
50 mM K-PO4 5.7, 5.8, 5.9, 6.0 SAS 45, 47, 49, 51, 53, 55 10 mM CoCl2 20, 30 20 Hanging Drop 
50 mM K-PO4 5.4, 5.6, 5.8, 6.0 SAS 47.5, 50, 52.5, 55, 57.5, 60 N.A 30, 40 20 Hanging Drop 
50 mM K-PO4 5.4, 5.6, 5.8, 6.0 SAS 47.5, 50, 52.5, 55, 57.5, 60 10 mM CoCl2 30, 40 20 Hanging Drop 
50 mM K-PO4 5.7, 5.8, 5.9, 6.0 SAS 51, 52, 53 5, 10 mM CoCl2 50 20 Hanging Drop 
50/100 mM K-PO4 5.7, 5.8, 5.9, 6.0 SAS 51, 52, 53 10 mM CoCl2 50 20 Hanging Drop 
 
 148 
Table A-2 (continued) 
 
50 mM K-PO4 5.7, 5.8, 5.9, 6.0 SAS 48, 49, 50, 51, 52, 53 N/A 50, 60  20 Hanging Drop 
50 mM K-PO4 5.4, 5.6, 5.8, 6.0 SAS 47.5, 50, 52.5, 55, 57.5, 60 N.A 60 20 Hanging Drop 
50 mM K-PO4 5.6, 5.7, 5.8, 5.9,  SAS 51, 52, 53 N.A 60 20 Hanging Drop 
50 mM K-PO4 5.6, 5.7, 5.8, 5.9 SAS 51, 52, 53, 54, 55, 56 N.A 50, 60  20 Hanging Drop 
50 mM K-PO4 5.6, 5.7, 5.8, 5.9 SAS 45, 46, 47, 48, 49, 50 N.A 50, 60  20 Hanging Drop 
50 mM K-PO4 5.5-6.0 SAS 51, 52, 53 N.A 50, 60  20 Hanging Drop 
50 mM K-PO4 5.6, 5.8, 6.0, 6.2 SAS 40, 45, 50, 55, 60 ,65 N.A 70, 80 20 Hanging Drop 
50 mM K-PO4 5.4 - 6.5 SAS 42, 44, 46, 48, 50, 52 N.A 70, 80 20 Hanging Drop 
50 mM K-PO4 5.5, 6.0, 6.5, 7.0 PEG 400 10, 20, 30, 40, 50, 60 N/A 60, 120 20 Hanging Drop 
50 mM K-PO4 5.5, 5.7, 5.9, 6.1 PEG 400 46, 48, 50, 52, 54, 56 N/A 120, 180 20 Hanging Drop 
100 mM MES 5.0, 5.5, 6.0, 6.5, 7.0 PEG 6000 10, 15, 20, 25, 30 1 M LiCl 10, 20 20 Hanging Drop 
100 mM MES 5.0, 5.5, 6.0, 6.5, 7.0 PEG 6000 20, 25, 30, 35, 40 N/A 10, 20 20 Sitting Drop 
100 mM MES 5.0,5.5,6.0, 6.5, 7.0 PEG 6000 10, 15, 20, 25, 30 1 M LiCl 5, 10, 20 20 Sitting Drop 
100 mM MES 5.5, 6.0, 6.5, 7.0 PEG 6000 10, 15, 20, 25, 30 1 M LiCl 10 20 Hanging Drop 
100 mM MES 5.8, 6.0, 6.2 PEG 6000 28% 5, 10, 25, 50 mM CoCl2 10 20 Hanging Drop 
100 mM MES 6.0 PEG 6000 28 0.01, 0.05, 0.2, 0.5, 1.0, 1.5 M NaCl 10 20 Hanging Drop 
100 mM MES 6.0 PEG 6000 28 0.01, 0.05, 0.2, 0.5, 1.0, 1.5 M KCl 10 20 Hanging Drop 
100 mM MES 6.0 PEG 6000 28 0.01,0.05 0.2 0.5 1.0 1.5 M NH4(SO4)2 10 20 Hanging Drop 
100 mM MES 6.0 PEG 6000 28 0.01, 0.05, 0.2, 0.5, 1.0, 1.5 M MgCl2 10 20 Hanging Drop 
100 mM MES 6.0 PEG 6000 24, 26, 28, 30, 32, 34 1 M LiCl 5, 10 20 Hanging Drop 
100 mM MES 5.6, 5.8, 6.0, 6.2 PEG 6000 28 1 M LiCl 30, 60 20 Hanging Drop 
100 mM MES 5.6, 5.8, 6.0, 6.2 PEG 6000 10, 15, 20, 25, 30, 35 1 M LiCl 30 20 Hanging Drop 
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Table A-2 (continued) 
 
100 mM MES 5.5, 5.8, 6.2, 6.5 PEG 6000 5, 10, 15, 20, 25, 30 1 M LiCl 30 20 Hanging Drop 
100 mM MES 5.0, 5.5, 6.0, 6.5 PEG 6000 5, 10, 15, 20, 25, 30 1 M LiCl 20, 30 20 Hanging Drop 
100 mM MES 5.7, 5.8, 5.9, 6.0 PEG 6000 10, 15, 20, 25, 30, 35 1 M LiCl 30, 60 20 Hanging Drop 
100 mM MES 5.5, 5.7, 5.9, 6.1 PEG 6000 46, 46, 50, 52, 54, 56 1 M LiCl 60 20 Hanging Drop 
100 mM MES 5.8, 6.0, 6.2, 6.4 PEG 6000 5, 10, 15, 20, 25, 30 1 M LiCl 60 20 Hanging Drop 
100 mM MES 5.8, 6.0, 6.2, 6.4 PEG 400 10, 15, 20, 25, 30, 35 1 M LiCl 30 20 Hanging Drop 
100 mM MES 5.5, 5.7, 5.9, 6.1 PEG 400 30, 35, 40, 45, 50, 55 1 M LiCl 30 20 Hanging Drop 
100 mM MES 5.5, 6.0, 6.5, 7.0 PEG 400 40, 45, 50, 55, 60, 65 N/A 30 20 Hanging Drop 
100 mM MES 6.0 PEG 400 28 1 M LiCl 10-60 20 Hanging Drop 
100 mM MES 6.0 PEG 600 28 1 M LiCl 10-60 20 Hanging Drop 
100 mM MES 6.0 PEG 1000 28 1 M LiCl 10-60 20 Hanging Drop 
100 mM MES 6.0 PEG MME 2000 28 1 M LiCl 10-60 20 Hanging Drop 
100 mM Tris 7.5, 8.0, 8.5, 9.0, 9.5 PEG MME 2000 10, 15, 20, 25, 30 10 mM NiCl2 10 20 Microbatch 
100 mM Tris 8.3, 8.6, 8.9, 9.2, 9.5 PEG MME 2000 21, 23, 25, 27, 29 10 mM NiCl2 5, 10, 20 20 Sitting Drop 
100 mM Tris 7.0, 7.5, 8.0, 8.5, 9.0 PEG MME 2000 20, 25, 30, 35, 40 10 mM NiCl2 5, 7.5 20 Sitting Drop 
100 mM Tris 7.0, 7.5, 8.0, 8.5, 9.0 PEG MME 2000 20, 25, 30, 35, 40 10 mM NiCl2 5, 10, 20, 30 20 Sitting Drop 
100 mM Tris 7.0, 7.5, 8.0, 8.5 PEG MME 2000 5, 10, 15, 20, 25, 30 10 mM NiCl2 10, 30 20 Hanging Drop 
100 mM Tris 7.5, 8.0, 8.5, 9.0, 9.5 1,6 Hexanediol 1.8, 2.6, 3.4, 4.2, 5.0 M 0.2 M MgCl2 10 20 Microbatch 
100 mM Tris 7.5, 8.0, 8.5, 9.0, 9.5 1,6 Hexanediol 1.8, 2.6, 3.4, 4.2, 5.0 M 0.2 M MgCl2 10 20 Sitting Drop 
100 mM Tris 7.0,7.5,8.0,8.5,9.0 PEG 6000 20, 25, 30, 35, 40 N/A 10 20 Microbatch 
100 mM CA 5.0, 5.3, 5.6, 5.9 SAS 46, 48, 50, 52, 54, 56 N/A 60 20 Hanging Drop 
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100 mM HEPES 7.0, 7.5, 8.0, 8.5, 9.0 PEG 6000 20, 25, 30, 35, 40 N/A 10 20 Microbatch 
100 mM HEPES 6.0, 6.5, 7.0, 7.5, 8.0 PEG 6000 2.5, 5.0, 7.5, 10, 12.5 N/A 10 20 HD/Microbatch 
100 mM HEPES-Na 6.5, 7.0, 7.5, 8.0, 8.5 IPA 20, 25, 30, 35, 40 0.2 M MgCl2 10 20 Microbatch 
100 mM Na-CACO 5.0, 5.5, 6.0, 6.5 SAS 10, 15, 20, 25, 30, 35 200 mM  (CH3COO)2Zn 
25, 50 20 Hanging Drop 
100 mM Na-CACO 5.0, 5.3, 5.5, 5.8 SAS 46, 48, 50, 52, 54, 56 N/A 60 20 Hanging Drop 
100 mM NaCit 5.6, 5.8, 6.0, 6.2 SAS 1.6, 2.0, 2.4 M / 55, 57.5, 60 0.2 M K/Na Tartrate 10 20 Hanging Drop 
100 mM NaCit 5.0, 5.3, 5.6, 5.9 SAS 10, 20, 30, 40, 50, 60 0.2 M K/Na Tartrate 25, 50 20 Hanging Drop 
100 mM NaCit 5.2, 5.4, 5.6, 5.8 SAS 46, 48, 50, 52, 54, 56 0.2 M K/Na Tartrate 60 20 Hanging Drop 
100 mM NaCit 5.6, 5.8, 6.0, 6.2 SAS 55, 57.5 ,60 0.2 M K/Na Tartrate 10 20 Hanging Drop 
100 mM NaCit 5.2, 5.4, 5.6, 5.8 SAS 44, 46, 48, 50, 52, 54 0.2 M K/Na Tartrate 80, 160 20 Hanging Drop 
100 mM NaCit 5.6, 5.8, 6.0, 6.2 NH4(SO4)2 1.6, 2.0, 2.4 M 0.2 M K/Na Tartrate 10 20 Hanging Drop 
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Table A-3: Purified Trx-2 Crystallization Trials at 20o C 
 
Buffer pH Precipitant [Precipitant] (%) Additive [Trx-2]  (mg/ml) Method 
100 mM CA 4.1, 4.3, 4.5, 4.7, 4.9 PEG 6000 24, 27, 30, 33, 36 0.025% Dichloromethane 7.5 Sitting Drop 
100 mM CA 4.1, 4.3, 4.5, 4.7, 4.9 PEG 6000 24, 27, 30, 33, 36 4% Acetonitrile 7.5 Sitting Drop 
100 mM CA 3.7, 3.9, 4.1, 4.3, 4.5  PEG 6000 24, 26, 28, 30, 32 0.7% N-Butanol 5.0 Sitting Drop 
100 mM CA 4.1, 4.3, 4.5, 4.7, 4.9 PEG 6000 24, 27, 30, 33, 36 0.7% N-Butanol 7.5 Sitting Drop 
100 mM CA 3.6 - 4.3 PEG 6000 20, 22, 24, 26, 28, 30 10 mM DTT 7.5 Hanging Drop 
100 mM CA 4.1, 4.3, 4.5, 4.7, 4.9 PEG 6000 24, 27, 30, 33, 36 10 mM DTT 7.5 Sitting Drop 
100 mM CA 3.7, 3.9, 4.1, 4.3, 4.5  PEG 6000 25, 27, 29, 31, 33 10 mM DTT 5.0 Sitting Drop 
100 mM CA 3.7, 3.9, 4.1, 4.3, 4.5  PEG 6000 25, 27, 29, 31, 33 10 mM DTT 7.5 Hanging Drop 
100 mM CA 3.7, 3.9, 4.1, 4.3, 4.5  PEG 6000 25, 27, 29, 31, 33 10 mM DTT 7.5 Sitting Drop 
100 mM CA 3.7, 3.9, 4.1, 4.3, 4.5  PEG 6000 25, 27, 29, 31, 33 10 mM DTT 7.5  MicroBatch 
100 mM CA 3.6 - 4.5 PEG 6000 25, 26, 27, 28, 29 10 mM DTT 7.5 Sitting Drop 
100 mM CA 4.0 - 4.5 PEG 6000 25, 26, 27, 28 10 mM DTT 7.5 Hanging Drop 
100 mM CA 3.7, 3.9, 4.1, 4.3 PEG 6000 20, 22, 24, 26, 28, 30 N/A 7.5 Hanging Drop 
100 mM CA 3.6 - 4.3 PEG 6000 24, 26, 28, 30, 32, 34 10 mM DTT 7.5 Hanging Drop 
100 mM CA 3.6 - 4.3 PEG 6000 14, 16, 18, 20, 22, 24 10 mM DTT 7.5 Hanging Drop 
100 mM CA 3.7, 3.8, 3.9, 4.0 PEG 6000 24, 25, 26, 27, 28, 29 10 mM DTT 7.5 Hanging Drop 
100 mM CA 4.1, 4.2, 4.3, 4.4 PEG 6000 23, 24, 25, 26, 27, 28 10 mM DTT 7.5 Hanging Drop 
100 mM CA 3.7, 3.8, 4.0, 4.2, 4.3  PEG 6000 21, 22, 23, 24, 25, 26 10 mM DTT 7.5 Hanging Drop 
100 mM CA 3.7, 3.8, 4.0, 4.2, 4.3  PEG 6000 21, 22, 23, 24, 25, 26, 27 10 mM DTT 7.5 Sitting Drop 
100 mM CA 3.7, 3.8, 3.9, 4.0 PEG 6000 21, 23, 25, 26, 27, 28 10 mM DTT 7.5 Hanging Drop 
100 mM CA 3.7 - 4.4 PEG 6000 21, 22, 23, 24, 25, 26 10 mM DTT 7.5 Hanging Drop 
100 mM CA 3.7 - 4.4  PEG 6000 21, 22, 23, 24, 25, 26 10 mM DTT 7.5 Sitting Drop 
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Table A-3: (continued) 
 
100 mM CA 3.7, 3.8, 3.9, 4.0  PEG 6000 20, 22, 24, 26, 28 10 mM DTT 7.5 Sitting Drop 
100 mM CA 3.8, 4.0, 4.2, 4.4 PEG 6000 20, 22, 24, 26, 28, 30 10 mM DTT 7.5 Sitting Drop 
100 mM CA 3.8, 4.0, 4.2, 4.4 PEG 6000 24, 25, 26, 27, 28, 29 10 mM DTT 7.5 Hanging Drop 
100 mM CA 3.8, 4.0, 4.2, 4.4 PEG 6000 24, 25, 26, 27, 28, 29 10 mM DTT 7.5 Sitting Drop 
100 mM CA 3.6, 3.8, 4.0, 4.2, 4.4 PEG 6000 22, 24, 26, 28, 30, 32 10 mM DTT 7.6 Sitting Drop 
100 mM CA 4.0, 4.2 PEG 6000 25, 26, 27 10 mM DTT 7.5 Hanging Drop 
100 mM CA 3.9, 4.0, 4.1, 4.2 PEG 6000 22, 23, 24, 25, 26, 27 10 mM DTT 7.5 Hanging Drop 
100 mM CA 3.8 PEG 6000 21, 22, 23, 24, 25, 26 10 mM DTT 7.5 Hanging Drop 
100 mM CA 3.8, 4.2 PEG 6000 21, 23, 25 10 mM DTT 7.5 Hanging Drop 
100 mM CA 3.8, 4.0, 4.2, 4.4 PEG 6000 24, 25, 26 10 mM DTT 7.5 Hanging Drop 
100 mM CA 4.0 PEG 6000 24, 25, 26 10 mM DTT 7.5 Hanging Drop 
100 mM CA 4.0, 4.1 PEG 6000 22, 23, 24, 25, 26, 27 N/A 7.5 Hanging Drop 
100 mM CA 4.0, 4.1 PEG 6000 22, 23, 24, 25, 26, 27 10 mM DTT 7.5 Hanging Drop 
100 mM CA 4.1, 4.2, 4.3, 4.4 PEG 6000 26, 27, 28 10 mM DTT 6.3 Hanging Drop 
100 mM CA 3.8, 4.2 PEG 6000 21, 22, 23, 24, 25, 26 10 mM DTT/5% Glycerol 7.5 Hanging Drop 
100 mM CA 3.8, 4.2 PEG 6000 21, 22, 23, 24, 25, 26 10 mM DTT/10% Glycerol 7.5 Hanging Drop 
100 mM CA 3.8, 4.2 PEG 6000 16, 18, 20, 22, 24, 26 10 mM DTT/5% Glycerol  7.5 Hanging Drop 
100 mM CA 3.8, 4.2 PEG 6000 5, 10, 15 10 mM DTT/5% Glycerol 7.5 Hanging Drop 
100 mM CA 3.8, 4.2 PEG 6000 19, 20, 21, 22, 23 10 mM DTT/5% Glycerol 7.5 Hanging Drop 
100 mM CA 4.0, 4.1 PEG 6000 24, 25, 26 10 mM DTT/10% Glycerol  7.5 Hanging Drop 
100 mM CA 4.0, 4.1 PEG 6000 24, 25, 26 10 mM DTT/15% Glycerol  7.5 Hanging Drop 
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Table A-3 (continued) 
 
100 mM CA 4.0, 4.2 PEG 6000 20, 22, 24, 26, 28, 30 10 mM DTT/10% Glycerol  6.3 Hanging Drop 
100 mM CA 4.0, 4.2 PEG 6000 20, 22, 24, 26, 28, 30 20 mM DTT/10% Glycerol  6.3 Hanging Drop 
100 mM CA 4.0, 4.1 PEG 6000 24, 25, 26, 27, 28, 29 N/A 6.3 Hanging Drop 
100 mM CA 4.0, 4.1 PEG 6000 24, 25, 26, 27, 28, 29 10 mM DTT 6.3 Hanging Drop 
100 mM CA 4.0, 4.2 PEG 6000 20, 22, 24, 26, 28, 30 10 mM DTT/10% PEG 400 6.3 Hanging Drop 
100 mM CA 4.0, 4.2 PEG 6000 20, 22, 24, 26, 28, 30 20  mM DTT/10% PEG 400 6.3 Hanging Drop 
50 mM CA 3.9, 4.0, 4.1, 4.2 PEG 6000 22, 23, 24, 25, 26, 27 10 mM DTT 7.5 Hanging Drop 
20/50/150/200 mM CA 4.0 PEG 6000 25 10 mM DTT 7.5 Hanging Drop 
10/25/50/100/200/300 
mM CA 4.5 PEG 6000 33 5/10/25/50 mM DTT 7.5 Hanging Drop 
25/50/75 mM CA 4.1 PEG 6000 25, 27, 29 10 mM DTT 7.5 Sitting Drop 
20/50/150/200 mM CA 3.8 PEG 4000/6000/8000 23, 28 10 mM DTT 7.5 Hanging Drop 
100 mM NaAc 3.9, 4.0, 4.1, 4.2 PEG 6000 24, 25, 26 10 mM DTT 7.5 Hanging Drop 
100 mM NaCit 3.9, 4.0, 4.1, 4.2 PEG 6000 24, 25, 26 10 mM DTT 7.5 Hanging Drop 
 
 
Note: 
N/A: no additive is applied   NaAc: Sodium Acetate   CA: Citric Acid 
Na-CACO: Sodium-Cacodylate    NaCit: tri-Sodium Citrate 
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APPENDIX 2 
 
SDS-PAGE Recipes for Preparing 2 Gels in 15 ml Separating Gel Solution 
 
APS: 50 mg in 500 µL prepared freshly every time 
 
Component 6% Gel 
(50 – 200) 
8% Gel 
(35 – 90) 
10% Gel 
(20 – 80) 
12% Gel 
(12 – 60) 
15% Gel 
(10 – 43) 
H2O 8.7 ml 7.9 ml 7.1 ml 6.4 ml 5.3 ml 
1.5 M Tris (pH 8.8) 3.8 ml 3.8 ml 3.8 ml 3.8 ml 3.8 ml 
40% Acrylamide 
Mixture 2.3 ml 3.0 ml 3.8 ml 4.5 ml 5.6 ml 
10% SDS 150 µl 150 µl 150 µl 150 µl 150 µl 
10% APS 150 µl 150 µl 150 µl 150 µl 150 µl 
TEMED 15 µl 15 µl 15 µl 15 µl 15 µl 
 
 
SDS-PAGE Recipe for Preparing 2 Gels in 5 ml Stacking Gel Solution 
 
 
Component 5% Staking Gel 
H2O 3.6 ml 
1.0 M Tris (pH 6.8) 630 µl 
40% Acrylamide Mixture 630 µl 
10% SDS 50 µl 
10% APS 50 µl 
TEMED 5 µl 
 
